<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis - Tunnicliffe, DJ - 2023 | Cochrane Library</title> <meta content="HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis - Tunnicliffe, DJ - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007784.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis - Tunnicliffe, DJ - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007784.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007784.pub3" name="dc.identifier" scheme="DOI"/> <meta content="HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis" name="citation_title"/> <meta content="David J Tunnicliffe" name="citation_author"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Brydee A Cashmore" name="citation_author"/> <meta content="Valeria M Saglimbene" name="citation_author"/> <meta content="Rathika Krishnasamy" name="citation_author"/> <meta content="Sunshine Coast University Hospital" name="citation_author_institution"/> <meta content="Kelly Lambert" name="citation_author"/> <meta content="University of Wollongong" name="citation_author_institution"/> <meta content="David W Johnson" name="citation_author"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="giovanni.strippoli@uniba.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD007784.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/11/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007784.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007784.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007784.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Creatinine; *Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse effects]; *Myocardial Infarction [prevention &amp; control]; Renal Dialysis; *Renal Insufficiency, Chronic [complications, therapy]; *Rhabdomyolysis [chemically induced, drug therapy]; *Stroke [drug therapy]; Systematic Reviews as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007784.pub3&amp;doi=10.1002/14651858.CD007784.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007784\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007784\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","ms","fa","fr","pl","hu","nl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007784.pub3",title:"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis",firstPublishedDate:"Nov 29, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007784.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007784.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007784.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007784.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007784.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007784.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;nl&quot;,&quot;title&quot;:&quot;Samenvatting in eenvoudige taal&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007784.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007784.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007784.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007784.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2658 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007784.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-sec-0097"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/appendices#CD007784-sec-0102"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/supinfo/CD007784-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/supinfo/CD007784-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0004">David J Tunnicliffe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0005">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0006">Brydee A Cashmore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0007">Valeria M Saglimbene</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0008">Rathika Krishnasamy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0009">Kelly Lambert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0010">David W Johnson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0011">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information#CD007784-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information/en#CD007784-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 November 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007784.pub3">https://doi.org/10.1002/14651858.CD007784.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007784-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007784-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007784-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007784-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007784-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007784-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007784-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007784-abs-0001" lang="en"> <section id="CD007784-sec-0001"> <h3 class="title" id="CD007784-sec-0001">Background</h3> <p>Cardiovascular disease is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), and the absolute risk of cardiovascular events is similar to people with coronary artery disease. This is an update of a review first published in 2009 and updated in 2014, which included 50 studies (45,285 participants). </p> </section> <section id="CD007784-sec-0002"> <h3 class="title" id="CD007784-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of statins compared with placebo, no treatment, standard care or another statin in adults with CKD not requiring dialysis. </p> </section> <section id="CD007784-sec-0003"> <h3 class="title" id="CD007784-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 4 October 2023. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. An updated search will be undertaken every three months. </p> </section> <section id="CD007784-sec-0004"> <h3 class="title" id="CD007784-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) and quasi‐RCTs that compared the effects of statins with placebo, no treatment, standard care, or other statins, on death, cardiovascular events, kidney function, toxicity, and lipid levels in adults with CKD (estimated glomerular filtration rate (eGFR) 90 to 15 mL/min/1.73 m<sup>2</sup>) were included. </p> </section> <section id="CD007784-sec-0005"> <h3 class="title" id="CD007784-sec-0005">Data collection and analysis</h3> <p>Two or more authors independently extracted data and assessed the study risk of bias. Treatment effects were expressed as mean difference (MD) for continuous outcomes and risk ratios (RR) for dichotomous benefits and harms with 95% confidence intervals (CI). The risk of bias was assessed using the Cochrane risk of bias tool, and the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD007784-sec-0006"> <h3 class="title" id="CD007784-sec-0006">Main results</h3> <p>We included 63 studies (50,725 randomised participants); of these, 53 studies (42,752 participants) compared statins with placebo or no treatment. The median duration of follow‐up was 12 months (range 2 to 64.8 months), the median dosage of statin was equivalent to 20 mg/day of simvastatin, and participants had a median eGFR of 55 mL/min/1.73 m<sup>2</sup>. Ten studies (7973 participants) compared two different statin regimens. We were able to meta‐analyse 43 studies (41,273 participants). Most studies had limited reporting and hence exhibited unclear risk of bias in most domains. </p> <p>Compared with placebo or standard of care, statins prevent major cardiovascular events (14 studies, 36,156 participants: RR 0.72, 95% CI 0.66 to 0.79; I<sup>2</sup> = 39%; high certainty evidence), death (13 studies, 34,978 participants: RR 0.83, 95% CI 0.73 to 0.96; I² = 53%; high certainty evidence), cardiovascular death (8 studies, 19,112 participants: RR 0.77, 95% CI 0.69 to 0.87; I² = 0%; high certainty evidence) and myocardial infarction (10 studies, 9475 participants: RR 0.55, 95% CI 0.42 to 0.73; I² = 0%; moderate certainty evidence). There were too few events to determine if statins made a difference in hospitalisation due to heart failure. Statins probably make little or no difference to stroke (7 studies, 9115 participants: RR 0.64, 95% CI 0.37 to 1.08; I² = 39%; moderate certainty evidence) and kidney failure (3 studies, 6704 participants: RR 0.98, 95% CI 0.91 to 1.05; I² = 0%; moderate certainty evidence) in people with CKD not requiring dialysis. </p> <p>Potential harms from statins were limited by a lack of systematic reporting. Statins compared to placebo may have little or no effect on elevated liver enzymes (7 studies, 7991 participants: RR 0.76, 95% CI 0.39 to 1.50; I² = 0%; low certainty evidence), withdrawal due to adverse events (13 studies, 4219 participants: RR 1.16, 95% CI 0.84 to 1.60; I² = 37%; low certainty evidence), and cancer (2 studies, 5581 participants: RR 1.03, 95% CI 0.82 to 1.30; I² = 0%; low certainty evidence). However, few studies reported rhabdomyolysis or elevated creatinine kinase; hence, we are unable to determine the effect due to very low certainty evidence. Statins reduce the risk of death, major cardiovascular events, and myocardial infarction in people with CKD who did not have cardiovascular disease at baseline (primary prevention). There was insufficient data to determine the benefits and harms of the type of statin therapy. </p> </section> <section id="CD007784-sec-0007"> <h3 class="title" id="CD007784-sec-0007">Authors' conclusions</h3> <p>Statins reduce death and major cardiovascular events by about 20% and probably make no difference to stroke or kidney failure in people with CKD not requiring dialysis. However, due to limited reporting, the effect of statins on elevated creatinine kinase or rhabdomyolysis is unclear. Statins have an important role in the primary prevention of cardiovascular events and death in people who have CKD and do not require dialysis. </p> <p><b>Editorial note:</b> This is a living systematic review. We will search for new evidence every three months and update the review when we identify relevant new evidence. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007784-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007784-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007784-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007784-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007784-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007784-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD007784-abs-0016">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007784-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007784-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/nl#CD007784-abs-0019">Nederlands</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007784-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007784-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007784-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007784-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007784-abs-0002" lang="en"> <h3>Statins can help reduce risk of death in people with chronic kidney disease who do not need dialysis </h3> <p><b>What is the issue?</b><br/>Adults with chronic kidney disease (CKD) have a high risk of cardiovascular events, with elevated serum cholesterol and triglycerides, a factor that contributes to cardiovascular disease. Statin therapy helps to lower the level of bad cholesterol (low‐density lipoprotein) and has cardiovascular protective effects beyond cholesterol reduction. For people not needing dialysis, statin therapy has been shown to reduce death and cardiovascular events. Still, studies in this population have shown unclear effects on stroke, kidney failure, and harms such as muscle damage (rhabdomyolysis). </p> <p><b>What did we do?</b><br/>We looked at 62 studies published before 4 October 2023 concerning statins in over 50,000 people with CKD who did not need dialysis treatment. This review is a living systematic review. A search for new evidence will be conducted every three months, and the review will be updated accordingly. </p> <p><b>What did we find?</b> </p> <p>We found that compared to placebo, statin therapy reduced death and major heart‐related events, with one in 13 people receiving statin therapy avoiding heart‐related events and one in 26 people avoiding death. Statin therapy probably had little or no effect on stroke and kidney failure (when people would benefit from dialysis or a kidney transplant). The benefits of statin therapy were also evident in patients with CKD but not heart disease. Statins have some potential harms; however, we found there was probably no effect on cancer, liver function or withdrawing from treatment due to adverse events. There was limited reporting of muscle damage in the studies. </p> <p>Studies did not identify a preferred type or dose of statin in treating people with CKD not requiring dialysis. </p> <p><b>Conclusions</b><br/>Statins decrease death, major cardiovascular events, and myocardial infarction in people with moderate CKD. Limited data related to treatment toxicity resulted in uncertain effects. </p> <p><b>Editorial note:</b> Please refer to the Cochrane Database of Systematic Reviews for the current status of this review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007784-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007784-sec-0097"></div> <h3 class="title" id="CD007784-sec-0098">Implications for practice</h3> <section id="CD007784-sec-0098"> <p>Moderate‐to‐high‐quality evidence currently supports the widespread use of statins for people with CKD not on dialysis to prevent death and cardiovascular events, including people without existing CVD. Statins reduce death and cardiovascular events, including MI, although effects on the risk of stroke were less certain. Treating 1000 people with CKD not on dialysis may prevent 32 major cardiovascular events and 10 deaths over one year. Statins have uncertain effects on the progression of CKD and cannot be recommended to slow the progression of CKD. Currently, the toxicity of statins for people with CKD is poorly characterised in studies, and this needs to be acknowledged when commencing treatment. </p> </section> <h3 class="title" id="CD007784-sec-0099">Implications for research</h3> <section id="CD007784-sec-0099"> <p>Available data confirms the benefit of statins in reducing lipid levels and improving death and cardiovascular death in people with CKD not needing dialysis. Future research, including post‐marketing surveillance, is required to monitor the safety of statins in people with CKD, with a focus on risks of muscle or liver damage associated with longer‐term treatment. A co‐ordinated approach to post‐marketing surveillance might be considered. </p> <p>Currently, the available evidence depends largely on post hoc analyses from larger studies. Future prospective studies of primary prevention in people with moderate to severe CKD (eGFR 15 to 60 mL/min/1.73 m²), including a detailed assessment of treatment toxicity, are warranted. <a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> and <a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> have demonstrated that the type of statin may have different effects on kidney function, including proteinuria. A network meta‐analysis to rank the efficacy of the type of statin is warranted. Additionally, future prospective studies comparing statins combined with ezetimibe with statins alone in people with moderate to severe CKD are warranted because of a lack of certainty regarding the benefits and harms of therapy from the several small published trials. Finally, further examination of the type of statin should be considered. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007784-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007784-sec-0008"></div> <div class="table" id="CD007784-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Statin therapy versus placebo or standard of care for people with chronic kidney disease not requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Statin therapy versus placebo or standard of care for people with chronic kidney disease not requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic kidney disease not requiring dialysis<br/><b>Setting:</b> primary and tertiary care<br/><b>Intervention:</b> statin therapy<br/><b>Comparison:</b> placebo or standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or standard of care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with statin therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major cardiovascular events (MACE)<br/>follow up: mean 46 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1,000<br/>(4 to 5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/>(0.66 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36156 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy reduces major cardiovascular events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>follow up: mean 40 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(2 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/>(0.73 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34978 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy reduces death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rhabdomyolysis<br/>follow up: mean 64 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(0 to 59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.07<br/>(0.13 to 75.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2618 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of statin therapy on rhabdomyolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction<br/>follow up: mean 39 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(1 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55<br/>(0.42 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9475 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy probably reduces myocardial infarction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke<br/>follow up: mean 40 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1,000<br/>(5 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/>(0.37 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9158 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy probably results in little to no difference in stroke</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney failure<br/>follow up: mean 34 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(2 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/>(0.91 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6704 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy probably results in little to no difference in kidney failure</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation due to heart failure<br/>follow up: 54 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/>(28 to 99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.37 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>579 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy may result in little to no difference in hospitalisation due to heart failure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the baseline risk of outcomes from observational studies (and its 95%CI) . The relevant studies in the Summary of Findings Table are listed below: </p> <p>Major cardiovascular events and death ‐ <a href="./references#CD007784-bbs2-0110" title="GoAS , ChertowGM , FanD , McCullochCE , HsuCY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine2004;351(13):1296-305. [MEDLINE: 15385656]">Go 2004</a> </p> <p>Rhabdomyolysis ‐ based on the assumed risk of outcomes in the comparison group</p> <p>Myocardial infarction ‐ <a href="./references#CD007784-bbs2-0128" title="MeisignerC , DöringA , LöwelH . Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. European Heart Journal2006;27(10):1245-50. [PMID: 16611670]">Meisinger 2006</a> </p> <p>Stroke and hospitalisation due to heart failure ‐ <a href="./references#CD007784-bbs2-0100" title="BansalN , KatzR , Robinson-CohenC , OddenMC , DalrympleL , ShlipakMG , et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiology2017;2(3):314-8. [PMID: 28002548]">Bansal 2017</a><br/>Kidney failure ‐ <a href="./references#CD007784-bbs2-0105" title="DalrympleLS , KatzR , KesetenbaumB , ShlipakMG , SarnakMJ , Stehman-BreenC , et al. Chronic kidney disease and the risk of end-stage renal disease versus death. Journal General Internal Medicine2011;26(4):379-85. [PMID: 20853156]">Dalrymple 2011</a><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MACE:</b> Major Adverse Cardiac Events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very few events </p> <p><sup>2</sup> Inadequate sequence generation/ generation of comparable groups, resulting in potential for selection bias </p> <p><sup>3</sup> Effect estimates were on both side of the null </p> <p><sup>4</sup> Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate concealment of allocation during randomisation process, resulting in potential for selection bias, </p> <p><sup>5</sup> Only one study </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007784-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007784-sec-0009"></div> <section id="CD007784-sec-0010"> <h3 class="title" id="CD007784-sec-0010">Description of the condition</h3> <p>The incidence and prevalence of chronic kidney disease (CKD) are increasing, with a global prevalence estimated at around 10% (<a href="./references#CD007784-bbs2-0109" title="Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2020;395(10225):709-33. [PMID: 32061315]">Global Burden of Disease CKD Collaboration 2020</a>). CKD is a known risk factor for cardiovascular disease (CVD) (<a href="./references#CD007784-bbs2-0110" title="GoAS , ChertowGM , FanD , McCullochCE , HsuCY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine2004;351(13):1296-305. [MEDLINE: 15385656]">Go 2004</a>). Overall cardiovascular deaths are more common than progression to kidney failure in patients with CKD (<a href="./references#CD007784-bbs2-0108" title="GargiuloR , SuhailF , LermaEV . Cardiovascular disease and chronic kidney disease. Disease-a-Month2015;61(9):403-13. [PMID: 26328516]">Gargiulo 2015</a>). For patients with severe kidney disease on long‐term dialysis, 39% of deaths are attributable to cardiovascular causes (<a href="./references#CD007784-bbs2-0144" title="USRDS. US Renal Data System 2018 Annual Data Report. Chapter 4. Cardiovascular disease in patients with CKD. American Journal of Kidney Diseases2019;73(3 (Suppl 1)):S79-98. [DOI: 10.1053/j.ajkd.2018.12.004]">USRDS 2019</a>). People with moderate CKD not on dialysis experience risks of death or complications from CVD equivalent to people with heart disease (<a href="./references#CD007784-bbs2-0110" title="GoAS , ChertowGM , FanD , McCullochCE , HsuCY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine2004;351(13):1296-305. [MEDLINE: 15385656]">Go 2004</a>; <a href="./references#CD007784-bbs2-0115" title="HenryRM , KostensePJ , BosG , DekkerJM , NijpelsG , HeineRJ , et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney International2002;62(4):1402-7. [MEDLINE: 12234312]">Henry 2002</a>). </p> </section> <section id="CD007784-sec-0011"> <h3 class="title" id="CD007784-sec-0011">Description of the intervention</h3> <p>HMG‐CoA reductase inhibitors, known as statins, are a commonly prescribed class of cholesterol‐lowering medications used in the primary prevention of atherosclerotic CVD and secondary prevention for those who have developed CVD (<a href="./references#CD007784-bbs2-0141" title="SidebottomAC , VacquierMC , JensenJC , BradleySM , KnickelbineT , StraussC , et al. Trends in prevalence of guideline‐based use of lipid‐lowering therapy in a large health system. Clinical Cardiology2020;43(6):560-7. [PMID: 32104922]">Sidebottom 2020</a>). Ezetimibe is another cholesterol‐lowering medication class which has been examined in combination with statins in clinical trials (<a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a>). </p> </section> <section id="CD007784-sec-0012"> <h3 class="title" id="CD007784-sec-0012">How the intervention might work</h3> <p>Many traditional and non‐traditional cardiovascular risk factors are prevalent in people with CKD (<a href="./references#CD007784-bbs2-0129" title="MuntnerP , HeJ , AstorBC , FolsomAR , CoreshJ . Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. Journal of the American Society of Nephrology2005;16(2):529-38. [MEDLINE: 15625072]">Muntner 2005</a>; <a href="./references#CD007784-bbs2-0140" title="ShlipakMG , FriedLF , CushmanM , ManolioTA , PetersonD , Stehman-BreenC , et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA2005;293(14):1737-45. [MEDLINE: 15827312]">Shilpak 2005</a>). The majority (60%) of people with CKD have elevated serum cholesterol and triglycerides levels and an even higher proportion in those with nephrotic syndrome (<a href="./references#CD007784-bbs2-0114" title="HarrisK , ThomasM , ShortC , MooreR . Assessment of the efficiency of treatment of dyslipidemia in renal outpatients. Journal of Nephrology2002;15(3):263-9. [MEDLINE: 12113597]">Harris 2002</a>). Abnormal lipid levels may contribute to the development of CVD and the initiation and progression of CKD (<a href="./references#CD007784-bbs2-0106" title="DruekeTB , Nguyen KhoaT , MassyZA , Witko-SarsatV , LacourB , Descamps-LatschaB . Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney International - Supplement2001;78:S114-9. [MEDLINE: 11168995]">Drueke 2001</a>; <a href="./references#CD007784-bbs2-0136" title="SchaeffnerES , KurthT , CurhanGC , GlynnRJ , RexrodeKM , BaigentC , et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. Journal of the American Society of Nephrology2003;14(8):2084-91. [MEDLINE: 12874462]">Schaeffner 2003</a>). In the Atherosclerosis Risk in Communities Study (ARIC) and Physicians Health study, elevated lipid levels were associated with lower kidney function (<a href="./references#CD007784-bbs2-0126" title="ManjunathG , TighiouartH , IbrahimH , MacLeodB , SalemDN , GriffithJL , et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. Journal of American College of Cardiology2003;41(1):47-55. [MEDLINE: 12570944]">Manjunath 2003</a>). Apart from their lipid‐lowering function, it is plausible that statin use may result in improved kidney function by decreasing urinary protein excretion and inflammation and reducing fibrosis of tubular cells (<a href="./references#CD007784-bbs2-0119" title="KasiskeBL , O'DonnellMP , GarvisWJ , KeaneWF . Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circulation Research1988;62(3):367-74. [MEDLINE: 3338121]">Kasiske 1988</a>). Ezetimibe prevents intestinal cholesterol absorption through inhibition of the synthetic 2‐azetidinone agent at the brush border of the small intestine (<a href="./references#CD007784-bbs2-0143" title="Omeed Sizar, Ali Nassereddin, Raja Talati. StatPearls - Ezetimibe [Internet]. Treasure Island Florida: StatPearls Publishing, 2023.">StatPearls Textbook</a>), while statins could reduce kidney disease progression and CVD incidence in people with kidney dysfunction (<a href="./references#CD007784-bbs2-0127" title="MassyZA , GuijarroC . Statins: effects beyond cholesterol lowering. Nephrology Dialysis Transplantation2001;16(9):1738-41. [MEDLINE: 11522848]">Massy 2001</a>). Clinical studies in people with CVD have shown that statins safely reduce the five‐year incidence of death or major cardiovascular events by about 20% (<a href="./references#CD007784-bbs2-0099" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358] [Erratum in: Lancet. 2008 Jun 21;371(9630):2084]. Lancet2005;366(9493):1267-78. [MEDLINE: 16214597]">Baigent 2005</a>). </p> </section> <section id="CD007784-sec-0013"> <h3 class="title" id="CD007784-sec-0013">Why it is important to do this review</h3> <p>In previous versions of this review published in 2009 and 2014, statins proportionally reduced the risk of death and major cardiovascular events in people with CKD. However, the risks of stroke, adverse events (muscle or liver damage), and kidney failure in these studies were uncertain due to few reported events (<a href="./references#CD007784-bbs2-0146" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD007784. [DOI: 10.1002/14651858.CD007784.pub2]">Palmer 2014</a>). The previous version of this review relied on the post‐hoc analysis of larger general population studies. Additional studies have been published, warranting a review update. This review has transitioned to a living systematic review. Clinical practice guidelines recommend using statins with or without ezetimibe for people with CKD, not on dialysis (<a href="./references#CD007784-bbs2-0104" title="JohnsonDW , AtaiE , ChanCM , PhoonRKS , ScottC , ToussaintND , TurnerGL , UsherwoodT , WigginsKJ . KHA-CARI Guideline: Early chronic kidney disease: Detection, prevention and management. Nephrology2013;18(5):340-50. [PMID: 23506545]">CARI 2013</a>; <a href="./references#CD007784-bbs2-0121" title="Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney International Supplement2013;3:259-305. [DOI: 10.1038/kisup.2013.27]">KDIGO 2013</a>). The Caring for Australian and New ZealandeRs with Kidney Impairment (CARI) Guideline is being updated, and this review will form the underlying evidence review for guideline recommendations. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007784-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007784-sec-0014"></div> <p>To evaluate the benefits and harms of statin therapy compared with placebo, standard care without statin therapy, or another different statin in adults with CKD who were not on dialysis. A secondary objective is to maintain the currency of the evidence using a living systematic review approach. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007784-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007784-sec-0015"></div> <section id="CD007784-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007784-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) that evaluated the benefits and harms of statins in adults with CKD who were not on dialysis. The first period of randomised cross‐over studies was included. We excluded studies of fewer than eight weeks duration as these studies were unlikely to enable detection of death or cardiovascular outcomes related to statin therapy (<a href="./references#CD007784-bbs2-0102" title="BrielM , SchwartzGG , ThompsonPL , deLemosJA , BlazingMA , vanEsGA , et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA2006;295(17):2046-56. [MEDLINE: 16670413]">Briel 2006</a>). </p> </section> <section id="CD007784-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD007784-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>We included studies enrolling adults with CKD (estimated glomerular filtration rate (eGFR) 90 to 15 mL/min/1.73 m<sup>2</sup>) (defined and staged according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines) (<a href="./references#CD007784-bbs2-0120" title="LevinA , StevensPE , BilousRW , CoreshJ , De FranciscoAL , De JongPE , et al. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplments2013;3(1):1-150. [EMBASE: 369856107]">KDIGO 2012</a>) who were not on dialysis, including people with persistent urine abnormalities (proteinuria or albuminuria) or structural kidney disease with normal kidney function. Studies were included irrespective of whether participants had CVD at baseline. </p> </section> <section id="CD007784-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>Studies of adults with kidney failure treated with dialysis (peritoneal dialysis or haemodialysis) and recipients of a kidney transplant were excluded. Other Cochrane Reviews have specifically reviewed these populations (<a href="./references#CD007784-bbs2-0131" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , NigwekarSU , et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2013, Issue 9. Art. No: CD004289. [DOI: 10.1002/14651858.CD004289.pub5]">Palmer 2013</a>; <a href="./references#CD007784-bbs2-0132" title="PalmerSC , NavaneethanSD , CraigJC , PerkovicV , JohnsonDW , NigwekarSU , et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD005019. [DOI: 10.1002/14651858.CD005019.pub4]">Palmer 2014a</a>). </p> </section> </section> <section id="CD007784-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared statins with placebo, standard care without statin therapy, or another statin. We excluded studies where a statin was compared with a different lipid‐lowering strategy, including fibrate therapy and ezetimibe. </p> </section> <section id="CD007784-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>Standardised Outcomes in NephroloGy (SONG) is currently developing a core outcome set for CKD. This finalised core outcome set will be incorporated in updated versions of this review. </p> <section id="CD007784-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007784-list-0001"> <li> <p>Major cardiovascular events</p> </li> <li> <p>Death</p> </li> <li> <p>Rhabdomyolysis</p> </li> </ol> </p> </section> <section id="CD007784-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007784-list-0002"> <li> <p>Cardiovascular death</p> </li> <li> <p>Myocardial infarction (MI) (fatal and non‐fatal)</p> </li> <li> <p>Stroke (fatal and non‐fatal)</p> </li> <li> <p>Hospitalisation due to heart failure</p> </li> <li> <p>Kidney failure</p> </li> <li> <p>Doubling of serum creatinine (SCr)</p> </li> <li> <p>Acute kidney injury (AKI)</p> </li> <li> <p>Elevated creatine kinase</p> </li> <li> <p>Elevated liver enzymes</p> </li> <li> <p>Withdrawal due to adverse events</p> </li> <li> <p>Cancer</p> </li> <li> <p>Onset of diabetes</p> </li> <li> <p>Revascularisation procedure</p> </li> <li> <p>End of treatment creatinine clearance (CrCl) or GFR (any measure)</p> </li> <li> <p>End of treatment proteinuria</p> </li> <li> <p>Serum lipid levels</p> <ol id="CD007784-list-0003"> <li> <p>Total cholesterol</p> </li> <li> <p>Low‐density lipoprotein (LDL) cholesterol</p> </li> <li> <p>High‐density lipoprotein (HDL) cholesterol</p> </li> <li> <p>Triglycerides</p> </li> </ol> </li> <li> <p>Fatigue</p> </li> <li> <p>Life participation</p> </li> <li> <p>Memory loss</p> </li> </ol> </p> </section> </section> </section> <section id="CD007784-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007784-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> to 4 October 2023 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources: </p> <p> <ul id="CD007784-list-0004"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. </p> </li> </ul> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, and a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD007784-sec-0103">Appendix 1</a> for search terms used in strategies for this review. </p> <section id="CD007784-sec-0027"> <h5 class="title">Living systematic review considerations</h5> <p>An updated search of the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> will be undertaken every three months. </p> </section> </section> <section id="CD007784-sec-0028"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD007784-list-0005"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Contacting relevant individuals/organisations seeking information about unpublished or incomplete studies. </p> </li> <li> <p>Grey literature sources (e.g. abstracts, dissertations and theses) in addition to those already included in the Cochrane Kidney and Transplant Register of Studies will be searched. </p> </li> </ul> </p> <section id="CD007784-sec-0029"> <h5 class="title">Living systematic review considerations</h5> <p>References lists of newly identified studies from updated searches were checked, and relevant individuals and organisations were contacted if appropriate. Grey literature sources screening will not be periodically undertaken during the living evidence surveillance period. </p> </section> </section> </section> <section id="CD007784-sec-0030"> <h3 class="title" id="CD007784-sec-0030">Data collection and analysis</h3> <section id="CD007784-sec-0031"> <h4 class="title">Selection of studies</h4> <p>The following processes were used in the current update and previous versions of the review. The search strategy described was used to obtain titles and abstracts of studies relevant to the review. Title and abstracts were screened independently by two authors (BC and DJT), who discarded studies that were not eligible. However, studies and reviews thought to include relevant data or information on studies were retained initially for full‐text review. Two authors (BC and DJT) independently assessed retrieved abstracts and the full text, where necessary, to determine which studies satisfied the inclusion criteria. Disagreements between authors were resolved in consultation with a third author (SP). </p> <section id="CD007784-sec-0032"> <h5 class="title">Living systematic review considerations</h5> <p>The 2023 review update undertook study selection in Covidence (<a href="https://www.covidence.org/" target="_blank">https://www.covidence.org/</a>). Two independent authors (BC and DJT) immediately screened the retrieved citations from three monthly searches. Disagreements were resolved in consultation with a third author (SP). </p> </section> </section> <section id="CD007784-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by authors (DJT, BC) using Robot Reviewer (<a href="https://www.robotreviewer.net/" target="_blank">https://www.robotreviewer.net/</a>). Data extraction was checked independently by authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped. Data were obtained from all relevant reports, including long‐term follow‐up data if the attrition rate was less than 80% of randomised participants. Any discrepancies between published versions were highlighted. </p> </section> <section id="CD007784-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the Cochrane risk of bias assessment tool (<a href="./references#CD007784-bbs2-0118" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>) (<a href="./appendices#CD007784-sec-0104">Appendix 2</a>). </p> <p> <ul id="CD007784-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD007784-list-0007"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD007784-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (major cardiovascular events, death, rhabdomyolysis, kidney failure, doubling of SCr, onset of diabetes, revascularisation procedure, memory loss, elevated liver enzymes, elevated creatine kinase, withdrawal due to adverse events, and cancer), results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (lipid parameters, proteinuria, kidney function (CrCl or eGFR), fatigue, and life participation), the mean difference (MD) was used, or the standardised mean difference (SMD) where different scales were used for outcome measurement. </p> </section> <section id="CD007784-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>Cross‐over RCTs were analysed using only the data from the first period. Studies with multiple treatment arms were included. When considering these studies, we tried to combine all relevant intervention groups into a single group when appropriate, i.e. high‐ and low‐dose statin, to allow a single pairwise comparison. If appropriate, we compared the intervention arms against one another. It was planned that cluster RCTs were not included in the meta‐analysis and were analysed and reported separately. However, no cluster RCTs were included in the review. </p> </section> <section id="CD007784-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested, and relevant information was included in the review. Evaluation of important numerical data, such as screened or randomised patients and intention‐to‐treat, as‐treated, and per‐protocol population, was performed. Attrition rates, such as drop‐outs, losses to follow‐up, and withdrawals, were investigated, including the balance between treatment groups. Issues of missing data and imputation methods (e.g. last observation carried forward) were critically appraised (<a href="./references#CD007784-bbs2-0118" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD007784-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies likely due to statistical heterogeneity rather than sampling error (<a href="./references#CD007784-bbs2-0117" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values was as follows. </p> <p> <ul id="CD007784-list-0008"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depended on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P value from the Chi² test or a CI for I²) (<a href="./references#CD007784-bbs2-0118" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> <p>Meta‐regression for age and GFR was undertaken for outcomes with more than 10 studies in which meta‐analysis demonstrated evidence of substantial or considerable heterogeneity. </p> </section> <section id="CD007784-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess potential bias from small‐study effects, we constructed funnel plots for the log risk ratio in individual studies against the standard error of the risk ratio. Statistical assessment of funnel plot asymmetry with the Egger regression test (<a href="./references#CD007784-bbs2-0113" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57. [MEDLINE: 16345038]">Harbord 2006</a>) using R (<a href="./references#CD007784-bbs2-0133" title="R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing2013;Vienna, Austria:URL http://www.R-project.org/.">R Core Team 2013</a> ‐ <a href="http://www.R-project.org/." target="_blank">http://www.R-project.org/</a>) to assess publication bias if required or sufficient data is available). </p> </section> <section id="CD007784-sec-0040"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model, but the fixed‐effect model was also used to ensure the robustness of the model chosen and susceptibility to outliers. </p> <p>The anticipated absolute effects have been calculated from baseline risks reported in published observational studies that examine the incidence of cardiovascular outcomes, death, and kidney failure in people with CKD (<a href="./references#CD007784-bbs2-0100" title="BansalN , KatzR , Robinson-CohenC , OddenMC , DalrympleL , ShlipakMG , et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiology2017;2(3):314-8. [PMID: 28002548]">Bansal 2017</a>; <a href="./references#CD007784-bbs2-0105" title="DalrympleLS , KatzR , KesetenbaumB , ShlipakMG , SarnakMJ , Stehman-BreenC , et al. Chronic kidney disease and the risk of end-stage renal disease versus death. Journal General Internal Medicine2011;26(4):379-85. [PMID: 20853156]">Dalrymple 2011</a>; <a href="./references#CD007784-bbs2-0110" title="GoAS , ChertowGM , FanD , McCullochCE , HsuCY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine2004;351(13):1296-305. [MEDLINE: 15385656]">Go 2004</a>; <a href="./references#CD007784-bbs2-0128" title="MeisignerC , DöringA , LöwelH . Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. European Heart Journal2006;27(10):1245-50. [PMID: 16611670]">Meisinger 2006</a>). These studies were selected as they were large multi‐national observational studies conducted on people with CKD that may be generalisable to the populations in the identified RCTs in this review. When no published data was available, the assumed risk of the outcomes was given by the event rates in the comparison group. </p> <section id="CD007784-sec-0041"> <h5 class="title">Living systematic review considerations</h5> <p>All included studies in future review updates will undergo data extraction and critical appraisal by two authors (BC and DJT) independently, using Robot Reviewer (<a href="https://www.robotreviewer.net/" target="_blank">https://www.robotreviewer.net/</a>) as a supportive tool. Whenever new evidence (i.e. studies, data or other information) relevant to the review is identified, we will extract the data and assess the risk of bias as appropriate. We will wait until the accumulating evidence changes one or more of the following components of the review before incorporating it and re‐publishing the review. </p> <p> <ul id="CD007784-list-0009"> <li> <p>The findings of one or more primary outcomes</p> </li> <li> <p>The credibility (e.g. GRADE rating) of one or more primary outcomes</p> </li> <li> <p>New settings, populations, interventions, comparisons or outcomes were examined</p> </li> <li> <p>New serious adverse events.</p> </li> </ul> </p> <p>Formal sequential meta‐analysis approaches will not be used for updated meta‐analyses.</p> </section> </section> <section id="CD007784-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For outcomes with more than 10 studies, we planned to conduct subgroup analyses to explore potential sources of heterogeneity in modifying estimates of the effects of statins if substantial or considerable heterogeneity or significant heterogeneity (P &lt; 0.1) was present in the primary analysis. We planned subgroup analyses according to participant, intervention, or study‐related characteristics when subgroups contained four or more independent studies (statin type, statin dose (equivalent to simvastatin, baseline total cholesterol (&lt; 230 mg/dL versus ≥ 230 mg/dL), age (≤ 55 years versus &gt; 55 years), the proportion with diabetes (≥ 20% versus &lt; 20%), presence or absence of CVD (primary versus secondary prevention), or adequacy of allocation concealment. Additionally, post‐hoc analyses were conducted on the impact of baseline kidney function on the following outcomes: kidney failure, doubling of SCr, end‐of‐treatment kidney function, and end‐of‐treatment proteinuria. </p> <p>We conducted meta‐regression using a mixed‐effects model with the Metafor package for R (<a href="./references#CD007784-bbs2-0133" title="R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing2013;Vienna, Austria:URL http://www.R-project.org/.">R Core Team 2013</a>) for primary outcomes with more than 10 studies and substantial or considerable heterogeneity. Age and kidney function were considered covariates for meta‐regression. </p> </section> <section id="CD007784-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>The following sensitivity analyses were considered to explore the influence of the following factors on effect size. </p> <p> <ul id="CD007784-list-0010"> <li> <p>Repeating the analysis, excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking into account the risk of bias</p> </li> <li> <p>Repeating the analysis, excluding any very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, the language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> <p>However, there were insufficient data for sensitivity analyses for unpublished studies, risk of bias, the language of publication, and country. </p> </section> <section id="CD007784-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in the 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD007784-bbs2-0137" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org/handbook.">Schünemann 2022a</a>). The 'Summary of findings' tables also include an overall grading of the evidence‐related main outcome using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD007784-bbs2-0111" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD007784-bbs2-0112" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of the within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, the precision of effect estimates and risk of publication bias (<a href="./references#CD007784-bbs2-0138" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD007784-list-0011"> <li> <p>Major cardiovascular events</p> </li> <li> <p>Death</p> </li> <li> <p>Rhabdomyolysis</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>MI</p> </li> <li> <p>Stroke</p> </li> <li> <p>Hospitalisation due to heart failure</p> </li> <li> <p>Kidney failure</p> </li> </ul> </p> <section id="CD007784-sec-0045"> <h5 class="title">Methods for future updates</h5> <section id="CD007784-sec-0046"> <h6 class="title">Living systematic review considerations</h6> <p>The conduct and production of this living systematic review will be overseen by the CARI Guidelines Living Evidence Working Group and the Statins in CKD Guideline Working Group. We will review the scope and methods when updating the review in light of potential changes in the topic area or new evidence (e.g. when additional comparisons, interventions, subgroups, outcomes, or new review methods become available). At every three‐month search, we will consider the necessity for the review to be living. By assessing the questions' ongoing relevance to decision‐makers and determining if continuing uncertainty in the evidence is present, we will determine whether further relevant research is likely to change recommendations for clinical practice via the CARI Guidelines Statins in CKD Living Guideline. </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007784-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007784-sec-0047"></div> <section id="CD007784-sec-0048"> <h3 class="title">Description of studies</h3> <p>The following section contains broad descriptions of the studies considered in this review. For further details on each individual study, please see <a href="./references#CD007784-bbs1-0001" title="">Included studies</a>; <a href="./references#CD007784-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD007784-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD007784-bbs1-0004" title="">Ongoing studies</a>. </p> <section id="CD007784-sec-0049"> <h4 class="title">Results of the search</h4> <p>Previous versions of this Cochrane review (<a href="./references#CD007784-bbs2-0145" title="NavaneethanSD , PansiniF , PerkovicV , MannoC , PellegriniF , JohnsonDW , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2009, Issue 2. Art. No: CD007784. [DOI: 10.1002/14651858.CD007784]">Navaneethan 2009</a>; <a href="./references#CD007784-bbs2-0146" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD007784. [DOI: 10.1002/14651858.CD007784.pub2]">Palmer 2014</a>) identified 47 studies (39,738 participants) compared statin therapy with placebo or no treatment, and three studies (5547 participants) compared a statin with another statin (<a href="#CD007784-tbl-0002">Table 1</a>). </p> <div class="table" id="CD007784-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">List of included studies according to Cochrane review update</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus placebo studies identified in the 2009 and 2014 version of the Cochrane review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus placebo studies identified in the updated 2023 Cochrane review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus statin studies identified in the 2009 and 2014 version of the Cochrane review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus statin studies identified in the updated 2023 Cochrane review</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0002" title="AbeM , MaruyamaN , OkadaK , MatsumotoS , MatsumotoK , SomaM . Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Journal of Atherosclerosis &amp; Thrombosis2011;18(11):1018-28. [MEDLINE: 21921413]">Abe 2011c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0022" title="HolmeI , CaterNB , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine2008;40(6):456-64. [MEDLINE: 19160529]HolmeI , FayyadR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine2010;267(6):567-75. [MEDLINE: 20141566]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology2004;94(6):720-4. [MEDLINE: 15374773]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum appears in JAMA. 2005 Dec 28;294(24):3092]. JAMA2005;294(19):2437-45. [MEDLINE: 16287954]">IDEAL 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0003" title="AbeM , MaruyamaN , MaruyamaT , OkadaK , SomaM . A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease. Journal of Atherosclerosis &amp; Thrombosis2015;22(12):1235-47. [MEDLINE: 26156625]">Abe 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0004" title="ClearfieldM , DownsJR , WeisS , WhitneyEJ , KruyerW , ShapiroDR , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health &amp; Gender-Based Medicine2001;10(10):971-81. [MEDLINE: 11788107]ClearfieldM , WhitneyEJ , WeisS , DownsJR , ShapiroDR , SteinEA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk2000;7(2):125-33. [MEDLINE: 10879416]ClearfieldMB , WeisSE , WillisJM , VaseniusKA , McConathyWJ . Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association2002;102(7):377-84. [MEDLINE: 12138952]CuiY , WatsonDJ , GirmanCJ , ShapiroDR , GottoAM , HiseroteP , et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology2009;104(6):829-34. [MEDLINE: 19733719]DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287-93. [MEDLINE: 9264420]DownsJR , ClearfieldM , TyrolerHA , WhitneyEJ , KruyerW , LangendorferA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology2001;87(9):1074-9. [MEDLINE: 11348605]DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22. [MEDLINE: 9613910]Gotto AM Jr, BoccuzziSJ , CookJR , AlexanderCM , RoehmJB , MeyerGS , et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology2000;86(11):1176-81. [MEDLINE: 11090787]KendrickJ , ShlipakMG , TargherG , CookT , LindenfeldJ , ChoncholM . Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases2010;55(1):42-9. [MEDLINE: 19932541]">AFCAPS/TexCAPS 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0008" title="KasaharaM , UeshimaK , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: design of the ASsessment of clinial usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: FR-PO194]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):413A. KimuraG , KasaharaM , UeshimaK , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2017;21(3):417-24. [MEDLINE: 27392909]KimuraG , UeshimaK , KashaharaM , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: ASsessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: SA-O1086]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):5B. KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between the control of LDL-cholesterol level and renal function in CKD patients with hyperlipidemia [abstract no: MP147]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii482. [EMBASE: 617290474]KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial. Clinical &amp; Experimental Nephrology2020;24(5):420-6. [MEDLINE: 31875936]UeshimaK , KasaharaM , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2013;17(2):211-7. [MEDLINE: 22948416]">ASUCA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0041" title="NarayananRP , GittinsM , SiddalsKW , OliverRL , HudsonJE , WhiteA , et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability. European Journal of Endocrinology2013;168(4):543-8. [MEDLINE: 23333902]RutterMK , DaviesRR , CruickshankJK , PraisHR , GittinsM , RobertsC , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): trial results [abstract no: 1207]. Diabetologia2009;52(Suppl 1):S466. [EMBASE: 70068693]RutterMK , PraisHR , Charlton-MenysV , GittinsM , RobertsC , DaviesRR , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabetic Medicine2011;28(1):100-8. [MEDLINE: 21166851]SoranH , LiuY , AdamS , SiahmansurT , HoJH , SchofieldJD , et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. Journal of Clinical Lipidology2018;12(1):44-55. [MEDLINE: 29246729]">PANDA 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0023" title="IkedaH , UraY , NakayamaM . Rosuvastatin reduces urinary protein excretion in patients with chronic glomerulonephritis compared to the pravastatin use: a crossover trial [abstract no: SA-PO274]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):699A. ">Ikeda 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0005" title="IsaacsohnJL , DavidsonMH , HunninghakeD , SingerR , McLainR , BlackDM . Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology2000;86(2):250-2. [MEDLINE: 10913499]KorenMJ , DavidsonMH , WilsonDJ , FayyadRS , ZuckermanA , ReedDP , et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases2009;53(5):741-50. [MEDLINE: 19216014]KorenMJ , DavidsonMH . Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. KorenMJ , HunninghakeDB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology2004;44(9):1772-9. [MEDLINE: 15519006]MullinsCD , RattingerGB , KuznikA , KorenMJ . Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics2008;30 Pt 2:2204-16. [MEDLINE: 19281915]">ALLIANCE 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0012" title="ChaJJ , KimK , MinHS , GheeJ , KimYJ , LeeEY , et al. Effect of fluvastatin treatment on proteinuria in diabetic patients with chronic kidney disease [abstract no: TH-PO656]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):239a. [EMBASE: 641102077]">Cha 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0027" title="KimuraS , InoguchiT , YokomizoH , MaedaY , SonodaN , TakayanagiR . Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes, Obesity &amp; Metabolism2012;14(7):666-9. [MEDLINE: 22268518]">Kimura 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0006" title="Aranda ArcasJL , SanchezR , GuijarroC , AraqueA , PulidoF , PragaM , et al. Effect of pravastatin on hypercholesterolemia associated with proteinuria [Efecto de la pravastatina en la hipercolesterolemia asociada a proteinuria]. Anales de Medicina Interna1994;11(11):523-7. [MEDLINE: 7654898]">Aranda Arcas 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0033" title="Masajtis-ZagajewskaA , NowickiM . Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Renal Failure2018;40(1):700-9. [MEDLINE: 30741616]">Masajtis‐Zagajewska 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0007" title="GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract no: O86]. In: British Renal Society Conference; 2013 May 14-May 16; Manchester, UK. 2013. GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract]. In: Renal Association &amp; British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK. 2011:1043. GuptaA , ChangCL , CollierD , DahlofB , PoulterNR , SeverPS . The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the Ascot-Lipid-Lowering Arm (LLA) [abstract]. Atherosclerosis Supplements2011;12(1):158-9. [EMBASE: 70805024]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: 5A.1]. Journal of Human Hypertension2011;25(10):633-4. [EMBASE: 70537932]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: P1480]. European Heart Journal2011;32:220. [EMBASE: 70533871]LindgrenP , BuxtonM , KahanT , PoulterNR , DahlofB , SeverPS , et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention &amp; Rehabilitation2005;12(1):29-36. [MEDLINE: 15703503]SeverPS , ChangCL , GuptaAK , WhitehouseA , PoulterNR . The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European Heart Journal2011;32(20):2525-32. [MEDLINE: 21873710]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs2004;64 Suppl 2:43-60. [MEDLINE: 15765890]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361(9364):1149-58. [MEDLINE: 12686036]SeverPS , PoulterNR , DahlofB , WedelH , BeeversG , CaulfieldM , et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal2008;29(4):499-508. [MEDLINE: 18175773]SeverPS , PoulterNR , DahlofB , WedelH , CollinsR , BeeversG , et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care2005;28(5):1151-7. [MEDLINE: 15855581]SeverPS , PoulterNR , DahlofB , WedelH . Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension2009;27(5):947-54. [MEDLINE: 19318984]">ASCOT‐LLA 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0009" title="BianchiS , BigazziR , CaiazzaA , CampeseVM . A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193]. American Journal of Kidney Diseases2003;41(3):565-70. [MEDLINE: 12612979]">Bianchi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0049" title="DeedwaniaP , StonePH , Bairey MerzCN , Cosin-AguilarJ , KoylanN , LuoD , et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation2007;115(6):700-7. [MEDLINE: 17283260]DeedwaniaPC , StoneP , FayyadR , LaskeyR , WilsonDJ . Improvement in renal function with intensive statin therapy in older patients without increased muscle symptoms: the SAGE trial [abstract no: SA-PO2762]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):743A. DeedwaniaPC , StonePH , FayyadRS , LaskeyRE , WilsonDJ . Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs &amp; Aging2015;32(12):1055-65. [MEDLINE: 26625880]DeedwaniaPC . Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American Heart Journal2004;148(6):1053-9. [MEDLINE: 15632893]">SAGE 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0010" title="BuemiM , AllegraA , CoricaF , AloisiC , GiacobbeM , PettinatoG , et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clinical Pharmacology &amp; Therapeutics2000;67(4):427-31. [MEDLINE: 10801253]">Buemi 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0062" title="YiYJ , KimHJ , JoSK , KimSG , SongYR , ChungW , et al. Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. Clinical Therapeutics2014;36(8):1182-90. [MEDLINE: 24996489]">Yi 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0013" title="Di LulloL , AddesseR , ComegnaC , FirmiG , GalderisiC , IannacciGR , et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Advances in Therapy2005;22(6):601-12. [MEDLINE: 16510377]Di LulloL , PolitoP . Effects of fluvastatin treatment on lipid profile, inflammatory status and renal function in dyslipidemic patients with chronic renal failure [abstract no: S-PO-0543]. In: 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:195. ">Di Lullo 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0014" title="DummerCD , Thome'FS , ZinganoB , LindosoA , VeroneseFV . Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. Journal of Nephrology2008;21(6):900-8. [MEDLINE: 19034875]">Dummer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0015" title="RemuzziG . Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual RAS blockade: esplanade trial [abstract no: F-PO1221]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):389A. RuggenentiP , PernaA , TonelliM , LorigaG , MotterliniN , RubisN , et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE Trial. Clinical Journal of the American Society of Nephrology: CJASN2010;5(11):1928-38. [MEDLINE: 20671225]">ESPLANADE 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0016" title="FassettRG , CoombesJS , PackhamD , FairleyKF , Kincaid-SmithP . Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology &amp; Nephrology2010;44(1):56-61. [MEDLINE: 20034362]">Fassett 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0017" title="FriedLF , ForrestKY , EllisD , ChangY , SilversN , OrchardTJ . Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. Journal of Diabetes &amp; its Complications2001;15(3):113-9. [MEDLINE: 11358679]">Fried 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0018" title="GheithO , SaadM , SobhM . Nephrotic dyslipidemia, harvest of treatment [abstract no: MP085]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:258. [CENTRAL: CN-00509210] GheithO , SobhM , GazarenS , AhmedH , El BazM . Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no: M182]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. [CENTRAL: CN-00520338] GheithOA , SobhMA , Mohamed Kel-E, El-BazM , El-HusseiniF , GazarinSS , et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612-9. [MEDLINE: 12138263]">Gheith 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0019" title="GoicoecheaM , deVinuesaSG , LaheraV , CachofeiroV , Gomez-CampderaF , VegaA , et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology2006;17(12 Suppl 3):S231-5. [MEDLINE: 17130267]">Goicoechea 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0020" title="HommelE , AndersenP , GallMA , NielsenF , JensenB , RossingP , et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia1992;35(5):447-51. [MEDLINE: 1521727]">Hommel 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0024" title="ImaiY , SuzukiH , SaitoT , TsujiI , AbeK , SarutaT . The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clinical &amp; Experimental Hypertension (New York)1999;21(8):1345-55. [MEDLINE: 10574417]">Imai 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0028" title="LamKS , ChengIK , JanusED , PangRW . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1995;38(5):604-9. [MEDLINE: 7489845]ParvingHH . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1996;39(3):367-8. [MEDLINE: 8721786]">Lam 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0029" title="LeeTM , LinMS , TsaiCH , ChangNC . Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney International2005;68(2):779-87. [MEDLINE: 16014056]LeeTM , SuSF , TsaiCH . Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension2002;40(1):67-73. [MEDLINE: 12105140]">Lee 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0030" title="LintottCJ , ScottRS , BremerJM , ShandBI . Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. American Journal of Cardiology1995;76(2):97-101A. [MEDLINE: 7604809]">Lintott 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0031" title="ArampatzisCA , GoedhartD , SerruysPW , SaiaF , LemosPA , deFeyterP . Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal2005;149(2):329-35. [MEDLINE: 15846273]LemosPA , SerruysPW , deFeyterP , MercadoNF , GoedhartD , SaiaF , et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology2005;95(4):445-51. [MEDLINE: 15695126]SerruysPW , De FeyterPJ , BenghoziR , HugenholtzPG , LesaffreE . The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions2001;4(4):165-72. [PMID: 12036459]SerruysPW , deFeyterP , MacayaC , KokottN , PuelJ , VrolixM , et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002;287(24):3215-22. [MEDLINE: 12076217]">LIPS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0032" title="FassettR , RobertsonI , BallM , GeraghtyD , SharmanJ , CoombesJ . A randomised trial assessing the effects of atorvastatin on arterial stiffness in chronic kidney disease [abstract no: SU193]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912394] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Atorvastatin and the progression of chronic kidney disease: the LORD Trial [abstract no: F-PO1919]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN-00773725] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Baseline serum lipids and renal function in chronic kidney disease patients entering the LORD trial. International Journal of Clinical Pharmacology &amp; Therapeutics2006;44(11):580-8. [MEDLINE: 17176625]FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrology2008;9:4. [MEDLINE: 18366658]FassettRG , CoombesJS , PurseLM , WattsM , ChuggKL , GeraghtyDP . Enrolment in a clinical trial improves renal function [abstract no: SU-PO1057]. Journal of the American Society of Nephrology2003;14(Nov):768A. [CENTRAL: CN-00583896] FassettRG , OliverK , SummersMJ , SmithM , AndersonLM , CoombesJS . Lipid lowering therapy and cognitive function in patients with chronic kidney disease [abstract no: PUB623]. Journal of the American Society of Nephrology2005;16:917A. [CENTRAL: CN-00636136] FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Atorvastatin slows the progression of chronic kidney disease in patients with inflammation [abstract no: TH-PO204]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):158A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with kidney function in CKD patients [abstract no: FR-PO1383]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):432A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with quality of life in CKD patients [abstract no: SA-PO2441]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):680A. FassettRG , RobertsonI , HealyHG , GeraghtyDP , BallMJ , CardinalJW , et al. Effect of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post-hoc analysis of the LORD trial [abstract no: SA-PO2320]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):641A. FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CardinalJW , CoombesJS . Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrology Dialysis Transplantation2012;27(1):182-9. [MEDLINE: 21543653]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis2010;213(1):218-24. [MEDLINE: 20810109]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clinical Nephrology2014;81(2):75-85. [MEDLINE: 24321183]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , SharmanJE , CoombesJS . Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. Journal of Atherosclerosis &amp; Thrombosis2010;17(3):235-41. [MEDLINE: 20032570]FassettRG , RobertsonIK , BallMJ , GeraghtyDP . Atorvastatin slows the progression of CKD in patients with inflammation [abstract no: 066]. Nephrology2011;16(Suppl 1):40-1. [EMBASE: 70532414]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , BurtonNW , CoombesJS . Physical activity levels in patients with chronic kidney disease entering the LORD trial. Medicine &amp; Science in Sports &amp; Exercise2009;41(5):985-91. [MEDLINE: 19346990]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , CoombesJS . Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting. Journal of Renal Nutrition2007;17(4):235-42. [MEDLINE: 17586421]FassettRG , SwansonCE , SharmaS , WhiteA , SinghG . Atorvastatin improves kidney function in chronic kidney disease patients undertaking high intensity exercise [abstract no: 067]. Nephrology2011;16(Suppl 1):41. [PMID: 70532415]SummersMJ , OliverKR , CoombesJS , FassettRG . Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy: The Journal of Human Pharmacology &amp; Drug Therapy2007;27(2):183-90. [MEDLINE: 17253908]">LORD 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0035" title="MoriY , TsuruokaA . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Journal of the Japan Diabetes Society1992;35(3):265-8. [EMBASE: 22147775]MoriY , YokoyamaJ , TsuruokaA , IkedaY . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - a randomized control study. Jikeikai Medical Journal1992;39(4):341-8. [EMBASE: 23068032]">Mori 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0036" title="NakamuraT , UshiyamaC , HirokawaK , OsadaS , InoueT , ShimadaN , et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrology Dialysis Transplantation2002;17(5):798-802. [MEDLINE: 11981066]">Nakamura 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0037" title="NakamuraT , SugayaT , KawagoeY , UedaY , OsadaS , KoideH . Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care2005;28(11):2728-32. [MEDLINE: 16249547]">Nakamura 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0038" title="NakamuraT , SugayaT , KawagoeY , SuzukiT , InoueT , NodeK . Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. American Journal of Nephrology2006;26(1):82-6. [MEDLINE: 16534182]">Nakamura 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0039" title="NellemannB , GormsenLC , DollerupJ , SchmitzO , MogensenCE , RasmussenLM , et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care2007;30(12):3122-4. [MEDLINE: 17804683]NielsenS , SchmitzO , MollerN , PorksenN , KlausenIC , AlbertiKG , et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia1993;36(10):1079-86. [MEDLINE: 8243858]">Nielsen 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0042" title="PanichiV , MantuanoE , PaolettiS , SantiS , Manca RizzaG , CutrupiS , et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. Journal of Nephrology2008;21(1):38-44. [MEDLINE: 18264935]PanichiV , PaolettiS , Manca-RizzaG , TaccolaD , InnocentiM , CastoG , et al. Effect of simvastatin therapy on inflammatory markers and lipids in pre-dialysis patients [abstract no: SP167]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v75. [CENTRAL: CN-00678037] PanichiV , PaolettiS , MantuanoE , Manca-RizzaG , FilippiC , SantiS , et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrology Dialysis Transplantation2006;21(2):337-44. [MEDLINE: 16249194]">Panichi 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0046" title="AsselbergsFW , DiercksGF , HillegeHL , vanBovenAJ , JanssenWM , VoorsAA , et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004;110(18):2809-16. [MEDLINE: 15492322]AsselbergsFW , vanRoonAM , HillegeHL , deJongPE , GansRO , SmitAJ , et al. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke2005;36(3):649-53. [MEDLINE: 15692120]AsselbergsFW , van derHarstP , vanRoonAM , HillegeHL , deJongPE , GansRO , et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis2008;196(1):349-55. [MEDLINE: 17141245]AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]. Journal of the American Society of Nephrology2005;16:36A. [CENTRAL: CN-00583782] AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics2006;28(3):432-44. [MEDLINE: 16750458]AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]. Journal of the American Society of Nephrology2005;16:71A. [CENTRAL: CN-00583784] AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation2006;21(11):3106-14. [MEDLINE: 16720593]BelloAK , deZeeuwD , El NahasM , BrantsmaAH , BakkerSJ , deJongPE , et al. Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation2007;22(6):1619-27. [MEDLINE: 17360767]BrouwersFP , AsselbergsFW , HillegeHL , deBoerRA , GansevoortRT , vanVeldhuisenDJ , et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). American Heart Journal2011;161(6):1171-8. [MEDLINE: 21641365]De JongMA , EisengaMF , vanBallegooijenAJ , BeulensJW , VervloetMG , NavisG , et al. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrology Dialysis Transplantation2021;36(1):121-8. [MEDLINE: 32124925]DiercksGF , JanssenWM , vanBovenAJ , BakAA , deJongPE , CrijnsHJ , et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology2000;86(6):635-8. [MEDLINE: 10980214]GelukCA , AsselbergsFW , HillegeHL , BakkerSJ , deJongPE , ZijlstraF , et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal2005;26(13):1314-20. [MEDLINE: 15820998]PouwelsKB , VisserST , HakE . Effect of pravastatin and fosinopril on recurrent urinary tract infections. Journal of Antimicrobial Chemotherapy2013;68(3):708-14. [MEDLINE: 23111852]vande WalRM , GansevoortRT , van derHarstP , BoomsmaF , Thijs PlokkerHW , vanVeldhuisenDJ , et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension2006;48(5):870-6. [MEDLINE: 17000930]vande WalRM , van derHarstP , GerritsenWB , van derHorstF , PlokkerTH , GansevoortRT , et al. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):177-80. [MEDLINE: 18205096]van derHarstP , AsselbergsFW , HillegeHL , VoorsAA , vanVeldhuisenDJ , vanGilstWH . Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. American Journal of Cardiology2008;102(2):223-5. [MEDLINE: 18602526]">PREVEND IT 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0047" title="RaynerB , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin and diet versus diet alone in patients with idiopathic membranous nephropathy: a preliminary report [abstract]. Kidney International1993;43:1183. RaynerBL , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin (sv) and diet versus diet alone in patients with idiopathic membranous nephropathy (IMN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:76. RaynerBL , ByrneM , vanZyl-SmitR . Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN) [abstract]. Nephrology Dialysis Transplantation1994;9(7):963. [CENTRAL: CN-00261011] RaynerBL , ByrneMJ , vanZyl SmitR . A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clinical Nephrology1996;46(4):219-24. [MEDLINE: 8905205]">Rayner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0048" title="RenkeM , TylickiL , RutkowskiP , NeuweltA , LarczynskiW , ZietkiewiczM , et al. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochimica Polonica2010;57(4):547-52. [MEDLINE: 21079818]">Renke 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0050" title="AlaupovicP , AttmanPO , Knight-GibsonC , MulecH , WeissL , SamuelssonO . Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney International2006;69(10):1865-71. [MEDLINE: 16572113]SamuelssonO , AttmanPO , Knight-GibsonC , MulecH , WeissL , AlaupovicP . Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. American Journal of Kidney Diseases2002;39(1):67-75. [MEDLINE: 11774104]">Samuelsson 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0051" title="SawaraY , TakeiT , UchidaK , OgawaT , YoshidaT , TsuchiyaK , et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Internal Medicine2008;47(17):1505-10. [MEDLINE: 18758125]SawaraY , TakeiT , UchidaK , TsuchiyaK , NittaK . Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease [abstract no: SA166]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912388] ">Sawara 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0052" title="ScanferlaF , ToffolettoPP , RoncaliD , BazzatoG . Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension1991;4(10 Pt 1):868-74. [MEDLINE: 1747221]">Scanferla 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0054" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503-10. [MEDLINE: 16303728]StegmayrBG , BrannstromM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489-97. [MEDLINE: 18161210]StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. In: 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. [CENTRAL: CN-00447842] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. [CENTRAL: CN-00583406] ">Stegmayr 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0055" title="ThomasME , HarrisKP , RamaswamyC , HattersleyJM , WheelerDC , VargheseZ , et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International1993;44(5):1124-9. [MEDLINE: 8264145]">Thomas 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0057" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Beneficial effects of pitavastatin on albuminuria and renal function in essential hypertensive patients with chronic kidney disease [abstract no: TH-PO875]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):307A. [CENTRAL: CN-00773767] ">Tokunaga 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0058" title="TonoloG , CiccareseM , BrizziP , PudduL , SecchiG , CalviaP , et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care1997;20(12):1891-5. [MEDLINE: 9405913]">Tonolo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0059" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0060" title="VermaA , GordonN , RangannaKM , ReddyRS , VermaM . Rosuvastatin reduces high sensitivity-C reactive protein and the decline in renal function in hyperlipidemic patients with chronic kidney disease [abstract no: SA-PO134]. Journal of the American Society of Nephrology2004;15(Oct):329A. [CENTRAL: CN-00583418] VermaA , RangannaKM , ReddyRS , VermaM , GordonNF . Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. American Journal of Cardiology2005;96(9):1290-2. [MEDLINE: 16253600]">Verma 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0061" title="YasudaG , KujiT , HasegawaK , OgawaN , ShimuraG , AndoD , et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Renal Failure2004;26(4):411-8. [MEDLINE: 15462110]">Yasuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0063" title="ZhangA , VertommenJ , Van GaalL , De LeeuwI . Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Research &amp; Clinical Practice1995;29(3):189-94. [MEDLINE: 8591712]">Zhang 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <section id="CD007784-sec-0050"> <h5 class="title">2023 review update</h5> <p>For this update, we searched the Cochrane Kidney and Transplant Register of Studies (4 October 2023) and identified 134 new reports. Thirteen new studies (22 reports) were included, 20 (50 reports) were excluded, and one ongoing study was identified. One new study is awaiting classification (recently completed; no data available). We also identified 61 new reports of existing included studies and studies awaiting classification. </p> <p>We reassessed and reclassified seven ongoing studies: three studies have been included (<a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a>; <a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a>; <a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a>); four studies were excluded (<a href="./references#CD007784-bbs2-0077" title="MoseFH , LarsenT , JensenJM , BechJN , PedersenE . Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes [abstract no: TH-PO447]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):204A. MoseFH , LarsenT , JensenJM , HansenAB , BechJN , PedersenEB . Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes. Scandinavian Journal of Clinical &amp; Laboratory Investigation2014;74(1):8-19. [MEDLINE: 24256611]">Mose 2014a</a>; <a href="./references#CD007784-bbs2-0078" title="LarsenT , JensenJ , BechJ , PedersenE , MoseF . Effect of atorvastatin on renal NO availability and tubular function in patients with non-diabetic, stage II-III chronic kidney disease [abstract no: MP219]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i367. [EMBASE: 71076128]MoseFH , LarsenT , JensenJM , BechJN , PedersenE . Increased NO activity during statin treatment in patients with non-diabetic nephropathy [abstract no: SA-PO169]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):673A. MoseFH , LarsenT , JensenJM , HansenAB , BechJN , PedersenEB . Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease. British Journal of Clinical Pharmacology2014;78(4):789-99. [MEDLINE: 24697877]">Mose 2014b</a>; <a href="./references#CD007784-bbs2-0091" title="WeinsteinDL , WilliamsLA , CarlsonDM , KellyMT , BurnsKM , SetzeCM , et al. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease [Erratum appears in Clin Ther. 2013 Nov;35(11):1862]. Clinical Therapeutics2013;35(8):1186-98. [MEDLINE: 23891363]">Weinstein 2013</a>; <a href="./references#CD007784-bbs2-0095" title="ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. Amino Acids2012;43(4):1499-507. [MEDLINE: 22278741]ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism &amp; Cardiovascular Diseases2015;25(2):153-9. [MEDLINE: 25534866]ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383-8. [MEDLINE: 27454090]ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117-23. [MEDLINE: 22659373]ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition Metabolism &amp; Cardiovascular Diseases2017;27(9):822-9. [MEDLINE: 28755807]">Zinellu 2012</a>); and one study has been moved to awaiting classification as no data have been published (<a href="./references#CD007784-bbs2-0096" title="AgharaziiM . The renal protective effects of low-dose and high-dose atorvastatin in patients with glomerular disease and proteinuria: a randomized controlled double blinded study. clinicaltrials gov/ct2/show/NCT00768638 (first received 8 October 2008). ">NCT00768638</a>). Eighteen previously excluded studies were deleted because they were not randomised (4), enrolled the wrong population (4), or did not use statins (10). </p> <p>A total of 63 studies were included (336 reports, 50,725 randomised participants), 32 were excluded, two are awaiting classification, and there is one ongoing study (<a href="#CD007784-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007784-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram showing study selection" data-id="CD007784-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram showing study selection</p> </div> </div> </div> </section> </section> <section id="CD007784-sec-0051"> <h4 class="title">Included studies</h4> <p>Details are provided in <a href="#CD007784-sec-0051">Included studies</a>. </p> <p>Fifty‐three studies (42,752 randomised participants) compared statin therapy to placebo or no treatment. Nine studies compared high to low‐dose statin (7851 randomised participants), and one study (122 randomised participants) compared continuous‐release versus intermittent‐release statin. Of the 63 included studies, 11 studies provided post hoc data for subgroups of 31,315 adults with CKD within larger studies that compared statins with placebo or no treatment (<a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a>; <a href="./references#CD007784-bbs2-0004" title="ClearfieldM , DownsJR , WeisS , WhitneyEJ , KruyerW , ShapiroDR , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health &amp; Gender-Based Medicine2001;10(10):971-81. [MEDLINE: 11788107]ClearfieldM , WhitneyEJ , WeisS , DownsJR , ShapiroDR , SteinEA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk2000;7(2):125-33. [MEDLINE: 10879416]ClearfieldMB , WeisSE , WillisJM , VaseniusKA , McConathyWJ . Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association2002;102(7):377-84. [MEDLINE: 12138952]CuiY , WatsonDJ , GirmanCJ , ShapiroDR , GottoAM , HiseroteP , et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology2009;104(6):829-34. [MEDLINE: 19733719]DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287-93. [MEDLINE: 9264420]DownsJR , ClearfieldM , TyrolerHA , WhitneyEJ , KruyerW , LangendorferA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology2001;87(9):1074-9. [MEDLINE: 11348605]DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22. [MEDLINE: 9613910]Gotto AM Jr, BoccuzziSJ , CookJR , AlexanderCM , RoehmJB , MeyerGS , et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology2000;86(11):1176-81. [MEDLINE: 11090787]KendrickJ , ShlipakMG , TargherG , CookT , LindenfeldJ , ChoncholM . Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases2010;55(1):42-9. [MEDLINE: 19932541]">AFCAPS/TexCAPS 1997</a>; <a href="./references#CD007784-bbs2-0005" title="IsaacsohnJL , DavidsonMH , HunninghakeD , SingerR , McLainR , BlackDM . Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology2000;86(2):250-2. [MEDLINE: 10913499]KorenMJ , DavidsonMH , WilsonDJ , FayyadRS , ZuckermanA , ReedDP , et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases2009;53(5):741-50. [MEDLINE: 19216014]KorenMJ , DavidsonMH . Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. KorenMJ , HunninghakeDB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology2004;44(9):1772-9. [MEDLINE: 15519006]MullinsCD , RattingerGB , KuznikA , KorenMJ . Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics2008;30 Pt 2:2204-16. [MEDLINE: 19281915]">ALLIANCE 2000</a>; <a href="./references#CD007784-bbs2-0007" title="GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract no: O86]. In: British Renal Society Conference; 2013 May 14-May 16; Manchester, UK. 2013. GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract]. In: Renal Association &amp; British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK. 2011:1043. GuptaA , ChangCL , CollierD , DahlofB , PoulterNR , SeverPS . The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the Ascot-Lipid-Lowering Arm (LLA) [abstract]. Atherosclerosis Supplements2011;12(1):158-9. [EMBASE: 70805024]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: 5A.1]. Journal of Human Hypertension2011;25(10):633-4. [EMBASE: 70537932]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: P1480]. European Heart Journal2011;32:220. [EMBASE: 70533871]LindgrenP , BuxtonM , KahanT , PoulterNR , DahlofB , SeverPS , et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention &amp; Rehabilitation2005;12(1):29-36. [MEDLINE: 15703503]SeverPS , ChangCL , GuptaAK , WhitehouseA , PoulterNR . The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European Heart Journal2011;32(20):2525-32. [MEDLINE: 21873710]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs2004;64 Suppl 2:43-60. [MEDLINE: 15765890]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361(9364):1149-58. [MEDLINE: 12686036]SeverPS , PoulterNR , DahlofB , WedelH , BeeversG , CaulfieldM , et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal2008;29(4):499-508. [MEDLINE: 18175773]SeverPS , PoulterNR , DahlofB , WedelH , CollinsR , BeeversG , et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care2005;28(5):1151-7. [MEDLINE: 15855581]SeverPS , PoulterNR , DahlofB , WedelH . Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension2009;27(5):947-54. [MEDLINE: 19318984]">ASCOT‐LLA 2003</a>; <a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a>; <a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a>; <a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a>; <a href="./references#CD007784-bbs2-0031" title="ArampatzisCA , GoedhartD , SerruysPW , SaiaF , LemosPA , deFeyterP . Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal2005;149(2):329-35. [MEDLINE: 15846273]LemosPA , SerruysPW , deFeyterP , MercadoNF , GoedhartD , SaiaF , et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology2005;95(4):445-51. [MEDLINE: 15695126]SerruysPW , De FeyterPJ , BenghoziR , HugenholtzPG , LesaffreE . The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions2001;4(4):165-72. [PMID: 12036459]SerruysPW , deFeyterP , MacayaC , KokottN , PuelJ , VrolixM , et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002;287(24):3215-22. [MEDLINE: 12076217]">LIPS 2001</a>; <a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a>; <a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a>; <a href="./references#CD007784-bbs2-0049" title="DeedwaniaP , StonePH , Bairey MerzCN , Cosin-AguilarJ , KoylanN , LuoD , et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation2007;115(6):700-7. [MEDLINE: 17283260]DeedwaniaPC , StoneP , FayyadR , LaskeyR , WilsonDJ . Improvement in renal function with intensive statin therapy in older patients without increased muscle symptoms: the SAGE trial [abstract no: SA-PO2762]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):743A. DeedwaniaPC , StonePH , FayyadRS , LaskeyRE , WilsonDJ . Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs &amp; Aging2015;32(12):1055-65. [MEDLINE: 26625880]DeedwaniaPC . Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American Heart Journal2004;148(6):1053-9. [MEDLINE: 15632893]">SAGE 2004</a>). Two comparisons provided post hoc data for 5428 adults comparing two statin regimens (<a href="./references#CD007784-bbs2-0022" title="HolmeI , CaterNB , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine2008;40(6):456-64. [MEDLINE: 19160529]HolmeI , FayyadR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine2010;267(6):567-75. [MEDLINE: 20141566]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology2004;94(6):720-4. [MEDLINE: 15374773]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum appears in JAMA. 2005 Dec 28;294(24):3092]. JAMA2005;294(19):2437-45. [MEDLINE: 16287954]">IDEAL 2004</a>; <a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a>). Overall, 43 studies (41,273 participants) contributed to the meta‐analyses. </p> <section id="CD007784-sec-0052"> <h5 class="title">Statin versus placebo or no treatment</h5> <p>Studies varied in sample size (median 55 participants; range 14 to 3107 participants). Seven comparisons that included more than 1000 participants (<a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a>; <a href="./references#CD007784-bbs2-0007" title="GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract no: O86]. In: British Renal Society Conference; 2013 May 14-May 16; Manchester, UK. 2013. GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract]. In: Renal Association &amp; British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK. 2011:1043. GuptaA , ChangCL , CollierD , DahlofB , PoulterNR , SeverPS . The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the Ascot-Lipid-Lowering Arm (LLA) [abstract]. Atherosclerosis Supplements2011;12(1):158-9. [EMBASE: 70805024]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: 5A.1]. Journal of Human Hypertension2011;25(10):633-4. [EMBASE: 70537932]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: P1480]. European Heart Journal2011;32:220. [EMBASE: 70533871]LindgrenP , BuxtonM , KahanT , PoulterNR , DahlofB , SeverPS , et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention &amp; Rehabilitation2005;12(1):29-36. [MEDLINE: 15703503]SeverPS , ChangCL , GuptaAK , WhitehouseA , PoulterNR . The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European Heart Journal2011;32(20):2525-32. [MEDLINE: 21873710]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs2004;64 Suppl 2:43-60. [MEDLINE: 15765890]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361(9364):1149-58. [MEDLINE: 12686036]SeverPS , PoulterNR , DahlofB , WedelH , BeeversG , CaulfieldM , et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal2008;29(4):499-508. [MEDLINE: 18175773]SeverPS , PoulterNR , DahlofB , WedelH , CollinsR , BeeversG , et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care2005;28(5):1151-7. [MEDLINE: 15855581]SeverPS , PoulterNR , DahlofB , WedelH . Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension2009;27(5):947-54. [MEDLINE: 19318984]">ASCOT‐LLA 2003</a>; <a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a>; <a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a>; <a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a>; <a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a>; <a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a>). </p> <p>The median statin dose (equivalent to simvastatin) was 20 mg (range 5 to 80 mg/day). Twelve studies used simvastatin, 10 studies used atorvastatin, nine studies used pravastatin, nine studies used fluvastatin, four studies used pitavastatin, four studies used rosuvastatin, two studies used lovastatin, one study used cerivastatin, one study used simvastatin with ezetimibe (<a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a>). One study used simvastatin or pravastatin (<a href="./references#CD007784-bbs2-0052" title="ScanferlaF , ToffolettoPP , RoncaliD , BazzatoG . Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension1991;4(10 Pt 1):868-74. [MEDLINE: 1747221]">Scanferla 1991</a>) (<a href="#CD007784-tbl-0003">Table 2</a>). </p> <div class="table" id="CD007784-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies classified by type of statin therapy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Atorvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cerviastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fluvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lovastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pitavastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pravastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rosuvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Simvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Simvastatin and ezetimibe (dose)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0005" title="IsaacsohnJL , DavidsonMH , HunninghakeD , SingerR , McLainR , BlackDM . Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology2000;86(2):250-2. [MEDLINE: 10913499]KorenMJ , DavidsonMH , WilsonDJ , FayyadRS , ZuckermanA , ReedDP , et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases2009;53(5):741-50. [MEDLINE: 19216014]KorenMJ , DavidsonMH . Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. KorenMJ , HunninghakeDB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology2004;44(9):1772-9. [MEDLINE: 15519006]MullinsCD , RattingerGB , KuznikA , KorenMJ . Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics2008;30 Pt 2:2204-16. [MEDLINE: 19281915]">ALLIANCE 2000</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0036" title="NakamuraT , UshiyamaC , HirokawaK , OsadaS , InoueT , ShimadaN , et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrology Dialysis Transplantation2002;17(5):798-802. [MEDLINE: 11981066]">Nakamura 2002</a> (0.15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0010" title="BuemiM , AllegraA , CoricaF , AloisiC , GiacobbeM , PettinatoG , et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clinical Pharmacology &amp; Therapeutics2000;67(4):427-31. [MEDLINE: 10801253]">Buemi 2000</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0004" title="ClearfieldM , DownsJR , WeisS , WhitneyEJ , KruyerW , ShapiroDR , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health &amp; Gender-Based Medicine2001;10(10):971-81. [MEDLINE: 11788107]ClearfieldM , WhitneyEJ , WeisS , DownsJR , ShapiroDR , SteinEA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk2000;7(2):125-33. [MEDLINE: 10879416]ClearfieldMB , WeisSE , WillisJM , VaseniusKA , McConathyWJ . Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association2002;102(7):377-84. [MEDLINE: 12138952]CuiY , WatsonDJ , GirmanCJ , ShapiroDR , GottoAM , HiseroteP , et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology2009;104(6):829-34. [MEDLINE: 19733719]DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287-93. [MEDLINE: 9264420]DownsJR , ClearfieldM , TyrolerHA , WhitneyEJ , KruyerW , LangendorferA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology2001;87(9):1074-9. [MEDLINE: 11348605]DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22. [MEDLINE: 9613910]Gotto AM Jr, BoccuzziSJ , CookJR , AlexanderCM , RoehmJB , MeyerGS , et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology2000;86(11):1176-81. [MEDLINE: 11090787]KendrickJ , ShlipakMG , TargherG , CookT , LindenfeldJ , ChoncholM . Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases2010;55(1):42-9. [MEDLINE: 19932541]">AFCAPS/TexCAPS 1997</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0037" title="NakamuraT , SugayaT , KawagoeY , UedaY , OsadaS , KoideH . Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care2005;28(11):2728-32. [MEDLINE: 16249547]">Nakamura 2005</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0006" title="Aranda ArcasJL , SanchezR , GuijarroC , AraqueA , PulidoF , PragaM , et al. Effect of pravastatin on hypercholesterolemia associated with proteinuria [Efecto de la pravastatina en la hipercolesterolemia asociada a proteinuria]. Anales de Medicina Interna1994;11(11):523-7. [MEDLINE: 7654898]">Aranda Arcas 1994</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0002" title="AbeM , MaruyamaN , OkadaK , MatsumotoS , MatsumotoK , SomaM . Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Journal of Atherosclerosis &amp; Thrombosis2011;18(11):1018-28. [MEDLINE: 21921413]">Abe 2011c</a> (5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> (20 mg/d and 10 mg/d) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0007" title="GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract no: O86]. In: British Renal Society Conference; 2013 May 14-May 16; Manchester, UK. 2013. GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract]. In: Renal Association &amp; British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK. 2011:1043. GuptaA , ChangCL , CollierD , DahlofB , PoulterNR , SeverPS . The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the Ascot-Lipid-Lowering Arm (LLA) [abstract]. Atherosclerosis Supplements2011;12(1):158-9. [EMBASE: 70805024]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: 5A.1]. Journal of Human Hypertension2011;25(10):633-4. [EMBASE: 70537932]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: P1480]. European Heart Journal2011;32:220. [EMBASE: 70533871]LindgrenP , BuxtonM , KahanT , PoulterNR , DahlofB , SeverPS , et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention &amp; Rehabilitation2005;12(1):29-36. [MEDLINE: 15703503]SeverPS , ChangCL , GuptaAK , WhitehouseA , PoulterNR . The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European Heart Journal2011;32(20):2525-32. [MEDLINE: 21873710]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs2004;64 Suppl 2:43-60. [MEDLINE: 15765890]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361(9364):1149-58. [MEDLINE: 12686036]SeverPS , PoulterNR , DahlofB , WedelH , BeeversG , CaulfieldM , et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal2008;29(4):499-508. [MEDLINE: 18175773]SeverPS , PoulterNR , DahlofB , WedelH , CollinsR , BeeversG , et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care2005;28(5):1151-7. [MEDLINE: 15855581]SeverPS , PoulterNR , DahlofB , WedelH . Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension2009;27(5):947-54. [MEDLINE: 19318984]">ASCOT‐LLA 2003</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0012" title="ChaJJ , KimK , MinHS , GheeJ , KimYJ , LeeEY , et al. Effect of fluvastatin treatment on proteinuria in diabetic patients with chronic kidney disease [abstract no: TH-PO656]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):239a. [EMBASE: 641102077]">Cha 2015</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0028" title="LamKS , ChengIK , JanusED , PangRW . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1995;38(5):604-9. [MEDLINE: 7489845]ParvingHH . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1996;39(3):367-8. [MEDLINE: 8721786]">Lam 1995</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0038" title="NakamuraT , SugayaT , KawagoeY , SuzukiT , InoueT , NodeK . Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. American Journal of Nephrology2006;26(1):82-6. [MEDLINE: 16534182]">Nakamura 2006</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0008" title="KasaharaM , UeshimaK , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: design of the ASsessment of clinial usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: FR-PO194]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):413A. KimuraG , KasaharaM , UeshimaK , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2017;21(3):417-24. [MEDLINE: 27392909]KimuraG , UeshimaK , KashaharaM , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: ASsessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: SA-O1086]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):5B. KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between the control of LDL-cholesterol level and renal function in CKD patients with hyperlipidemia [abstract no: MP147]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii482. [EMBASE: 617290474]KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial. Clinical &amp; Experimental Nephrology2020;24(5):420-6. [MEDLINE: 31875936]UeshimaK , KasaharaM , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2013;17(2):211-7. [MEDLINE: 22948416]">ASUCA 2013</a> (mean 12.5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0014" title="DummerCD , Thome'FS , ZinganoB , LindosoA , VeroneseFV . Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. Journal of Nephrology2008;21(6):900-8. [MEDLINE: 19034875]">Dummer 2008</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0009" title="BianchiS , BigazziR , CaiazzaA , CampeseVM . A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193]. American Journal of Kidney Diseases2003;41(3):565-70. [MEDLINE: 12612979]">Bianchi 2003</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0013" title="Di LulloL , AddesseR , ComegnaC , FirmiG , GalderisiC , IannacciGR , et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Advances in Therapy2005;22(6):601-12. [MEDLINE: 16510377]Di LulloL , PolitoP . Effects of fluvastatin treatment on lipid profile, inflammatory status and renal function in dyslipidemic patients with chronic renal failure [abstract no: S-PO-0543]. In: 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:195. ">Di Lullo 2005</a> (80 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0024" title="ImaiY , SuzukiH , SaitoT , TsujiI , AbeK , SarutaT . The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clinical &amp; Experimental Hypertension (New York)1999;21(8):1345-55. [MEDLINE: 10574417]">Imai 1999</a> (mean 7.5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0051" title="SawaraY , TakeiT , UchidaK , OgawaT , YoshidaT , TsuchiyaK , et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Internal Medicine2008;47(17):1505-10. [MEDLINE: 18758125]SawaraY , TakeiT , UchidaK , TsuchiyaK , NittaK . Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease [abstract no: SA166]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912388] ">Sawara 2008</a> (2.5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0016" title="FassettRG , CoombesJS , PackhamD , FairleyKF , Kincaid-SmithP . Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology &amp; Nephrology2010;44(1):56-61. [MEDLINE: 20034362]">Fassett 2010</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0015" title="RemuzziG . Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual RAS blockade: esplanade trial [abstract no: F-PO1221]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):389A. RuggenentiP , PernaA , TonelliM , LorigaG , MotterliniN , RubisN , et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE Trial. Clinical Journal of the American Society of Nephrology: CJASN2010;5(11):1928-38. [MEDLINE: 20671225]">ESPLANADE 2010</a> (80 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0057" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Beneficial effects of pitavastatin on albuminuria and renal function in essential hypertensive patients with chronic kidney disease [abstract no: TH-PO875]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):307A. [CENTRAL: CN-00773767] ">Tokunaga 2008</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0029" title="LeeTM , LinMS , TsaiCH , ChangNC . Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney International2005;68(2):779-87. [MEDLINE: 16014056]LeeTM , SuSF , TsaiCH . Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension2002;40(1):67-73. [MEDLINE: 12105140]">Lee 2002</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0060" title="VermaA , GordonN , RangannaKM , ReddyRS , VermaM . Rosuvastatin reduces high sensitivity-C reactive protein and the decline in renal function in hyperlipidemic patients with chronic kidney disease [abstract no: SA-PO134]. Journal of the American Society of Nephrology2004;15(Oct):329A. [CENTRAL: CN-00583418] VermaA , RangannaKM , ReddyRS , VermaM , GordonNF . Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. American Journal of Cardiology2005;96(9):1290-2. [MEDLINE: 16253600]">Verma 2005</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0017" title="FriedLF , ForrestKY , EllisD , ChangY , SilversN , OrchardTJ . Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. Journal of Diabetes &amp; its Complications2001;15(3):113-9. [MEDLINE: 11358679]">Fried 2001</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0019" title="GoicoecheaM , deVinuesaSG , LaheraV , CachofeiroV , Gomez-CampderaF , VegaA , et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology2006;17(12 Suppl 3):S231-5. [MEDLINE: 17130267]">Goicoechea 2006</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0018" title="GheithO , SaadM , SobhM . Nephrotic dyslipidemia, harvest of treatment [abstract no: MP085]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:258. [CENTRAL: CN-00509210] GheithO , SobhM , GazarenS , AhmedH , El BazM . Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no: M182]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. [CENTRAL: CN-00520338] GheithOA , SobhMA , Mohamed Kel-E, El-BazM , El-HusseiniF , GazarinSS , et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612-9. [MEDLINE: 12138263]">Gheith 2002</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a> (15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0020" title="HommelE , AndersenP , GallMA , NielsenF , JensenB , RossingP , et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia1992;35(5):447-51. [MEDLINE: 1521727]">Hommel 1992</a> (15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0025" title="InukaiK , IuchiT , SumitaT , ItoD , IkebukuroK , ImaiK , et al. Combination therapy with angiotensin receptor blocker (ARB) plus atorvastatin reduced proteinuria in type 2 diabetic patients with diabetic nephropathy. Therapeutic Research2011;32(7):947-53. [EMBASE: 362412882]">Inukai 2011</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0030" title="LintottCJ , ScottRS , BremerJM , ShandBI . Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. American Journal of Cardiology1995;76(2):97-101A. [MEDLINE: 7604809]">Lintott 1995</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0035" title="MoriY , TsuruokaA . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Journal of the Japan Diabetes Society1992;35(3):265-8. [EMBASE: 22147775]MoriY , YokoyamaJ , TsuruokaA , IkedaY . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - a randomized control study. Jikeikai Medical Journal1992;39(4):341-8. [EMBASE: 23068032]">Mori 1992</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0032" title="FassettR , RobertsonI , BallM , GeraghtyD , SharmanJ , CoombesJ . A randomised trial assessing the effects of atorvastatin on arterial stiffness in chronic kidney disease [abstract no: SU193]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912394] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Atorvastatin and the progression of chronic kidney disease: the LORD Trial [abstract no: F-PO1919]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN-00773725] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Baseline serum lipids and renal function in chronic kidney disease patients entering the LORD trial. International Journal of Clinical Pharmacology &amp; Therapeutics2006;44(11):580-8. [MEDLINE: 17176625]FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrology2008;9:4. [MEDLINE: 18366658]FassettRG , CoombesJS , PurseLM , WattsM , ChuggKL , GeraghtyDP . Enrolment in a clinical trial improves renal function [abstract no: SU-PO1057]. Journal of the American Society of Nephrology2003;14(Nov):768A. [CENTRAL: CN-00583896] FassettRG , OliverK , SummersMJ , SmithM , AndersonLM , CoombesJS . Lipid lowering therapy and cognitive function in patients with chronic kidney disease [abstract no: PUB623]. Journal of the American Society of Nephrology2005;16:917A. [CENTRAL: CN-00636136] FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Atorvastatin slows the progression of chronic kidney disease in patients with inflammation [abstract no: TH-PO204]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):158A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with kidney function in CKD patients [abstract no: FR-PO1383]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):432A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with quality of life in CKD patients [abstract no: SA-PO2441]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):680A. FassettRG , RobertsonI , HealyHG , GeraghtyDP , BallMJ , CardinalJW , et al. Effect of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post-hoc analysis of the LORD trial [abstract no: SA-PO2320]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):641A. FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CardinalJW , CoombesJS . Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrology Dialysis Transplantation2012;27(1):182-9. [MEDLINE: 21543653]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis2010;213(1):218-24. [MEDLINE: 20810109]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clinical Nephrology2014;81(2):75-85. [MEDLINE: 24321183]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , SharmanJE , CoombesJS . Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. Journal of Atherosclerosis &amp; Thrombosis2010;17(3):235-41. [MEDLINE: 20032570]FassettRG , RobertsonIK , BallMJ , GeraghtyDP . Atorvastatin slows the progression of CKD in patients with inflammation [abstract no: 066]. Nephrology2011;16(Suppl 1):40-1. [EMBASE: 70532414]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , BurtonNW , CoombesJS . Physical activity levels in patients with chronic kidney disease entering the LORD trial. Medicine &amp; Science in Sports &amp; Exercise2009;41(5):985-91. [MEDLINE: 19346990]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , CoombesJS . Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting. Journal of Renal Nutrition2007;17(4):235-42. [MEDLINE: 17586421]FassettRG , SwansonCE , SharmaS , WhiteA , SinghG . Atorvastatin improves kidney function in chronic kidney disease patients undertaking high intensity exercise [abstract no: 067]. Nephrology2011;16(Suppl 1):41. [PMID: 70532415]SummersMJ , OliverKR , CoombesJS , FassettRG . Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy: The Journal of Human Pharmacology &amp; Drug Therapy2007;27(2):183-90. [MEDLINE: 17253908]">LORD 2006</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0031" title="ArampatzisCA , GoedhartD , SerruysPW , SaiaF , LemosPA , deFeyterP . Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal2005;149(2):329-35. [MEDLINE: 15846273]LemosPA , SerruysPW , deFeyterP , MercadoNF , GoedhartD , SaiaF , et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology2005;95(4):445-51. [MEDLINE: 15695126]SerruysPW , De FeyterPJ , BenghoziR , HugenholtzPG , LesaffreE . The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions2001;4(4):165-72. [PMID: 12036459]SerruysPW , deFeyterP , MacayaC , KokottN , PuelJ , VrolixM , et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002;287(24):3215-22. [MEDLINE: 12076217]">LIPS 2001</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0039" title="NellemannB , GormsenLC , DollerupJ , SchmitzO , MogensenCE , RasmussenLM , et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care2007;30(12):3122-4. [MEDLINE: 17804683]NielsenS , SchmitzO , MollerN , PorksenN , KlausenIC , AlbertiKG , et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia1993;36(10):1079-86. [MEDLINE: 8243858]">Nielsen 1993</a> (15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0033" title="Masajtis-ZagajewskaA , NowickiM . Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Renal Failure2018;40(1):700-9. [MEDLINE: 30741616]">Masajtis‐Zagajewska 2018</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0050" title="AlaupovicP , AttmanPO , Knight-GibsonC , MulecH , WeissL , SamuelssonO . Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney International2006;69(10):1865-71. [MEDLINE: 16572113]SamuelssonO , AttmanPO , Knight-GibsonC , MulecH , WeissL , AlaupovicP . Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. American Journal of Kidney Diseases2002;39(1):67-75. [MEDLINE: 11774104]">Samuelsson 2002</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0046" title="AsselbergsFW , DiercksGF , HillegeHL , vanBovenAJ , JanssenWM , VoorsAA , et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004;110(18):2809-16. [MEDLINE: 15492322]AsselbergsFW , vanRoonAM , HillegeHL , deJongPE , GansRO , SmitAJ , et al. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke2005;36(3):649-53. [MEDLINE: 15692120]AsselbergsFW , van derHarstP , vanRoonAM , HillegeHL , deJongPE , GansRO , et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis2008;196(1):349-55. [MEDLINE: 17141245]AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]. Journal of the American Society of Nephrology2005;16:36A. [CENTRAL: CN-00583782] AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics2006;28(3):432-44. [MEDLINE: 16750458]AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]. Journal of the American Society of Nephrology2005;16:71A. [CENTRAL: CN-00583784] AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation2006;21(11):3106-14. [MEDLINE: 16720593]BelloAK , deZeeuwD , El NahasM , BrantsmaAH , BakkerSJ , deJongPE , et al. Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation2007;22(6):1619-27. [MEDLINE: 17360767]BrouwersFP , AsselbergsFW , HillegeHL , deBoerRA , GansevoortRT , vanVeldhuisenDJ , et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). American Heart Journal2011;161(6):1171-8. [MEDLINE: 21641365]De JongMA , EisengaMF , vanBallegooijenAJ , BeulensJW , VervloetMG , NavisG , et al. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrology Dialysis Transplantation2021;36(1):121-8. [MEDLINE: 32124925]DiercksGF , JanssenWM , vanBovenAJ , BakAA , deJongPE , CrijnsHJ , et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology2000;86(6):635-8. [MEDLINE: 10980214]GelukCA , AsselbergsFW , HillegeHL , BakkerSJ , deJongPE , ZijlstraF , et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal2005;26(13):1314-20. [MEDLINE: 15820998]PouwelsKB , VisserST , HakE . Effect of pravastatin and fosinopril on recurrent urinary tract infections. Journal of Antimicrobial Chemotherapy2013;68(3):708-14. [MEDLINE: 23111852]vande WalRM , GansevoortRT , van derHarstP , BoomsmaF , Thijs PlokkerHW , vanVeldhuisenDJ , et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension2006;48(5):870-6. [MEDLINE: 17000930]vande WalRM , van derHarstP , GerritsenWB , van derHorstF , PlokkerTH , GansevoortRT , et al. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):177-80. [MEDLINE: 18205096]van derHarstP , AsselbergsFW , HillegeHL , VoorsAA , vanVeldhuisenDJ , vanGilstWH . Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. American Journal of Cardiology2008;102(2):223-5. [MEDLINE: 18602526]">PREVEND IT 2000</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0042" title="PanichiV , MantuanoE , PaolettiS , SantiS , Manca RizzaG , CutrupiS , et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. Journal of Nephrology2008;21(1):38-44. [MEDLINE: 18264935]PanichiV , PaolettiS , Manca-RizzaG , TaccolaD , InnocentiM , CastoG , et al. Effect of simvastatin therapy on inflammatory markers and lipids in pre-dialysis patients [abstract no: SP167]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v75. [CENTRAL: CN-00678037] PanichiV , PaolettiS , MantuanoE , Manca-RizzaG , FilippiC , SantiS , et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrology Dialysis Transplantation2006;21(2):337-44. [MEDLINE: 16249194]">Panichi 2006a</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0048" title="RenkeM , TylickiL , RutkowskiP , NeuweltA , LarczynskiW , ZietkiewiczM , et al. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochimica Polonica2010;57(4):547-52. [MEDLINE: 21079818]">Renke 2010a</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0061" title="YasudaG , KujiT , HasegawaK , OgawaN , ShimuraG , AndoD , et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Renal Failure2004;26(4):411-8. [MEDLINE: 15462110]">Yasuda 2004</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0052" title="ScanferlaF , ToffolettoPP , RoncaliD , BazzatoG . Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension1991;4(10 Pt 1):868-74. [MEDLINE: 1747221]">Scanferla 1991</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0047" title="RaynerB , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin and diet versus diet alone in patients with idiopathic membranous nephropathy: a preliminary report [abstract]. Kidney International1993;43:1183. RaynerBL , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin (sv) and diet versus diet alone in patients with idiopathic membranous nephropathy (IMN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:76. RaynerBL , ByrneM , vanZyl-SmitR . Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN) [abstract]. Nephrology Dialysis Transplantation1994;9(7):963. [CENTRAL: CN-00261011] RaynerBL , ByrneMJ , vanZyl SmitR . A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clinical Nephrology1996;46(4):219-24. [MEDLINE: 8905205]">Rayner 1996</a> (25 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0054" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503-10. [MEDLINE: 16303728]StegmayrBG , BrannstromM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489-97. [MEDLINE: 18161210]StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. In: 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. [CENTRAL: CN-00447842] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. [CENTRAL: CN-00583406] ">Stegmayr 2005</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0063" title="ZhangA , VertommenJ , Van GaalL , De LeeuwI . Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Research &amp; Clinical Practice1995;29(3):189-94. [MEDLINE: 8591712]">Zhang 1995</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0052" title="ScanferlaF , ToffolettoPP , RoncaliD , BazzatoG . Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension1991;4(10 Pt 1):868-74. [MEDLINE: 1747221]">Scanferla 1991</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> (20 mg/d with ezetimibe 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0055" title="ThomasME , HarrisKP , RamaswamyC , HattersleyJM , WheelerDC , VargheseZ , et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International1993;44(5):1124-9. [MEDLINE: 8264145]">Thomas 1993</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0058" title="TonoloG , CiccareseM , BrizziP , PudduL , SecchiG , CalviaP , et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care1997;20(12):1891-5. [MEDLINE: 9405913]">Tonolo 1997</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0059" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>High‐dose statin versus low‐dose statin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0041" title="NarayananRP , GittinsM , SiddalsKW , OliverRL , HudsonJE , WhiteA , et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability. European Journal of Endocrinology2013;168(4):543-8. [MEDLINE: 23333902]RutterMK , DaviesRR , CruickshankJK , PraisHR , GittinsM , RobertsC , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): trial results [abstract no: 1207]. Diabetologia2009;52(Suppl 1):S466. [EMBASE: 70068693]RutterMK , PraisHR , Charlton-MenysV , GittinsM , RobertsC , DaviesRR , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabetic Medicine2011;28(1):100-8. [MEDLINE: 21166851]SoranH , LiuY , AdamS , SiahmansurT , HoJH , SchofieldJD , et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. Journal of Clinical Lipidology2018;12(1):44-55. [MEDLINE: 29246729]">PANDA 2011</a> (80 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> (40 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a> (80 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> (40 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <p>The median follow‐up duration was 12 months (range 2 to 66 months). Studies reporting death outcomes that could be included in meta‐analyses had a median follow‐up duration of 44 months (range 5 to 65 months). </p> <p>Although three studies enrolled participants with established acute or stable coronary artery disease (<a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a>; <a href="./references#CD007784-bbs2-0005" title="IsaacsohnJL , DavidsonMH , HunninghakeD , SingerR , McLainR , BlackDM . Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology2000;86(2):250-2. [MEDLINE: 10913499]KorenMJ , DavidsonMH , WilsonDJ , FayyadRS , ZuckermanA , ReedDP , et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases2009;53(5):741-50. [MEDLINE: 19216014]KorenMJ , DavidsonMH . Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. KorenMJ , HunninghakeDB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology2004;44(9):1772-9. [MEDLINE: 15519006]MullinsCD , RattingerGB , KuznikA , KorenMJ . Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics2008;30 Pt 2:2204-16. [MEDLINE: 19281915]">ALLIANCE 2000</a>; <a href="./references#CD007784-bbs2-0031" title="ArampatzisCA , GoedhartD , SerruysPW , SaiaF , LemosPA , deFeyterP . Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal2005;149(2):329-35. [MEDLINE: 15846273]LemosPA , SerruysPW , deFeyterP , MercadoNF , GoedhartD , SaiaF , et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology2005;95(4):445-51. [MEDLINE: 15695126]SerruysPW , De FeyterPJ , BenghoziR , HugenholtzPG , LesaffreE . The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions2001;4(4):165-72. [PMID: 12036459]SerruysPW , deFeyterP , MacayaC , KokottN , PuelJ , VrolixM , et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002;287(24):3215-22. [MEDLINE: 12076217]">LIPS 2001</a>), 12 studies excluded participants with clinical coronary artery disease (<a href="./references#CD007784-bbs2-0002" title="AbeM , MaruyamaN , OkadaK , MatsumotoS , MatsumotoK , SomaM . Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Journal of Atherosclerosis &amp; Thrombosis2011;18(11):1018-28. [MEDLINE: 21921413]">Abe 2011c</a>; <a href="./references#CD007784-bbs2-0004" title="ClearfieldM , DownsJR , WeisS , WhitneyEJ , KruyerW , ShapiroDR , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health &amp; Gender-Based Medicine2001;10(10):971-81. [MEDLINE: 11788107]ClearfieldM , WhitneyEJ , WeisS , DownsJR , ShapiroDR , SteinEA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk2000;7(2):125-33. [MEDLINE: 10879416]ClearfieldMB , WeisSE , WillisJM , VaseniusKA , McConathyWJ . Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association2002;102(7):377-84. [MEDLINE: 12138952]CuiY , WatsonDJ , GirmanCJ , ShapiroDR , GottoAM , HiseroteP , et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology2009;104(6):829-34. [MEDLINE: 19733719]DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287-93. [MEDLINE: 9264420]DownsJR , ClearfieldM , TyrolerHA , WhitneyEJ , KruyerW , LangendorferA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology2001;87(9):1074-9. [MEDLINE: 11348605]DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22. [MEDLINE: 9613910]Gotto AM Jr, BoccuzziSJ , CookJR , AlexanderCM , RoehmJB , MeyerGS , et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology2000;86(11):1176-81. [MEDLINE: 11090787]KendrickJ , ShlipakMG , TargherG , CookT , LindenfeldJ , ChoncholM . Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases2010;55(1):42-9. [MEDLINE: 19932541]">AFCAPS/TexCAPS 1997</a>; <a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a>; <a href="./references#CD007784-bbs2-0017" title="FriedLF , ForrestKY , EllisD , ChangY , SilversN , OrchardTJ . Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. Journal of Diabetes &amp; its Complications2001;15(3):113-9. [MEDLINE: 11358679]">Fried 2001</a>; <a href="./references#CD007784-bbs2-0024" title="ImaiY , SuzukiH , SaitoT , TsujiI , AbeK , SarutaT . The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clinical &amp; Experimental Hypertension (New York)1999;21(8):1345-55. [MEDLINE: 10574417]">Imai 1999</a>; <a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a>; <a href="./references#CD007784-bbs2-0028" title="LamKS , ChengIK , JanusED , PangRW . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1995;38(5):604-9. [MEDLINE: 7489845]ParvingHH . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1996;39(3):367-8. [MEDLINE: 8721786]">Lam 1995</a>; <a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a>; <a href="./references#CD007784-bbs2-0036" title="NakamuraT , UshiyamaC , HirokawaK , OsadaS , InoueT , ShimadaN , et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrology Dialysis Transplantation2002;17(5):798-802. [MEDLINE: 11981066]">Nakamura 2002</a>; <a href="./references#CD007784-bbs2-0037" title="NakamuraT , SugayaT , KawagoeY , UedaY , OsadaS , KoideH . Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care2005;28(11):2728-32. [MEDLINE: 16249547]">Nakamura 2005</a>; <a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a>; <a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a>). Median baseline LDL cholesterol was 143.9 mg/dL (range 108.5 to 189 mg/dL) (3.72 mmol/L; range 2.80 to 4.89 mmol/L) </p> <p>Ten studies included only participants who had diabetes (<a href="./references#CD007784-bbs2-0002" title="AbeM , MaruyamaN , OkadaK , MatsumotoS , MatsumotoK , SomaM . Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Journal of Atherosclerosis &amp; Thrombosis2011;18(11):1018-28. [MEDLINE: 21921413]">Abe 2011c</a>; <a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a>; <a href="./references#CD007784-bbs2-0020" title="HommelE , AndersenP , GallMA , NielsenF , JensenB , RossingP , et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia1992;35(5):447-51. [MEDLINE: 1521727]">Hommel 1992</a>; <a href="./references#CD007784-bbs2-0025" title="InukaiK , IuchiT , SumitaT , ItoD , IkebukuroK , ImaiK , et al. Combination therapy with angiotensin receptor blocker (ARB) plus atorvastatin reduced proteinuria in type 2 diabetic patients with diabetic nephropathy. Therapeutic Research2011;32(7):947-53. [EMBASE: 362412882]">Inukai 2011</a>; <a href="./references#CD007784-bbs2-0028" title="LamKS , ChengIK , JanusED , PangRW . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1995;38(5):604-9. [MEDLINE: 7489845]ParvingHH . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1996;39(3):367-8. [MEDLINE: 8721786]">Lam 1995</a>; <a href="./references#CD007784-bbs2-0035" title="MoriY , TsuruokaA . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Journal of the Japan Diabetes Society1992;35(3):265-8. [EMBASE: 22147775]MoriY , YokoyamaJ , TsuruokaA , IkedaY . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - a randomized control study. Jikeikai Medical Journal1992;39(4):341-8. [EMBASE: 23068032]">Mori 1992</a>; <a href="./references#CD007784-bbs2-0037" title="NakamuraT , SugayaT , KawagoeY , UedaY , OsadaS , KoideH . Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care2005;28(11):2728-32. [MEDLINE: 16249547]">Nakamura 2005</a>; <a href="./references#CD007784-bbs2-0039" title="NellemannB , GormsenLC , DollerupJ , SchmitzO , MogensenCE , RasmussenLM , et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care2007;30(12):3122-4. [MEDLINE: 17804683]NielsenS , SchmitzO , MollerN , PorksenN , KlausenIC , AlbertiKG , et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia1993;36(10):1079-86. [MEDLINE: 8243858]">Nielsen 1993</a>; <a href="./references#CD007784-bbs2-0058" title="TonoloG , CiccareseM , BrizziP , PudduL , SecchiG , CalviaP , et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care1997;20(12):1891-5. [MEDLINE: 9405913]">Tonolo 1997</a>; <a href="./references#CD007784-bbs2-0063" title="ZhangA , VertommenJ , Van GaalL , De LeeuwI . Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Research &amp; Clinical Practice1995;29(3):189-94. [MEDLINE: 8591712]">Zhang 1995</a>); and people with diabetes were excluded from eight studies (<a href="./references#CD007784-bbs2-0009" title="BianchiS , BigazziR , CaiazzaA , CampeseVM . A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193]. American Journal of Kidney Diseases2003;41(3):565-70. [MEDLINE: 12612979]">Bianchi 2003</a>; <a href="./references#CD007784-bbs2-0018" title="GheithO , SaadM , SobhM . Nephrotic dyslipidemia, harvest of treatment [abstract no: MP085]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:258. [CENTRAL: CN-00509210] GheithO , SobhM , GazarenS , AhmedH , El BazM . Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no: M182]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. [CENTRAL: CN-00520338] GheithOA , SobhMA , Mohamed Kel-E, El-BazM , El-HusseiniF , GazarinSS , et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612-9. [MEDLINE: 12138263]">Gheith 2002</a>; <a href="./references#CD007784-bbs2-0029" title="LeeTM , LinMS , TsaiCH , ChangNC . Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney International2005;68(2):779-87. [MEDLINE: 16014056]LeeTM , SuSF , TsaiCH . Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension2002;40(1):67-73. [MEDLINE: 12105140]">Lee 2002</a>; <a href="./references#CD007784-bbs2-0036" title="NakamuraT , UshiyamaC , HirokawaK , OsadaS , InoueT , ShimadaN , et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrology Dialysis Transplantation2002;17(5):798-802. [MEDLINE: 11981066]">Nakamura 2002</a>; <a href="./references#CD007784-bbs2-0038" title="NakamuraT , SugayaT , KawagoeY , SuzukiT , InoueT , NodeK . Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. American Journal of Nephrology2006;26(1):82-6. [MEDLINE: 16534182]">Nakamura 2006</a>; <a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a>; <a href="./references#CD007784-bbs2-0042" title="PanichiV , MantuanoE , PaolettiS , SantiS , Manca RizzaG , CutrupiS , et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. Journal of Nephrology2008;21(1):38-44. [MEDLINE: 18264935]PanichiV , PaolettiS , Manca-RizzaG , TaccolaD , InnocentiM , CastoG , et al. Effect of simvastatin therapy on inflammatory markers and lipids in pre-dialysis patients [abstract no: SP167]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v75. [CENTRAL: CN-00678037] PanichiV , PaolettiS , MantuanoE , Manca-RizzaG , FilippiC , SantiS , et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrology Dialysis Transplantation2006;21(2):337-44. [MEDLINE: 16249194]">Panichi 2006a</a>; <a href="./references#CD007784-bbs2-0048" title="RenkeM , TylickiL , RutkowskiP , NeuweltA , LarczynskiW , ZietkiewiczM , et al. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochimica Polonica2010;57(4):547-52. [MEDLINE: 21079818]">Renke 2010a</a>). <a href="./references#CD007784-bbs2-0054" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503-10. [MEDLINE: 16303728]StegmayrBG , BrannstromM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489-97. [MEDLINE: 18161210]StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. In: 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. [CENTRAL: CN-00447842] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. [CENTRAL: CN-00583406] ">Stegmayr 2005</a> combined outcome data for adults not on dialysis with those on dialysis; data from this study were not included in the meta‐analyses. </p> <p>Effects of statins on adverse events data from <a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> could not be included in analyses because disaggregated data for 6247 adults with CKD were not available. </p> <p>The Pravastatin Pooling Project (<a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a>) was a pooled analysis of three large data sets of participants with kidney impairment who were included in three major statin studies (<a href="./references#CD007784-bbs2-0125" title="Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]">LIPID 1998</a>; <a href="./references#CD007784-bbs2-0135" title="SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]">Sacks 1996</a>; <a href="./references#CD007784-bbs2-0139" title="ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]">Shepherd 1995</a>) conducted in the general population and were included as a single comparison. </p> </section> <section id="CD007784-sec-0053"> <h5 class="title">High versus low dose statin</h5> <p><a href="./references#CD007784-bbs2-0041" title="NarayananRP , GittinsM , SiddalsKW , OliverRL , HudsonJE , WhiteA , et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability. European Journal of Endocrinology2013;168(4):543-8. [MEDLINE: 23333902]RutterMK , DaviesRR , CruickshankJK , PraisHR , GittinsM , RobertsC , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): trial results [abstract no: 1207]. Diabetologia2009;52(Suppl 1):S466. [EMBASE: 70068693]RutterMK , PraisHR , Charlton-MenysV , GittinsM , RobertsC , DaviesRR , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabetic Medicine2011;28(1):100-8. [MEDLINE: 21166851]SoranH , LiuY , AdamS , SiahmansurT , HoJH , SchofieldJD , et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. Journal of Clinical Lipidology2018;12(1):44-55. [MEDLINE: 29246729]">PANDA 2011</a> and <a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a> compared two doses of atorvastatin, while <a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> and <a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> compared low‐ and high‐dose rosuvastatin. The median follow‐up was 24 months (range 12 to 58.8 months). Meta‐analysis was undertaken when two or more studies were available. </p> </section> <section id="CD007784-sec-0054"> <h5 class="title">Continuous release versus intermittent release statin</h5> <p><a href="./references#CD007784-bbs2-0062" title="YiYJ , KimHJ , JoSK , KimSG , SongYR , ChungW , et al. Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. Clinical Therapeutics2014;36(8):1182-90. [MEDLINE: 24996489]">Yi 2014</a> compared continuous‐release statin (20 mg/day) administered in the morning with intermittent‐release statin (20 mg/day) administered in the evening for two months. The study included 122 participants, with a mean LDL cholesterol of 140.5 ± 28.3 mg/day (3.63 ± 0.73 mmol/L). </p> </section> <section id="CD007784-sec-0055"> <h5 class="title">Statin versus another statin</h5> <p> <ul id="CD007784-list-0012"> <li> <p><a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> and <a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> compared rosuvastatin and atorvastatin </p> </li> <li> <p><a href="./references#CD007784-bbs2-0022" title="HolmeI , CaterNB , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine2008;40(6):456-64. [MEDLINE: 19160529]HolmeI , FayyadR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine2010;267(6):567-75. [MEDLINE: 20141566]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology2004;94(6):720-4. [MEDLINE: 15374773]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum appears in JAMA. 2005 Dec 28;294(24):3092]. JAMA2005;294(19):2437-45. [MEDLINE: 16287954]">IDEAL 2004</a> compared simvastatin with atorvastatin </p> </li> <li> <p><a href="./references#CD007784-bbs2-0003" title="AbeM , MaruyamaN , MaruyamaT , OkadaK , SomaM . A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease. Journal of Atherosclerosis &amp; Thrombosis2015;22(12):1235-47. [MEDLINE: 26156625]">Abe 2015</a> compared rosuvastatin with pitavastatin </p> </li> <li> <p><a href="./references#CD007784-bbs2-0023" title="IkedaH , UraY , NakayamaM . Rosuvastatin reduces urinary protein excretion in patients with chronic glomerulonephritis compared to the pravastatin use: a crossover trial [abstract no: SA-PO274]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):699A. ">Ikeda 2012</a> compared pravastatin with rosuvastatin </p> </li> <li> <p><a href="./references#CD007784-bbs2-0027" title="KimuraS , InoguchiT , YokomizoH , MaedaY , SonodaN , TakayanagiR . Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes, Obesity &amp; Metabolism2012;14(7):666-9. [MEDLINE: 22268518]">Kimura 2012</a> compared pitavastatin with pravastatin </p> </li> <li> <p><a href="./references#CD007784-bbs2-0049" title="DeedwaniaP , StonePH , Bairey MerzCN , Cosin-AguilarJ , KoylanN , LuoD , et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation2007;115(6):700-7. [MEDLINE: 17283260]DeedwaniaPC , StoneP , FayyadR , LaskeyR , WilsonDJ . Improvement in renal function with intensive statin therapy in older patients without increased muscle symptoms: the SAGE trial [abstract no: SA-PO2762]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):743A. DeedwaniaPC , StonePH , FayyadRS , LaskeyRE , WilsonDJ . Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs &amp; Aging2015;32(12):1055-65. [MEDLINE: 26625880]DeedwaniaPC . Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American Heart Journal2004;148(6):1053-9. [MEDLINE: 15632893]">SAGE 2004</a> compared atorvastatin with pravastatin. </p> </li> </ul> </p> <p>Sample sizes ranged from 28 to 3107 participants. The median follow‐up was 12 months (range 12 to 57.6 months). Baseline LDL cholesterol levels ranged from 123.6 to 150.8 mg/dL (3.20 to 3.90 mmol/L). Meta‐analysis was not possible because three or more studies were not available for each comparison. </p> </section> </section> <section id="CD007784-sec-0056"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD007784-bbs1-0002" title="">Excluded studies</a>. </p> <p>Thirty‐two studies did not meet our eligibility criteria for the following reasons.</p> <p> <ul id="CD007784-list-0013"> <li> <p>Wrong intervention (11 studies): did not compare a statin with placebo or standard of care without a statin (<a href="./references#CD007784-bbs2-0064" title="AlmquistT , JacobsonSH , LinsPE , FarndaleRW , HjemdahlP . Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial. Nephrology Dialysis Transplantation2012;27(9):3540-6. [MEDLINE: 22700717]AlmquistT , JacobsonSH , LinsRL , HjemdahlP . Effects of lipid-lowering treatment on inflammatory markers in diabetic patients with chronic kidney disease [abstract no: TH-PO506]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):213A. AlmquistT , JacobsonSH , MobarrezF , NasmanP , HjemdahlP . Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. European Journal of Clinical Investigation2014;44(3):276-84. [MEDLINE: 24720535]AlmquistT , MobarrezF , JacobsonSH , WallenH , HjemdahlP . Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation2016;31(6):944-52. [MEDLINE: 26394646]AlmquistTC , JacobsonSH , LinsPE , FarndaleRW , HjemdahlP . Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients with chronic kidney disease- a randomized trial [abstract no: TH-PO516]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):231A. ">Almquist 2012</a>; <a href="./references#CD007784-bbs2-0072" title="AzarRR , BadaouiG , SarkisA , AzarM , AydanianH , HarbS , et al. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. American Journal of Cardiology2010;106(2):193-7. [MEDLINE: 20599002]BlazingMA , GiuglianoRP , CannonCP , MuslinerTA , TershakovecAM , WhiteJA , et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. American Heart Journal2014;168(2):205-12. [MEDLINE: 25066560]BohulaEA , GiuglianoRP , CannonCP , ZhouJ , MurphySA , WhiteJA , et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation2015;132(13):1224-33. [MEDLINE: 26330412]BohulaEA , MorrowDA , GiuglianoRP , BlazingMA , HeP , ParkJG , et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. Journal of the American College of Cardiology2017;69(8):911-21. [MEDLINE: 28231942]BohulaEA , WiviottSD , GiuglianoRP , BlazingMA , ParkJG , MurphySA , et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2017;136(25):2440-50. [MEDLINE: 28972004]CannonCP , BlazingMA , GiuglianoRP , McCaggA , WhiteJA , TherouxP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine2015;372(25):2387-97. [MEDLINE: 26039521]CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , SiskCM , et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826-32. [MEDLINE: 19061694]GiuglianoRP , CannonCP , BlazingMA , NicolauJC , CorbalanR , SpinarJ , et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation2018;137(15):1571-82. [MEDLINE: 29263150]GiuglianoRP , WiviottSD , BlazingMA , De FerrariGM , ParkJG , MurphySA , et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiology2017;2(5):547-55. [MEDLINE: 28291866]KatoET , CannonCP , BlazingMA , BohulaE , GuneriS , WhiteJA , et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association2017;6(11):e006901. [MEDLINE: 29151034]MurphySA , CannonCP , BlazingMA , GiuglianoRP , WhiteJA , LokhnyginaY , et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial. Journal of the American College of Cardiology2016;67(4):353-61. [MEDLINE: 26821621]PetoR , EmbersonJ , LandrayM , BaigentC , CollinsR , ClareR , et al. Analyses of cancer data from three ezetimibe trials. New England Journal of Medicine2008;359(13):1357-66. [MEDLINE: 18765432]PokharelY , ChinnakondepalliK , VilainK , WangK , MarkDB , DaviesG , et al. Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: results from the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation: Cardiovascular Quality &amp; Outcomes2017;10(5):e003201. [MEDLINE: 28506979]SimonTG , CoreyKE , CannonCP , BlazingM , ParkJG , O'DonoghueML , et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology2018;270:245-52. [MEDLINE: 29903515]StaniferJW , CharytanDM , WhiteJ , LokhnyginaY , CannonCP , RoeMT , et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. Journal of the American Society of Nephrology2017;28(10):3034-43. [MEDLINE: 28507057]">IMPROVE‐IT 2008</a>; <a href="./references#CD007784-bbs2-0073" title="IshimitsuT , OhnoE , UenoY , OnodaS , NagaseA , OhiraT , et al. Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease. Clinical &amp; Experimental Nephrology2014;18(5):704-10. [MEDLINE: 24198051]">Ishimitsu 2014</a>; <a href="./references#CD007784-bbs2-0074" title="KouvelosGN , ArnaoutoglouEM , MatsagkasMI , KostaraC , GartzonikaC , BairaktariET , et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(1):5-12. [MEDLINE: 22573476]KouvelosGN , ArnaoutoglouEM , MilionisHJ , RaikouVD , PapaN , MatsagkasMI . The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology2015;66(2):128-35. [MEDLINE: 24458801]">Kouvelos 2013</a>; <a href="./references#CD007784-bbs2-0079" title="LanDT . Lipid-lowering therapies in Vietnamese chronic kidney disease population (VietCKD) [Lipid-lowering regimes improve oxidative stress, tryptophan degradation in hypercholesterolemia chronic kidney disease patients]. www.clinicaltrials.gov/show/NCT03543774 (first received 1 June 2018). ">NCT03543774</a>; <a href="./references#CD007784-bbs2-0085" title="SuzukiH , TakenakaT , OkadaH , InoueT . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic disease (CKD) patients [abstract no: SA-PO161]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):672A. SuzukiH , WatanabeY , KumagaiH , ShutoH . Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease2013;7(6):306-15. [MEDLINE: 24280596]">Suzuki 2013a</a>; <a href="./references#CD007784-bbs2-0087" title="LandrayM , BaigentC , LeaperC , AduD , AltmannP , ArmitageJ , et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. American Journal of Kidney Diseases2006;47(3):385-95. [MEDLINE: 16490616]LandrayM , BaigentC , LeaperC , UK-HARP Steering Committee. Biochemical safety and efficacy of co-administration of ezetimibe and simvastatin among patients with chronic kidney disease: the second UK-heart and renal protection (UK-HARP-II) study [abstract no: M383]. Nephrology Dialysis Transplantation2003;18(Suppl 4):119-20. [CENTRAL: CN-00446268] ">UK‐HARP‐II 2006</a>; <a href="./references#CD007784-bbs2-0091" title="WeinsteinDL , WilliamsLA , CarlsonDM , KellyMT , BurnsKM , SetzeCM , et al. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease [Erratum appears in Clin Ther. 2013 Nov;35(11):1862]. Clinical Therapeutics2013;35(8):1186-98. [MEDLINE: 23891363]">Weinstein 2013</a>; <a href="./references#CD007784-bbs2-0092" title="YasmeenG , DawaniML , MahboobT . Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease. Iranian Journal of Kidney Diseases2015;9(1):39-45. [MEDLINE: 25599735]">Yasmeen 2015</a>; <a href="./references#CD007784-bbs2-0093" title="YasudaG , AndoD , HirawaN , UmemuraS . Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy. Renal Failure2010;32(6):680-6. [MEDLINE: 20540635]">Yasuda 2010</a>; <a href="./references#CD007784-bbs2-0095" title="ZinelluA , SotgiaS , LorigaG , DeianaL , SattaAE , CarruC . Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. Amino Acids2012;43(4):1499-507. [MEDLINE: 22278741]ZinelluA , SotgiaS , MangoniAA , SannaM , SattaAE , CarruC . Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutrition Metabolism &amp; Cardiovascular Diseases2015;25(2):153-9. [MEDLINE: 25534866]ZinelluA , SotgiaS , MangoniAA , SotgiuE , EnaS , SattaAE , et al. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical &amp; Biomedical Analysis2016;129:383-8. [MEDLINE: 27454090]ZinelluA , SotgiaS , PisanuE , LorigaG , DeianaL , SattaAE , et al. LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences2012;47(1):117-23. [MEDLINE: 22659373]ZinelluA , SotgiaS , SotgiuE , AssarettiS , BarallaA , MangoniAA , et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition Metabolism &amp; Cardiovascular Diseases2017;27(9):822-9. [MEDLINE: 28755807]">Zinellu 2012</a>) </p> </li> <li> <p>No comparator: one study (<a href="./references#CD007784-bbs2-0068" title="DohiT , MiyauchiK , OkazakiS , YokoyamaT , TamuraH , KojimaT , et al. Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Nephrology Dialysis Transplantation2011;26(9):2906-11. [MEDLINE: 21300704]DohiT , MiyauchiK , OkazakiS , YokoyamaT , YanagisawaN , TamuraH , et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis2010;210(2):497-502. [MEDLINE: 20036363]DohiT , MiyauchiK , OkazakiS , YokoyamaT , YanagisawaN , TamuraH , et al. Higher baseline LDL-C levels amplify the short-term benefit of early intensive statin treatment in acute coronary syndrome. Journal of Atherosclerosis &amp; Thrombosis2011;18(1):42-8. [MEDLINE: 20972351]OkazakiS , YokoyamaT , MiyauchiK , ShimadaK , KurataT , SatoH , et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation2004;110(9):1061-8. [MEDLINE: 15326073]">ESTABLISH 2004</a>) </p> </li> <li> <p>Wrong study design: three studies (<a href="./references#CD007784-bbs2-0077" title="MoseFH , LarsenT , JensenJM , BechJN , PedersenE . Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes [abstract no: TH-PO447]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):204A. MoseFH , LarsenT , JensenJM , HansenAB , BechJN , PedersenEB . Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes. Scandinavian Journal of Clinical &amp; Laboratory Investigation2014;74(1):8-19. [MEDLINE: 24256611]">Mose 2014a</a>; <a href="./references#CD007784-bbs2-0078" title="LarsenT , JensenJ , BechJ , PedersenE , MoseF . Effect of atorvastatin on renal NO availability and tubular function in patients with non-diabetic, stage II-III chronic kidney disease [abstract no: MP219]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i367. [EMBASE: 71076128]MoseFH , LarsenT , JensenJM , BechJN , PedersenE . Increased NO activity during statin treatment in patients with non-diabetic nephropathy [abstract no: SA-PO169]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):673A. MoseFH , LarsenT , JensenJM , HansenAB , BechJN , PedersenEB . Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease. British Journal of Clinical Pharmacology2014;78(4):789-99. [MEDLINE: 24697877]">Mose 2014b</a>; <a href="./references#CD007784-bbs2-0084" title="SiddiqiL , JolesJA , OeyPL , BlankestijnPJ . Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. Journal of Hypertension2011;29(11):2176-80. [MEDLINE: 21897294]">Siddiqi 2011</a>) </p> </li> <li> <p>Wrong population: eight studies (<a href="./references#CD007784-bbs2-0065" title="AlmukhtarHM , FaisalIM , MerkhanMM . Acute effect of atorvastatin in comparison with rosuvastatin on glucose homeostasis in hypercholesteremic patients. Current Topics in Pharmacology2021;25:25‐34. [EMBASE: 2013766821]">Almukhtar 2021</a>; <a href="./references#CD007784-bbs2-0069" title="Fotso SohJ , BeaulieuS , TrepiccioneF , LinnarantaO , Torres-PlatasG , PlattRW , et al. A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. Bipolar Disorders2021;23(1):66‐75. [PMID: 32621644]">Fotso 2021</a>; <a href="./references#CD007784-bbs2-0075" title="MackieF , RosenbergA , HarmerJ , KainerG , CelermajerD . HMG CoA reductase inhibitors - effects on endothelial function and lipoprotein levels in children with chronic kidney disease [abstract no: P053]. Pediatric Nephrology2008;23:1610. ">Mackie 2008</a>; <a href="./references#CD007784-bbs2-0076" title="Mohammadi KebarS , AtighiE , HosseniniaS , BabapourB . Preventive effects of nicorandil and atorvastatin in contrastinduced nephropathy in patients with renal dysfunction undergoing coronary artery angiography: a double blind, randomized, controlled clinical trial. Iranian Journal of Kidney Diseases2023;17(4):205‐14. [PMID: 37634247]">Mohammadi 2023</a>; <a href="./references#CD007784-bbs2-0081" title="Impact of ATOrvastatin REload on the Prevention of Contrast-INduced Nephropathy in patients on Chronic Statin Therapy: a prospective randomized trial (ATORE-CIN) [Impact of atorvastatin reload on the prevention of contrast-induced nephropathy]. https://trialsearch.who.int/Trial2.aspx?TrialID=PACTR202110707328144 (first posted 16 September 2021). ">PACTR202110707328144</a>; <a href="./references#CD007784-bbs2-0089" title="VasinA , MironovaO , FominV . The role of short-term, high-dose atorvastatin for prevention of contrast-induced acute kidney injury (CI-AKI) in patients with cardiovascular diseases undergoing computed tomography with intravenous contrast administration. Nephrology Dialysis Transplantation2021;36(Suppl 1):i274. [EMBASE: 635918386]">Vasin 2021</a>; <a href="./references#CD007784-bbs2-0090" title="WatanabeM , AonumaK , MuroharaT , OkumuraY , MorimotoT , OkadaS , et al. Prevention of contrast-induced nephropathy after cardiovascular catheterization and intervention with high-dose strong statin therapy in Japan - The PREVENT CINC-J Study. Circulation Journal2022;86(9):1455‐63. [PMID: 35466156]">Watanabe 2022</a>; <a href="./references#CD007784-bbs2-0094" title="YenCL , FanPC , LeeCC , ChenJJ , KuoG , TuYR , et al. Association of low-density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease. Journal of the American Heart Association2022;11(19):e027516. [PMID: 36172933]">Yen 2022</a>) </p> </li> <li> <p>Unclear duration or less than eight weeks: nine studies (<a href="./references#CD007784-bbs2-0066" title="DograGK , WattsGF , ChanDC , StantonK . Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabetic Medicine2005;22(3):239-42. [MEDLINE: 15717868]">Dogra 2005</a>; <a href="./references#CD007784-bbs2-0067" title="DograG , IrishA , ChanD , WattsG . A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. American Journal of Kidney Diseases2007;49(6):776-85. [MEDLINE: 17533020]DograS , KanganasC , ChanD , IrishA , WattsG . Effect of statin and fibrate therapy on vascular function in chronic kidney disease (CKD) [abstract no: 160]. Nephrology2005;10(Suppl 3):A422. [CENTRAL: CN-00774612] ">Dogra 2007</a>; <a href="./references#CD007784-bbs2-0070" title="GolperTA , IllingworthDR , BennettWM . Correction of nephrotic hypercholesterolemia with the HMG-CoA reductase inhibitor lovastatin [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:64. [CENTRAL: CN-00583909] GolperTA , IllingworthDR , BennettWM . Effective and safe short term improvement in nephrotic hypercholesterolemia with the HMG CO-A reductase inhibitor mevinolin [abstract]. Kidney International1987;31(1):200. [CENTRAL: CN-00774455] ">Golper 1987</a>; <a href="./references#CD007784-bbs2-0071" title="GolperTA , IllingworthDR , MorrisCD , BennettWM . Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. American Journal of Kidney Diseases1989;13(4):312-20. [MEDLINE: 2650539]">Golper 1989</a>; <a href="./references#CD007784-bbs2-0080" title="OttC , SchlaichMP , SchmidtBM , TitzeSI , SchaufeleT , SchmiederRE . Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis2008;196(2):704-11. [MEDLINE: 17298834]">Ott 2008</a>; <a href="./references#CD007784-bbs2-0082" title="PaulsenL , MatthesenSK , BechJN , StarklintJ , PedersenEB . Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes. Journal of Clinical Pharmacology2010;50(7):816-22. [MEDLINE: 20056802]">Paulsen 2010</a>; <a href="./references#CD007784-bbs2-0083" title="SchmiederRE , SchneiderMP , DellesC , OehmerS , JohnS . Evidence for the lipid independent effects of statins on endothelial function [abstract no: T245]. Nephrology Dialysis Transplantation2003;18(Suppl 4):359. [CENTRAL: CN-00447626] ">Schmieder 2003</a>; <a href="./references#CD007784-bbs2-0086" title="TorracaS , NazzaroP , ViscianoB , PisaniA , Di MiccoL , CaputoDL , et al. Effects of high doses of atorvastatin (ATO) on renal dynamics and vascular reactivity in patients with chronic renal failure (CRF) [abstract no: MP272]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv390. [CENTRAL: CN-00774679] ">Torraca 2006</a>; <a href="./references#CD007784-bbs2-0088" title="vanDijkMA , KamperAM , vanVeenS , SouverijnJH , BlauwGJ . Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation2001;16(11):2152-7. [MEDLINE: 11682660]">Van Dijk 2001</a>). </p> </li> </ul> </p> </section> </section> <section id="CD007784-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>Seven studies comparing statins with placebo or no treatment were conducted according to published protocols, outcomes were adjudicated by a committee, specified outcomes were reported, and analyses were conducted using intention‐to‐treat methods (<a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a>; <a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a>; <a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a>; <a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a>; <a href="./references#CD007784-bbs2-0046" title="AsselbergsFW , DiercksGF , HillegeHL , vanBovenAJ , JanssenWM , VoorsAA , et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004;110(18):2809-16. [MEDLINE: 15492322]AsselbergsFW , vanRoonAM , HillegeHL , deJongPE , GansRO , SmitAJ , et al. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke2005;36(3):649-53. [MEDLINE: 15692120]AsselbergsFW , van derHarstP , vanRoonAM , HillegeHL , deJongPE , GansRO , et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis2008;196(1):349-55. [MEDLINE: 17141245]AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]. Journal of the American Society of Nephrology2005;16:36A. [CENTRAL: CN-00583782] AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics2006;28(3):432-44. [MEDLINE: 16750458]AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]. Journal of the American Society of Nephrology2005;16:71A. [CENTRAL: CN-00583784] AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation2006;21(11):3106-14. [MEDLINE: 16720593]BelloAK , deZeeuwD , El NahasM , BrantsmaAH , BakkerSJ , deJongPE , et al. Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation2007;22(6):1619-27. [MEDLINE: 17360767]BrouwersFP , AsselbergsFW , HillegeHL , deBoerRA , GansevoortRT , vanVeldhuisenDJ , et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). American Heart Journal2011;161(6):1171-8. [MEDLINE: 21641365]De JongMA , EisengaMF , vanBallegooijenAJ , BeulensJW , VervloetMG , NavisG , et al. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrology Dialysis Transplantation2021;36(1):121-8. [MEDLINE: 32124925]DiercksGF , JanssenWM , vanBovenAJ , BakAA , deJongPE , CrijnsHJ , et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology2000;86(6):635-8. [MEDLINE: 10980214]GelukCA , AsselbergsFW , HillegeHL , BakkerSJ , deJongPE , ZijlstraF , et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal2005;26(13):1314-20. [MEDLINE: 15820998]PouwelsKB , VisserST , HakE . Effect of pravastatin and fosinopril on recurrent urinary tract infections. Journal of Antimicrobial Chemotherapy2013;68(3):708-14. [MEDLINE: 23111852]vande WalRM , GansevoortRT , van derHarstP , BoomsmaF , Thijs PlokkerHW , vanVeldhuisenDJ , et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension2006;48(5):870-6. [MEDLINE: 17000930]vande WalRM , van derHarstP , GerritsenWB , van derHorstF , PlokkerTH , GansevoortRT , et al. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):177-80. [MEDLINE: 18205096]van derHarstP , AsselbergsFW , HillegeHL , VoorsAA , vanVeldhuisenDJ , vanGilstWH . Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. American Journal of Cardiology2008;102(2):223-5. [MEDLINE: 18602526]">PREVEND IT 2000</a>; <a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a>; <a href="./references#CD007784-bbs2-0059" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>). In placebo or no treatment‐controlled studies, adverse events were reported in 33 studies (63%) and systematically evaluated in 17 studies (33%). See <a href="#CD007784-sec-0051">Included studies</a> for detailed information on study risk of bias assessment. </p> <p>See <a href="#CD007784-fig-0002">Figure 2</a> and <a href="#CD007784-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD007784-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007784-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD007784-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD007784-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD007784-sec-0058"> <h4 class="title">Allocation</h4> <section id="CD007784-sec-0059"> <h5 class="title">Random sequence generation</h5> <p>Random sequence generation was low risk in 15 of the included studies, and the remaining 48 studies were judged to have an unclear risk of bias. </p> </section> <section id="CD007784-sec-0060"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was low risk in 19 studies, and the remaining 44 studies were judged to have an unclear risk of bias. </p> <p>In studies that examined the primary outcomes, six of 17 studies were low risk for random sequence generation, and nine of 17 were low risk for allocation concealment. </p> </section> </section> <section id="CD007784-sec-0061"> <h4 class="title">Blinding</h4> <section id="CD007784-sec-0062"> <h5 class="title">Performance bias</h5> <p>Participants and personnel were blinded in 27 studies and considered low risk, and 24 studies were open‐label and hence high risk, with the remaining 12 studies did not report blinding and were judged to have an unclear risk of bias. </p> </section> <section id="CD007784-sec-0063"> <h5 class="title">Detection bias</h5> <p>Sixteen blinded outcome assessors and four studies were high risk with no blinding of outcome assessors. The remaining 43 studies were judged to have an unclear risk of bias. </p> <p>In studies that reported the primary outcome, nine of 17 studies were blinded study participants and personnel, and outcome assessors. </p> </section> </section> <section id="CD007784-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>Completeness of outcome reporting was applied in 26 of the included studies, and 18 included studies exhibited a high risk of incomplete outcome reporting. The remaining 19 studies did not provide sufficient information to permit judgement and were judged to have an unclear risk of bias. Ten of the 17 studies that reported the primary outcomes exhibited a low risk of attrition bias. </p> </section> <section id="CD007784-sec-0065"> <h4 class="title">Selective reporting</h4> <p>Selective outcome reporting occurred in four studies, and only four studies exhibited a low risk of selective outcome reporting. The remaining 55 studies had unclear reporting, with studies not reporting a protocol or clinical registry number. Only two studies that reported the primary outcomes of the review exhibited a low risk of selective reporting. </p> </section> <section id="CD007784-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>The risk of bias due to sources of funding was high in 14 studies, 21 studies exhibited a low risk of any other bias, while in 28 studies the risk of bias was unclear. Nine studies that reported the primary outcomes of the review exhibited a low risk for other potential sources of bias. </p> </section> </section> <section id="CD007784-sec-0067"> <h3 class="title" id="CD007784-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD007784-tbl-0001"><b>Summary of findings 1</b> Statin therapy versus placebo or standard of care for people with chronic kidney disease not requiring dialysis</a> </p> <section id="CD007784-sec-0068"> <h4 class="title">Statin therapy versus placebo</h4> <p>The main findings of the analysis are presented in <a href="./full#CD007784-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD007784-sec-0069"> <h5 class="title">Primary outcomes</h5> <p>Compared to placebo, statin therapy reduces major cardiovascular events (<a href="./references#CD007784-fig-0007" title="">Analysis 1.1</a> (14 studies, 36,156 participants): RR 0.72, 95% CI 0.66 to 0.79; I² = 39%; high certainty evidence) and death (<a href="./references#CD007784-fig-0008" title="">Analysis 1.2</a> (13 studies, 34,978 participants): RR 0.83, 95% CI 0.73 to 0.96; I² = 53%; high certainty evidence). </p> <p>Statins had uncertain effects on rhabdomyolysis due to study limitations and very serious imprecision (<a href="./references#CD007784-fig-0009" title="">Analysis 1.3</a> (2 studies, 2618 participants): RR 3.07, 95% CI 0.13 to 75.37; very low certainty). </p> </section> <section id="CD007784-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD007784-sec-0071"> <h6 class="title">Cardiovascular endpoints</h6> <p>Compared to placebo, statin therapy probably reduces cardiovascular death (<a href="./references#CD007784-fig-0010" title="">Analysis 1.4</a> (8 studies, 19,112 participants): RR 0.77, 95% CI 0.69 to 0.87; I² = 0; moderate certainty evidence) and MI (<a href="./references#CD007784-fig-0011" title="">Analysis 1.5</a> (10 studies, 9475 participants): RR 0.55, 95% CI 0.42 to 0.73; I² = 0%; moderate certainty evidence). </p> <p>Statin therapy probably has little or no effect on stroke (<a href="./references#CD007784-fig-0012" title="">Analysis 1.6</a> (7 studies, 9115 participants): RR 0.64, 95% CI 0.37 to 1.08; I² = 39%; moderate certainty evidence) but probably decreases revascularisation procedures (<a href="./references#CD007784-fig-0013" title="">Analysis 1.7</a> (3 studies, 4156): RR 0.62, 95% CI 0.47 to 0.82; I² = 0%; moderate certainty evidence), and may have no difference on hospitalisation due to heart failure (<a href="./references#CD007784-fig-0014" title="">Analysis 1.8</a> (1 study, 579 participants): RR 0.70, 95% CI 0.37, to 1.32; low certainty evidence). </p> </section> <section id="CD007784-sec-0072"> <h6 class="title">Kidney endpoints</h6> <p>Compared to placebo, statin therapy probably has no protective kidney effect with little or no effect on kidney failure (<a href="./references#CD007784-fig-0015" title="">Analysis 1.9</a> (3 studies, 6704 participants): RR 0.98, 95% CI 0.91 to 1.05, I² = 0%; moderate certainty evidence), and doubling of SCr (<a href="./references#CD007784-fig-0016" title="">Analysis 1.10</a> (1 study, 6245 participants): RR 0.90, 95% CI 0.79 to 1.02; moderate certainty evidence). </p> <p>Statin therapy probably improves kidney function (CrCl or eGFR) (<a href="./references#CD007784-fig-0017" title="">Analysis 1.11</a> (18 studies, 4213 participants): MD 1.83, 95% CI 0.27 to 3.39 mL/min; I² = 17%; moderate certainty evidence). No difference was found with the use of measured CrCl compared to eGFR (test for subgroup differences: Chi² = 3.11, df = 1 (P = 0.08), I² = 67.8%). </p> <p>Compared to placebo, statin therapy may lower proteinuria (<a href="./references#CD007784-fig-0018" title="">Analysis 1.12</a> (7 studies, 356 participants): MD ‐0.47 g/24 hours, 95% CI ‐0.75 to ‐0.19; I² = 81%; low certainty evidence) with substantial heterogeneity. </p> </section> <section id="CD007784-sec-0073"> <h6 class="title">Safety endpoints</h6> <p>Statin therapy may have little to no effect on elevated liver enzymes (<a href="./references#CD007784-fig-0019" title="">Analysis 1.13</a> (7 studies, 7991 participants): RR 0.76, 95% CI 0.39 to 1.50; I² = 0%; low certainty evidence), withdrawal due to adverse events (<a href="./references#CD007784-fig-0020" title="">Analysis 1.14</a> (13 studies, 4219 participants): RR 1.10, 95% CI 0.83 to 1.48; I² = 37%; low certainty evidence), cancer (<a href="./references#CD007784-fig-0021" title="">Analysis 1.15</a> (2 studies, 5581 participants): RR 1.03, 95% CI 0.82 to 1.30; I² = 0%; low certainty evidence), and onset of diabetes (<a href="./references#CD007784-fig-0022" title="">Analysis 1.16</a>) (1 study, 3267 participants): RR 1.03, 95%CI 0.71 to 1.50; low certainty evidence). </p> <p>Compared to placebo, the effect of statin therapy on elevated creatinine kinase was unclear because of serious study limitations and very serious imprecision (<a href="./references#CD007784-fig-0023" title="">Analysis 1.17</a> (7 studies, 4514 participants): RR 0.84, 95% CI 0.20 to 3.48; I<sup>2</sup> = 0%; very low certainty evidence). </p> <p>Fatigue, life participation, and memory loss were not reported by any of the included studies. </p> </section> <section id="CD007784-sec-0074"> <h6 class="title">Lipid endpoints</h6> <p>Statins compared to placebo probably lowers total serum cholesterol (<a href="./references#CD007784-fig-0024" title="">Analysis 1.18</a> (27 studies, 2234 participants): MD ‐50.26 mg/dL, 95%CI ‐64.34 to ‐36.17 mg/dL (MD ‐1.3 mmol/L, 95% CI ‐1.67 to ‐0.97 mmol/L); I² = 96%; moderate certainty evidence), may decrease LDL cholesterol (<a href="./references#CD007784-fig-0025" title="">Analysis 1.19</a> (24 studies, 2183 participants): MD ‐43.84 mg/dL, 95%CI ‐52.56 to ‐35.12 mg/dL (MD ‐1.14 mmol/L, 95% CI ‐1.37 to 0.91 mmol/L); I² = 92%; low certainty evidence) and triglycerides (<a href="./references#CD007784-fig-0026" title="">Analysis 1.20</a> (20 studies, 1186 participants): MD ‐26.02 mg/dL, 95%CI ‐40.99 to ‐11.06 mg/dL (MD ‐0.29 mmol/L, 95% CI ‐0.45 to ‐1.22 mmol/L); I² = 82%; low certainty evidence), and may increase HDL cholesterol (<a href="./references#CD007784-fig-0027" title="">Analysis 1.21</a> (22 studies, 1374 participants): MD 2.92 mg/dL, 95% CI ‐0.03 to 5.88 mg/dL (MD 0.08 mmol/L, 95% CI 0.0001 to 0.15 mmol/L); I² = 81%; low certainty evidence). Analyses of treatment effects on serum lipids showed evidence for substantial heterogeneity (I² &gt; 80%) for all outcomes. </p> <p>No other secondary outcomes were reported in the included studies.</p> </section> </section> <section id="CD007784-sec-0075"> <h5 class="title">Subgroup analyses</h5> <section id="CD007784-sec-0076"> <h6 class="title">Cardiovascular disease</h6> <p>When we limited analyses to studies in which CVD was an exclusion criterion at baseline, effect modification was not evident for death (<a href="./references#CD007784-fig-0028" title="">Analysis 1.22</a>: test for subgroup differences: Chi² = 1.40, df = 1 (P = 0.24), I² = 28.5%). However, the test of subgroup differences indicated potential effect modification for major cardiovascular events, but it was considered not important as the direction of the effect estimates were in the same direction, indicating a benefit of therapy and cross‐over of the 95% CIs (<a href="./references#CD007784-fig-0029" title="">Analysis 1.23</a>: test for subgroup differences: Chi² = 2.71, df = 1 (P = 0.10), I² = 63.0%). </p> </section> <section id="CD007784-sec-0077"> <h6 class="title">Statin dose</h6> <p>When comparing &lt; 20 mg/day simvastatin equivalent with ≥ 20 mg/day simvastatin equivalent, effect modification was evident for major cardiovascular events (<a href="./references#CD007784-fig-0030" title="">Analysis 1.24</a>: test for subgroup differences: Chi² = 10.27, df = 1 (P = 0.001), I² = 90.3%) but was not important as the effect estimates were in the same direction and overlap of the 95% CIs. Test for subgroup differences found no evidence of effect modification for statin dose for the outcomes of death (<a href="./references#CD007784-fig-0031" title="">Analysis 1.25</a>), withdrawal due to adverse effects (<a href="./references#CD007784-fig-0032" title="">Analysis 1.26</a>), total cholesterol (<a href="./references#CD007784-fig-0033" title="">Analysis 1.27</a>), LDL cholesterol (<a href="./references#CD007784-fig-0034" title="">Analysis 1.28</a>), HDL cholesterol (<a href="./references#CD007784-fig-0035" title="">Analysis 1.29</a>), or triglycerides (<a href="./references#CD007784-fig-0036" title="">Analysis 1.30</a>). </p> </section> <section id="CD007784-sec-0078"> <h6 class="title">Age</h6> <p>Comparing age (&lt; 55 years versus ≥ 55 years), a test of subgroup difference was significant for total cholesterol (<a href="./references#CD007784-fig-0037" title="">Analysis 1.31</a>: test for subgroup differences: Chi² = 2.91, df = 1 (P = 0.09), I² = 65.6%). However, effect modification was not considered important because the subgroup effect estimates were in the same direction and overlap of the 95% CIs. Other outcomes did not demonstrate any effect modification (withdrawal due to adverse effects (<a href="./references#CD007784-fig-0038" title="">Analysis 1.32</a>), LDL cholesterol (<a href="./references#CD007784-fig-0039" title="">Analysis 1.33</a>), HDL cholesterol (<a href="./references#CD007784-fig-0040" title="">Analysis 1.34</a>), or triglycerides (<a href="./references#CD007784-fig-0041" title="">Analysis 1.35</a>)). </p> </section> <section id="CD007784-sec-0079"> <h6 class="title">Diabetes mellitus</h6> <p>Effect modification was examined for DM (&lt; 20% versus ≥ 20%) and was evident for withdrawal due to adverse events (<a href="./references#CD007784-fig-0042" title="">Analysis 1.36</a>: test for subgroup differences: Chi² = 3.60, df = 1 (P = 0.06), I² = 72.2%) but not for death (<a href="./references#CD007784-fig-0043" title="">Analysis 1.37</a>), major cardiovascular death (<a href="./references#CD007784-fig-0044" title="">Analysis 1.38</a>), total cholesterol (<a href="./references#CD007784-fig-0045" title="">Analysis 1.39</a>), LDL cholesterol (<a href="./references#CD007784-fig-0046" title="">Analysis 1.40</a>) HDL cholesterol (<a href="./references#CD007784-fig-0047" title="">Analysis 1.41</a>), or triglycerides (<a href="./references#CD007784-fig-0048" title="">Analysis 1.42</a>). </p> </section> <section id="CD007784-sec-0080"> <h6 class="title">Baseline cholesterol</h6> <p>When baseline cholesterol at study entry was ≥ 230 mg/dL compared to &lt; 230 mg/dL, test for subgroup differences were found for the outcomes, total cholesterol (<a href="./references#CD007784-fig-0049" title="">Analysis 1.43</a>: test for subgroup differences: Chi² = 4.47, df = 1 (P = 0.03), I² = 77.6%) and LDL cholesterol (<a href="./references#CD007784-fig-0050" title="">Analysis 1.44</a>: test for subgroup differences: Chi² = 10.02, df = 1 (P = 0.002), I² = 90.0%). The subgroup differences were not considered important because the subgroups are in the same direction and the 95% CI overlap. For the outcomes of withdrawal due to adverse events (<a href="./references#CD007784-fig-0051" title="">Analysis 1.45</a>), HDL cholesterol (<a href="./references#CD007784-fig-0052" title="">Analysis 1.46</a>), and triglycerides (<a href="./references#CD007784-fig-0053" title="">Analysis 1.47</a>), no effect modification was evident. </p> </section> <section id="CD007784-sec-0081"> <h6 class="title">Allocation concealment</h6> <p>We assessed if allocation concealment resulted in effect modification and found that for the outcome of death, a test of subgroup differences was significant (<a href="./references#CD007784-fig-0054" title="">Analysis 1.48</a>: test for subgroup differences: Chi² = 5.70, df = 1 (P = 0.02), I² = 82.5%). Studies with high or unclear risk of bias indicated little to no effect (5 studies, 2838 participants: RR 0.98 95% CI 0.82 to 1.16), while studies with appropriate allocation concealment demonstrated a benefit of statin therapy (8 studies, 32,142 participants: RR 0.77, 95% CI 0.70 to 0.84). Furthermore, subgroup differences were demonstrated in total cholesterol (<a href="./references#CD007784-fig-0055" title="">Analysis 1.49</a>: test for subgroup differences: Chi² = 4.83, df = 1 (P = 0.03), I² = 79.3%), but the subgroup effect estimates are in the same direction and the 95% CI overlapped and hence considered not important. No effect modification was evident for major cardiovascular events (<a href="./references#CD007784-fig-0056" title="">Analysis 1.50</a>) and triglycerides (<a href="./references#CD007784-fig-0057" title="">Analysis 1.51</a>). </p> </section> <section id="CD007784-sec-0082"> <h6 class="title">Baseline kidney function</h6> <p>A post hoc analysis was undertaken to examine the influence of baseline kidney function on the outcome end of treatment kidney function. We found that there was no effect modification evident (<a href="./references#CD007784-fig-0058" title="">Analysis 1.52</a>: test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%). Studies with lower kidney function at baseline (&lt; 55 mL/min/1.73 m<sup>2</sup>)demonstrated little or no effect on (5 studies, 3207 participants: MD 1.56 mL/min/1.73 m<sup>2</sup>, 95% CI ‐3.02 to 6.15), but studies with higher kidney function at baseline (≥ 55 mL/min/1.73 m<sup>2</sup>)indicated that there might be a small increase in kidney function at the end of treatment (12 studies, 963 participants: MD 2.24 mL/min/1.73 m<sup>2</sup>, 95% CI 0.30 to 4.17). </p> </section> </section> <section id="CD007784-sec-0083"> <h5 class="title">Sensitivity analyses</h5> <p>We excluded <a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> from the meta‐analysis for primary outcomes because it added ezetimibe to statin therapy. We found no differences for major cardiovascular events and death. The summary treatment estimates were essentially unchanged (<a href="./references#CD007784-fig-0059" title="">Analysis 1.53</a>: RR 0.70, 95% CI 0.63 to 0.77) (<a href="./references#CD007784-fig-0060" title="">Analysis 1.54</a>: RR 0.80, 95% CI 0.70 to 0.90). </p> <p>Excluding studies with industry funding, we found that in studies with non‐industry funding or where funding was not reported, major cardiovascular events were decreased with statin therapy compared to placebo (<a href="./references#CD007784-fig-0061" title="">Analysis 1.55</a>), similar to the meta‐analysis with all included studies (<a href="./references#CD007784-fig-0007" title="">Analysis 1.1</a>). However, for death, studies with no industry funding or where funding was not reported, statins compared to placebo made no difference (<a href="./references#CD007784-fig-0062" title="">Analysis 1.56</a>), unlike the full analysis that found statins decreased death compared to placebo. Although the effect estimates direction indicates a decrease in death, the exclusion of studies may decrease the precision of the finding, and hence the finding should be interpreted with caution. There was insufficient data to examine the effect on rhabdomyolysis. </p> <p>Excluding large studies from the analysis (N &gt; 3500) did not change the direction and size of the effect estimates for the primary outcomes, major cardiovascular events and death (data not shown). </p> <p>The following sensitivity analyses were considered but not undertaken.</p> <p> <ul id="CD007784-list-0014"> <li> <p>Repeating the analysis excluding unpublished studies (due to limited unpublished studies)</p> </li> <li> <p>Repeating analysis taking account of risk of bias (due to limited low risk of bias studies) </p> </li> <li> <p>Repeating the analysis using the following filters: diagnostic criteria, language of publication, and country. </p> </li> </ul> </p> </section> <section id="CD007784-sec-0084"> <h5 class="title">Meta‐regression</h5> <p>Considerable heterogeneity (I<sup>2</sup> = 53%) was found for the primary outcome of death. Subgroup analyses to explore heterogeneity among the studies found that kidney function at baseline accounted for 100% of the observed heterogeneity in the meta‐analysis for death. Additionally, subgroup analysis indicated that baseline kidney function (98.8% of heterogeneity explained), the proportion with diabetes (99.6%), and adequacy of allocation concealment (100%) modified the observed risks of withdrawal due to adverse events. These findings were exploratory and should be interpreted with caution. </p> </section> <section id="CD007784-sec-0085"> <h5 class="title">Assessment of publication bias</h5> <p>Publication bias was assessed for all outcomes listed in <a href="./full#CD007784-tbl-0001">summary of findings Table 1</a>, which included more than 10 studies. The funnel plots for the outcomes of major cardiovascular events (<a href="#CD007784-fig-0004">Figure 4</a>), death (<a href="#CD007784-fig-0005">Figure 5</a>), and MI (<a href="#CD007784-fig-0006">Figure 6</a>) were symmetrical and indicated little concern regarding small study effects. No further statistical testing was undertaken to assess publication bias for these outcomes. </p> <div class="figure" id="CD007784-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.1 Major cardiovascular events." data-id="CD007784-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.1 Major cardiovascular events. </p> </div> </div> </div> <div class="figure" id="CD007784-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.2 Death." data-id="CD007784-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.2 Death. </p> </div> </div> </div> <div class="figure" id="CD007784-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.5 Myocardial infarction." data-id="CD007784-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.5 Myocardial infarction. </p> </div> </div> </div> </section> </section> <section id="CD007784-sec-0086"> <h4 class="title">Statin therapy versus different statin therapy</h4> <p><a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> and <a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> compared low‐ and high‐dose rosuvastatin and atorvastatin and found both therapies were well tolerated, with few events to determine the difference between primary outcome death and secondary outcomes, doubling of SCr and AKI. </p> <p><a href="./references#CD007784-bbs2-0022" title="HolmeI , CaterNB , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine2008;40(6):456-64. [MEDLINE: 19160529]HolmeI , FayyadR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine2010;267(6):567-75. [MEDLINE: 20141566]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology2004;94(6):720-4. [MEDLINE: 15374773]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum appears in JAMA. 2005 Dec 28;294(24):3092]. JAMA2005;294(19):2437-45. [MEDLINE: 16287954]">IDEAL 2004</a> compared simvastatin with atorvastatin, <a href="./references#CD007784-bbs2-0003" title="AbeM , MaruyamaN , MaruyamaT , OkadaK , SomaM . A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease. Journal of Atherosclerosis &amp; Thrombosis2015;22(12):1235-47. [MEDLINE: 26156625]">Abe 2015</a> compared rosuvastatin with pitavastatin, <a href="./references#CD007784-bbs2-0023" title="IkedaH , UraY , NakayamaM . Rosuvastatin reduces urinary protein excretion in patients with chronic glomerulonephritis compared to the pravastatin use: a crossover trial [abstract no: SA-PO274]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):699A. ">Ikeda 2012</a> compared pravastatin with rosuvastatin, <a href="./references#CD007784-bbs2-0027" title="KimuraS , InoguchiT , YokomizoH , MaedaY , SonodaN , TakayanagiR . Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes, Obesity &amp; Metabolism2012;14(7):666-9. [MEDLINE: 22268518]">Kimura 2012</a> compared pitavastatin with pravastatin, and <a href="./references#CD007784-bbs2-0049" title="DeedwaniaP , StonePH , Bairey MerzCN , Cosin-AguilarJ , KoylanN , LuoD , et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation2007;115(6):700-7. [MEDLINE: 17283260]DeedwaniaPC , StoneP , FayyadR , LaskeyR , WilsonDJ . Improvement in renal function with intensive statin therapy in older patients without increased muscle symptoms: the SAGE trial [abstract no: SA-PO2762]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):743A. DeedwaniaPC , StonePH , FayyadRS , LaskeyRE , WilsonDJ . Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs &amp; Aging2015;32(12):1055-65. [MEDLINE: 26625880]DeedwaniaPC . Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American Heart Journal2004;148(6):1053-9. [MEDLINE: 15632893]">SAGE 2004</a> compared atorvastatin with pravastatin. Sample sizes ranged from 28 to 3107 participants. The median follow‐up was 12 months (range 12 to 58.8 months). Baseline LDL cholesterol levels ranged from 3.05 to 3.9 mmol/L. Meta‐analysis was not possible because there was insufficient data for each comparison. It was unclear which statin therapy was the most effective and safe from these studies. <a href="./references#CD007784-bbs2-0022" title="HolmeI , CaterNB , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine2008;40(6):456-64. [MEDLINE: 19160529]HolmeI , FayyadR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine2010;267(6):567-75. [MEDLINE: 20141566]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology2004;94(6):720-4. [MEDLINE: 15374773]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum appears in JAMA. 2005 Dec 28;294(24):3092]. JAMA2005;294(19):2437-45. [MEDLINE: 16287954]">IDEAL 2004</a> reported the primary outcome of major cardiovascular events, </p> <p>Secondary outcomes reported in the identified studies included LDL cholesterol, HDL cholesterol, total cholesterol, triglyceride, MDA‐LDL, non‐HDL cholesterol, SCr, cystine C, urinary albumin/creatinine ratio, hs‐CRP, HbA1c, eGFR, adverse events, the cost to lower LDL cholesterol by 10 mg/dL, onset of diabetes, time to first occurrence of a major coronary event, any chronic heart disease event, any cardiovascular event, urinary protein excretion, kidney failure, AKI, and serum uric acid. </p> </section> <section id="CD007784-sec-0087"> <h4 class="title">High versus low dose statin</h4> <p><a href="./references#CD007784-bbs2-0041" title="NarayananRP , GittinsM , SiddalsKW , OliverRL , HudsonJE , WhiteA , et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability. European Journal of Endocrinology2013;168(4):543-8. [MEDLINE: 23333902]RutterMK , DaviesRR , CruickshankJK , PraisHR , GittinsM , RobertsC , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): trial results [abstract no: 1207]. Diabetologia2009;52(Suppl 1):S466. [EMBASE: 70068693]RutterMK , PraisHR , Charlton-MenysV , GittinsM , RobertsC , DaviesRR , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabetic Medicine2011;28(1):100-8. [MEDLINE: 21166851]SoranH , LiuY , AdamS , SiahmansurT , HoJH , SchofieldJD , et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. Journal of Clinical Lipidology2018;12(1):44-55. [MEDLINE: 29246729]">PANDA 2011</a> and <a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a> compared two doses of atorvastatin, and <a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> and <a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> compared low‐ and high‐dose rosuvastatin. </p> <section id="CD007784-sec-0088"> <h5 class="title">Primary outcomes</h5> <p>High‐dose statin compared to low‐dose statin may have little or no effect on major cardiovascular events (<a href="./references#CD007784-fig-0068" title="">Analysis 2.1</a> (2 studies, 3226 participants): RR 1.17, 95% CI 0.25 to 5.55; I<sup>2</sup> = 59%; low certainty evidence), and death (<a href="./references#CD007784-fig-0069" title="">Analysis 2.2</a> (3 studies, 3465 participants): RR 1.05, 95% CI 0.29 to 3.83; I<sup>2</sup> = 56%; low certainty evidence). No events of rhabdomyolysis were reported. </p> </section> <section id="CD007784-sec-0089"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a> (3107 participants) reported high‐dose statin may decrease stroke (<a href="./references#CD007784-fig-0070" title="">Analysis 2.3</a>: RR 0.67, 95% CI 0.50 to 0.89) and hospitalisation due to heart failure (<a href="./references#CD007784-fig-0071" title="">Analysis 2.4</a>: RR 0.55, 95% CI 0.39 to 0.77; low certainty evidence) compared to low‐dose statin. High‐dose statin, compared to low‐dose statin, probably has little or no effect on serious adverse events (<a href="./references#CD007784-fig-0072" title="">Analysis 2.5</a> (2 studies, 358 participants): RR 1.12, 95% CI 0.73 to 1.72; I<sup>2</sup> = 0%; moderate certainty evidence), but there was limited data on AKI and doubling of SCr to determine if high‐dose statin made a difference. However, high‐dose statins may increase elevated liver enzymes (<a href="./references#CD007784-fig-0073" title="">Analysis 2.6</a>: RR 20.67, 95% CI 2.79 to 153.14; low certainty evidence) compared to low‐dose statins. <a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> (223 participants) reported high‐ versus low‐dose rosuvastatin may improve change in total cholesterol and LDL cholesterol at 12 months, but there was no difference in change in HDL cholesterol and change in triglycerides. No other secondary outcomes were reported in the included studies. </p> </section> </section> <section id="CD007784-sec-0090"> <h4 class="title">Continuous release versus intermittent release statin</h4> <p><a href="./references#CD007784-bbs2-0062" title="YiYJ , KimHJ , JoSK , KimSG , SongYR , ChungW , et al. Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. Clinical Therapeutics2014;36(8):1182-90. [MEDLINE: 24996489]">Yi 2014</a> (122 participants) compared continuous‐release to intermittent‐release statin (20 mg/day). No primary outcomes of major cardiovascular events, death, or rhabdomyolysis were reported. There were few withdrawals due to adverse events in the study. Continuous‐release versus intermittent‐release statin may have little or no effect on total cholesterol, LDL cholesterol, and HDL cholesterol, but may increase triglycerides. No other secondary outcomes were reported. </p> <p>There was insufficient data to perform a meta‐analysis for this comparison.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007784-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007784-sec-0091"></div> <section id="CD007784-sec-0092"> <h3 class="title" id="CD007784-sec-0092">Summary of main results</h3> <p>This update confirmed findings from the previous 2014 review (<a href="./references#CD007784-bbs2-0146" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD007784. [DOI: 10.1002/14651858.CD007784.pub2]">Palmer 2014</a>). Compared to placebo, statins reduced the risk of death by 20% and major cardiovascular events by 28% in people with CKD not needing dialysis. Statins probably reduce the risk of MI by nearly half, but the effects on stroke and hospitalisation due to heart failure remain uncertain. Statins decreased death, major cardiovascular events, and MI in people with (secondary prevention) and without CVD (primary prevention). </p> <p>Considering the estimated baseline risk of people with CKD not needing dialysis (<a href="./full#CD007784-tbl-0001">summary of findings Table 1</a>), statins given to 1000 people with CKD for one year might be expected to prevent 32 major cardiovascular events, 10 deaths from any cause, and seven non‐fatal or fatal MIs. There was limited reporting of adverse effects of statins in people with CKD not needing dialysis. Withdrawal due to adverse effects probably occurs more frequently among those with lower kidney function or pre‐existing diabetes, suggesting that these people may be more at risk of treatment‐related toxicity. However, there was uncertainty regarding the effect on rhabdomyolysis due to the few events reported and no reporting of patient‐important outcomes such as fatigue, life participation, and memory loss. </p> <p>Data comparing different statins were sparse in patients with CKD. One study reported a benefit of high‐dose statins in reducing stroke and heart failure events compared to low‐dose statins, but a further examination of this finding is required. Additionally, there was limited reporting of safety in studies comparing high‐ versus low‐dose statins. </p> </section> <section id="CD007784-sec-0093"> <h3 class="title" id="CD007784-sec-0093">Overall completeness and applicability of evidence</h3> <p>Based on current evidence, statins probably make little to no difference to CKD progression, as treatment effects were similar to placebo with more than 2000 events. However, statins probably have a slight benefit on kidney function and may reduce proteinuria due to the pleiotropic effects of statins, but the clinical importance of these outcomes is unclear. Nearly two‐thirds of the included studies did not systematically evaluate and report adverse events, such as rhabdomyolysis and elevated liver enzymes. There was no reporting of patient‐important outcomes, such as fatigue, memory loss, and life participation. </p> <p><a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> assessed ezetimibe (a drug that lowers cholesterol absorption in the intestine) combined with simvastatin. There was insufficient data to determine if treatment effects differed between combination therapy and treatment with a statin alone. There was limited data that could be used to determine the most effective and safe type of statin or dose of statin in the CKD population. Furthermore, it was unclear if treatment benefits for statins depended on treatment‐related reductions in serum cholesterol or by another mechanism of action, as there were insufficient number of studies that reported both cardiovascular and death outcomes and changes in cholesterol levels with treatment. </p> </section> <section id="CD007784-sec-0094"> <h3 class="title" id="CD007784-sec-0094">Quality of the evidence</h3> <p>Overall, the quality of the evidence in clinical outcomes (death, cardiovascular events, kidney failure) for shared decision‐making for statin with or without ezetimibe is high to moderate certainty evidence. However, the data for patient‐important outcomes, such as rhabdomyolysis is very low or not reported for fatigue, life participation and memory loss. </p> <p>Current data on the effects of statins in people with earlier stages of kidney disease relating to the primary outcomes of death and cardiovascular events were derived from post hoc subgroup analyses from major studies in larger populations (<a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a>; <a href="./references#CD007784-bbs2-0004" title="ClearfieldM , DownsJR , WeisS , WhitneyEJ , KruyerW , ShapiroDR , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health &amp; Gender-Based Medicine2001;10(10):971-81. [MEDLINE: 11788107]ClearfieldM , WhitneyEJ , WeisS , DownsJR , ShapiroDR , SteinEA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk2000;7(2):125-33. [MEDLINE: 10879416]ClearfieldMB , WeisSE , WillisJM , VaseniusKA , McConathyWJ . Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association2002;102(7):377-84. [MEDLINE: 12138952]CuiY , WatsonDJ , GirmanCJ , ShapiroDR , GottoAM , HiseroteP , et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology2009;104(6):829-34. [MEDLINE: 19733719]DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287-93. [MEDLINE: 9264420]DownsJR , ClearfieldM , TyrolerHA , WhitneyEJ , KruyerW , LangendorferA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology2001;87(9):1074-9. [MEDLINE: 11348605]DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22. [MEDLINE: 9613910]Gotto AM Jr, BoccuzziSJ , CookJR , AlexanderCM , RoehmJB , MeyerGS , et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology2000;86(11):1176-81. [MEDLINE: 11090787]KendrickJ , ShlipakMG , TargherG , CookT , LindenfeldJ , ChoncholM . Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases2010;55(1):42-9. [MEDLINE: 19932541]">AFCAPS/TexCAPS 1997</a>; <a href="./references#CD007784-bbs2-0005" title="IsaacsohnJL , DavidsonMH , HunninghakeD , SingerR , McLainR , BlackDM . Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology2000;86(2):250-2. [MEDLINE: 10913499]KorenMJ , DavidsonMH , WilsonDJ , FayyadRS , ZuckermanA , ReedDP , et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases2009;53(5):741-50. [MEDLINE: 19216014]KorenMJ , DavidsonMH . Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. KorenMJ , HunninghakeDB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology2004;44(9):1772-9. [MEDLINE: 15519006]MullinsCD , RattingerGB , KuznikA , KorenMJ . Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics2008;30 Pt 2:2204-16. [MEDLINE: 19281915]">ALLIANCE 2000</a>; <a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a>; <a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a>; <a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a>; <a href="./references#CD007784-bbs2-0031" title="ArampatzisCA , GoedhartD , SerruysPW , SaiaF , LemosPA , deFeyterP . Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal2005;149(2):329-35. [MEDLINE: 15846273]LemosPA , SerruysPW , deFeyterP , MercadoNF , GoedhartD , SaiaF , et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology2005;95(4):445-51. [MEDLINE: 15695126]SerruysPW , De FeyterPJ , BenghoziR , HugenholtzPG , LesaffreE . The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions2001;4(4):165-72. [PMID: 12036459]SerruysPW , deFeyterP , MacayaC , KokottN , PuelJ , VrolixM , et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002;287(24):3215-22. [MEDLINE: 12076217]">LIPS 2001</a>; <a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a>; <a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a>; <a href="./references#CD007784-bbs2-0046" title="AsselbergsFW , DiercksGF , HillegeHL , vanBovenAJ , JanssenWM , VoorsAA , et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004;110(18):2809-16. [MEDLINE: 15492322]AsselbergsFW , vanRoonAM , HillegeHL , deJongPE , GansRO , SmitAJ , et al. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke2005;36(3):649-53. [MEDLINE: 15692120]AsselbergsFW , van derHarstP , vanRoonAM , HillegeHL , deJongPE , GansRO , et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis2008;196(1):349-55. [MEDLINE: 17141245]AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]. Journal of the American Society of Nephrology2005;16:36A. [CENTRAL: CN-00583782] AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics2006;28(3):432-44. [MEDLINE: 16750458]AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]. Journal of the American Society of Nephrology2005;16:71A. [CENTRAL: CN-00583784] AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation2006;21(11):3106-14. [MEDLINE: 16720593]BelloAK , deZeeuwD , El NahasM , BrantsmaAH , BakkerSJ , deJongPE , et al. Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation2007;22(6):1619-27. [MEDLINE: 17360767]BrouwersFP , AsselbergsFW , HillegeHL , deBoerRA , GansevoortRT , vanVeldhuisenDJ , et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). American Heart Journal2011;161(6):1171-8. [MEDLINE: 21641365]De JongMA , EisengaMF , vanBallegooijenAJ , BeulensJW , VervloetMG , NavisG , et al. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrology Dialysis Transplantation2021;36(1):121-8. [MEDLINE: 32124925]DiercksGF , JanssenWM , vanBovenAJ , BakAA , deJongPE , CrijnsHJ , et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology2000;86(6):635-8. [MEDLINE: 10980214]GelukCA , AsselbergsFW , HillegeHL , BakkerSJ , deJongPE , ZijlstraF , et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal2005;26(13):1314-20. [MEDLINE: 15820998]PouwelsKB , VisserST , HakE . Effect of pravastatin and fosinopril on recurrent urinary tract infections. Journal of Antimicrobial Chemotherapy2013;68(3):708-14. [MEDLINE: 23111852]vande WalRM , GansevoortRT , van derHarstP , BoomsmaF , Thijs PlokkerHW , vanVeldhuisenDJ , et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension2006;48(5):870-6. [MEDLINE: 17000930]vande WalRM , van derHarstP , GerritsenWB , van derHorstF , PlokkerTH , GansevoortRT , et al. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):177-80. [MEDLINE: 18205096]van derHarstP , AsselbergsFW , HillegeHL , VoorsAA , vanVeldhuisenDJ , vanGilstWH . Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. American Journal of Cardiology2008;102(2):223-5. [MEDLINE: 18602526]">PREVEND IT 2000</a>; <a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a>). Data for treatment effects in people with CKD derived from post hoc analyses of larger studies may be less reliable (<a href="./references#CD007784-bbs2-0101" title="BoutronI , DuttonS , RavaudP , AltmanDG . Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA2010;303(20):2058-64. [MEDLINE: 20501928]">Boutron 2010</a>). The heterogeneity observed in our review was not explained by prespecified or post hoc studies of people with CKD, as the effects estimates in all studies were similar<i>.</i> </p> </section> <section id="CD007784-sec-0095"> <h3 class="title" id="CD007784-sec-0095">Potential biases in the review process</h3> <p>This review is reported using standardised Cochrane methods and the PRISMA checklist (<a href="./references#CD007784-bbs2-0124" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzscheGC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700. [PMID: 19622552]">Liberati 2009</a>). It includes a highly sensitive electronic search of the Cochrane Kidney and Transplant's Specialised Registry of Studies, designed by an Information Specialist. Despite applying these best practice approaches, potential biases may exist in the review process. Incomplete reporting of outcomes in the identified studies limited the power to detect differences among interventions for important outcomes. For example, data for treatment effects on stroke and hospitalisation due to heart failure suggest a potential for benefit, but the small number of events resulted in imprecision in the effect estimate. This incomplete reporting of outcomes may also limit the statistical power to detect heterogeneity. However, the analysis of most outcomes exhibits low to moderate heterogeneity, indicating that the meta‐analysis was appropriate. Additionally, we could not include data for people with CKD not on dialysis from <a href="./references#CD007784-bbs2-0054" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503-10. [MEDLINE: 16303728]StegmayrBG , BrannstromM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489-97. [MEDLINE: 18161210]StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. In: 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. [CENTRAL: CN-00447842] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. [CENTRAL: CN-00583406] ">Stegmayr 2005</a> for death and cardiovascular death. Reported data for these outcomes combined results for people on dialysis with those at earlier stages of kidney disease not on dialysis; separate unpublished data for earlier stages of kidney disease were not available. </p> </section> <section id="CD007784-sec-0096"> <h3 class="title" id="CD007784-sec-0096">Agreements and disagreements with other studies or reviews</h3> <p>This update confirmed our earlier review findings that statins reduce serious cardiovascular events and death in people with CKD not requiring dialysis (<a href="./references#CD007784-bbs2-0146" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD007784. [DOI: 10.1002/14651858.CD007784.pub2]">Palmer 2014</a>). The finding that statins proportionally reduce cardiovascular death by 20% is similar to the prospective meta‐analysis in broader populations of people who had or were at risk for CVD, which showed that statins lowered lipids to reduce coronary‐related death at a rate of 20% (<a href="./references#CD007784-bbs2-0099" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358] [Erratum in: Lancet. 2008 Jun 21;371(9630):2084]. Lancet2005;366(9493):1267-78. [MEDLINE: 16214597]">Baigent 2005</a>). People with CKD risk cardiovascular events equivalent to those with existing coronary artery disease (<a href="./references#CD007784-bbs2-0107" title="FoleyRN , ParfreyPS , SarnakMJ . Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases1998;32(5 Suppl 3):S112-9. [MEDLINE: 9820470]">Foley 1998</a>). The absolute benefits of statins in people with CKD are similar to people with a 20% or more 10‐year absolute cardiovascular risk, for whom statins are recommended (<a href="./references#CD007784-bbs2-0130" title="National Institute for Health and Clinical Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. https://www.nice.org.uk/guidance/cg181 (accessed 11 October 2023).">NICE 2014</a>). </p> <p>We also found that statins reduced death by approximately 28%, similar to the 10% proportional reduction in broader populations (<a href="./references#CD007784-bbs2-0099" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358] [Erratum in: Lancet. 2008 Jun 21;371(9630):2084]. Lancet2005;366(9493):1267-78. [MEDLINE: 16214597]">Baigent 2005</a>). The inclusion of studies conducted in people with CKD without clinically evident CVD in this review (<a href="./references#CD007784-bbs2-0002" title="AbeM , MaruyamaN , OkadaK , MatsumotoS , MatsumotoK , SomaM . Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Journal of Atherosclerosis &amp; Thrombosis2011;18(11):1018-28. [MEDLINE: 21921413]">Abe 2011c</a>; <a href="./references#CD007784-bbs2-0033" title="Masajtis-ZagajewskaA , NowickiM . Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Renal Failure2018;40(1):700-9. [MEDLINE: 30741616]">Masajtis‐Zagajewska 2018</a>; <a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a>) reaffirmed the previous finding that statins have a role in the primary prevention of death and major cardiovascular events (<a href="./references#CD007784-bbs2-0146" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD007784. [DOI: 10.1002/14651858.CD007784.pub2]">Palmer 2014</a>). The beneficial effect of statins on cardiovascular end‐points observed in our review may be potentially explained by either cholesterol‐dependent or cholesterol‐independent effects or both. In addition to the well‐documented association between cholesterol‐lowering and cardiovascular risk reduction in non‐CKD populations (<a href="./references#CD007784-bbs2-0099" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358] [Erratum in: Lancet. 2008 Jun 21;371(9630):2084]. Lancet2005;366(9493):1267-78. [MEDLINE: 16214597]">Baigent 2005</a>), statins may modulate cardiovascular risk by decreasing inflammation, enhancing endothelial function, inhibiting smooth muscle proliferation, exerting direct anti‐thrombotic properties and stabilising pre‐existing atherosclerotic plaque (<a href="./references#CD007784-bbs2-0123" title="KinlayS , SelwynAP . Effects of statins on inflammation in patients with acute and chronic coronary syndromes. American Journal of Cardiology2003;91(4A):9-13B. [MEDLINE: 12615293]">Kinlay 2003</a>; <a href="./references#CD007784-bbs2-0134" title="RobinsonJG , SmithB , MaheshwariN , SchrottH . Pleiotropic effects of statins: benefit beyond cholesterol reduction. A meta-regression analysis. Journal of the American College of Cardiology2005;46(10):1855-62. [MEDLINE: 16286171]">Robinson 2005</a>; <a href="./references#CD007784-bbs2-0142" title="SotiriouCG , ChengJW . Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol. Annals of Pharmacotherapy2000;34(12):1432-9. [MEDLINE: 11144702]">Sotiriou 2000</a>). Similar mechanisms may underpin the beneficial actions of statins on the progression of kidney disease, although other cholesterol‐independent renoprotective actions such as inhibition of renal cell proliferation, anti‐fibrotic effects, suppression of macrophage recruitment, anti‐oxidation, and down‐regulation of inflammatory cytokines, may also contribute (<a href="./references#CD007784-bbs2-0103" title="CampeseVM , NadimMK , EpsteinM . Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?Journal of the American Society of Nephrology2005;16 Suppl 1:S11-7. [MEDLINE: 15938026]">Campese 2005</a>; <a href="./references#CD007784-bbs2-0122" title="KeaneWF . The role of lipids in renal disease: future challenges. Kidney International - Supplement2000;75:S27-31. [MEDLINE: 10828758]">Keane 2000</a>). </p> <p>Notably, the finding that statins significantly reduce adverse cardiovascular outcomes in people with earlier stages of CKD contrasts with a similar systematic review and meta‐analysis we have conducted of studies in people with advanced kidney disease on dialysis (<a href="./references#CD007784-bbs2-0131" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , NigwekarSU , et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2013, Issue 9. Art. No: CD004289. [DOI: 10.1002/14651858.CD004289.pub5]">Palmer 2013</a>). Statin therapy in people with advanced CKD on dialysis has little or no effect on major cardiovascular events (RR 0.95, 95% CI 0.88 to 1.03), death (any cause) (RR 0.96, 95% CI 0.90 to 1.02), cardiovascular death (RR 0.94, 95% CI 0.84 to 1.06), or MI (RR 0.87, 95% CI 0.71 to 1.07) with uncertain effects on liver or muscle function or cancer, despite a similar reduction in cholesterol levels. Similarly, an individual patient‐level meta‐analysis of 28 RCTs found that the effects of statins decreased with declining kidney function, with patients on dialysis receiving little to no benefit from statins (<a href="./references#CD007784-bbs2-0116" title="HerringtonWG , EmbersonJ , MihaylovaB , BlackwellL , ReithC , SolbuMD , et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. The Lancet Diabetes &amp; Endocrinology2016;4(10):829-39. [PMID: 27477773]">Herrington 2016</a>). </p> <p>The KDIGO Lipids in CKD guideline recommends statins for patients 50 years or older and an eGFR ≥ 60 mL/min/1.73 m<sup>2</sup> "For patients 50 years of age and older and eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> not needing dialysis, a statin with or without ezetimibe" (<a href="./references#CD007784-bbs2-0121" title="Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney International Supplement2013;3:259-305. [DOI: 10.1038/kisup.2013.27]">KDIGO 2013</a>). Additionally, CARI Guidelines (<a href="./references#CD007784-bbs2-0104" title="JohnsonDW , AtaiE , ChanCM , PhoonRKS , ScottC , ToussaintND , TurnerGL , UsherwoodT , WigginsKJ . KHA-CARI Guideline: Early chronic kidney disease: Detection, prevention and management. Nephrology2013;18(5):340-50. [PMID: 23506545]">CARI 2013</a>) recommend using statins with or without ezetimibe in patients with early CKD (stages 1 to 3) to reduce the risk of atherosclerotic disease. Our analysis confirms the benefits of statins in people with CKD (including primary prevention of death and cardiovascular events) and supports the present guidelines. However, there is limited data on the incremental benefit of ezetimibe combined with statins in people with CKD. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007784-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram showing study selection" data-id="CD007784-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram showing study selection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007784-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD007784-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.1 Major cardiovascular events." data-id="CD007784-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.1 Major cardiovascular events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.2 Death." data-id="CD007784-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.2 Death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.5 Myocardial infarction." data-id="CD007784-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Statins versus placebo or no treatment, outcome: 1.5 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 1: Major cardiovascular events" data-id="CD007784-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 1: Major cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 2: Death" data-id="CD007784-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 2: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 3: Rhabdomyolysis" data-id="CD007784-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 3: Rhabdomyolysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 4: Cardiovascular death" data-id="CD007784-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 4: Cardiovascular death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 5: Myocardial infarction" data-id="CD007784-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 5: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 6: Stroke" data-id="CD007784-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 6: Stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 7: Revascularisation procedure" data-id="CD007784-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 7: Revascularisation procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 8: Hospitilsation due to heart failure" data-id="CD007784-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 8: Hospitilsation due to heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 9: Kidney failure" data-id="CD007784-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 9: Kidney failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 10: Doubling serum creatinine" data-id="CD007784-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 10: Doubling serum creatinine</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 11: End of treatment kidney function" data-id="CD007784-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 11: End of treatment kidney function </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 12: End of treatment proteinuria" data-id="CD007784-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 12: End of treatment proteinuria </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 13: Elevated liver enzymes" data-id="CD007784-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 13: Elevated liver enzymes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 14: Withdrawal due to adverse events" data-id="CD007784-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 14: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 15: Cancer" data-id="CD007784-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 15: Cancer</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 16: Onset of diabetes" data-id="CD007784-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 16: Onset of diabetes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 17: Elevated creatine kinase" data-id="CD007784-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 17: Elevated creatine kinase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 18: Total cholesterol" data-id="CD007784-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 18: Total cholesterol</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 19: LDL cholesterol" data-id="CD007784-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 19: LDL cholesterol</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 20: Triglycerides" data-id="CD007784-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 20: Triglycerides</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 21: HDL cholesterol" data-id="CD007784-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 21: HDL cholesterol</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 22: Subgroup analysis (cardiovascular disease): death" data-id="CD007784-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 22: Subgroup analysis (cardiovascular disease): death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 23: Subgroup analysis (cardiovascular disease): major cardiovascular events" data-id="CD007784-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 23: Subgroup analysis (cardiovascular disease): major cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 24: Subgroup analysis (statin dose): major cardiovascular death" data-id="CD007784-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 24: Subgroup analysis (statin dose): major cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 25: Subgroup analysis (statin dose): death" data-id="CD007784-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 25: Subgroup analysis (statin dose): death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 26: Subgroup analysis (statin dose): withdrawal due to adverse events" data-id="CD007784-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 26: Subgroup analysis (statin dose): withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 27: Subgroup analysis (statin dose): total cholesterol" data-id="CD007784-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 27: Subgroup analysis (statin dose): total cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 28: Subgroup analysis (statin dose): LDL cholesterol" data-id="CD007784-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 28: Subgroup analysis (statin dose): LDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 29: Subgroup analysis (statin dose): HDL cholesterol" data-id="CD007784-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 29: Subgroup analysis (statin dose): HDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 30: Subgroup analysis (statin dose): triglycerides" data-id="CD007784-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 30: Subgroup analysis (statin dose): triglycerides </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 31: Subgroup analysis (age): total cholesterol" data-id="CD007784-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 31: Subgroup analysis (age): total cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 32: Subgroup analysis (age): withdrawal due to adverse events" data-id="CD007784-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 32: Subgroup analysis (age): withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 33: Subgroup analysis (age): LDL cholesterol" data-id="CD007784-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 33: Subgroup analysis (age): LDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 34: Subgroup analysis (age): HDL cholesterol" data-id="CD007784-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 34: Subgroup analysis (age): HDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 35: Subgroup analysis (age): triglycerides" data-id="CD007784-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 35: Subgroup analysis (age): triglycerides </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 36: Subgroup analysis (diabetes mellitus): withdrawal due to adverse events" data-id="CD007784-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 36: Subgroup analysis (diabetes mellitus): withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 37: Subgroup analysis (diabetes mellitus): death" data-id="CD007784-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 37: Subgroup analysis (diabetes mellitus): death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 38: Subgroup analysis (diabetes mellitus): major cardiovascular death" data-id="CD007784-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 38: Subgroup analysis (diabetes mellitus): major cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 39: Subgroup analysis (diabetes mellitus): total cholesterol" data-id="CD007784-fig-0045" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 39: Subgroup analysis (diabetes mellitus): total cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 40: Subgroup analysis (diabetes mellitus): LDL cholesterol" data-id="CD007784-fig-0046" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 40: Subgroup analysis (diabetes mellitus): LDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 41: Subgroup analysis (diabetes mellitus): HDL cholesterol" data-id="CD007784-fig-0047" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 41: Subgroup analysis (diabetes mellitus): HDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 42: Subgroup analysis (diabetes mellitus): triglycerides" data-id="CD007784-fig-0048" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 42: Subgroup analysis (diabetes mellitus): triglycerides </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 43: Subgroup analysis (baseline cholesterol): total cholesterol" data-id="CD007784-fig-0049" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 43: Subgroup analysis (baseline cholesterol): total cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 44: Subgroup analysis (baseline cholesterol): LDL cholesterol" data-id="CD007784-fig-0050" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 44: Subgroup analysis (baseline cholesterol): LDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 45: Subgroup analysis (baseline cholesterol): withdrawal due to adverse events" data-id="CD007784-fig-0051" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 45: Subgroup analysis (baseline cholesterol): withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 46: Subgroup analysis (baseline cholesterol): HDL cholesterol" data-id="CD007784-fig-0052" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 46: Subgroup analysis (baseline cholesterol): HDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.46.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.47" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 47: Subgroup analysis (baseline cholesterol): triglycerides" data-id="CD007784-fig-0053" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.47.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.47.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 47: Subgroup analysis (baseline cholesterol): triglycerides </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.47.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.48" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 48: Subgroup analysis (allocation concealment): death" data-id="CD007784-fig-0054" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.48.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.48.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 48: Subgroup analysis (allocation concealment): death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.48.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.49" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 49: Subgroup analysis (allocation concealment): total cholesterol" data-id="CD007784-fig-0055" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.49.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.49.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 49: Subgroup analysis (allocation concealment): total cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.49.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.50" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 50: Subgroup analysis (allocation concealment): major cardiovascular events" data-id="CD007784-fig-0056" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.50.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.50.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 50: Subgroup analysis (allocation concealment): major cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.50.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.51" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 51: Subgroup analysis (allocation concealment): triglycerides" data-id="CD007784-fig-0057" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.51.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.51.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 51: Subgroup analysis (allocation concealment): triglycerides </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.51.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.52" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 52: Subgroup analysis (kidney function): end of treatment kidney function" data-id="CD007784-fig-0058" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.52.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.52.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 52: Subgroup analysis (kidney function): end of treatment kidney function </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.52.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.53" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 53: Sensitivity analysis (excluding SHARP): major cardiovascular events" data-id="CD007784-fig-0059" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.53.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.53.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 53: Sensitivity analysis (excluding SHARP): major cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.53.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.54" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 54: Sensitivity analysis (excluding SHARP): death" data-id="CD007784-fig-0060" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.54.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.54.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 54: Sensitivity analysis (excluding SHARP): death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.54.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.55" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 55: Sensitivity analysis (funding): major cardiovascular events" data-id="CD007784-fig-0061" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.55.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.55.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 55: Sensitivity analysis (funding): major cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.55.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.56" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 56: Sensitivity analysis (funding): death" data-id="CD007784-fig-0062" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.56.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.56.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 56: Sensitivity analysis (funding): death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.56.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.57" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 57: Sensitivity analysis (funding): withdrawal due to adverse events" data-id="CD007784-fig-0063" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.57.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.57.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 57: Sensitivity analysis (funding): withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.57.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.58" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 58: Sensitvitiy analysis (funding): total cholesterol" data-id="CD007784-fig-0064" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.58.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.58.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 58: Sensitvitiy analysis (funding): total cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.58.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.59" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 59: Sensitivity analysis (funding): LDL cholesterol" data-id="CD007784-fig-0065" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.59.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.59.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.59</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 59: Sensitivity analysis (funding): LDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.59.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.60" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 60: Sensitivy analysis (funding): HDL cholesterol" data-id="CD007784-fig-0066" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.60.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.60.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.60</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 60: Sensitivy analysis (funding): HDL cholesterol </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.60.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-001.61" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statins versus placebo or no treatment, Outcome 61: Sensitivity analysis (funding): triglycerides" data-id="CD007784-fig-0067" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.61.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-001.61.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.61</div> <div class="figure-caption"> <p>Comparison 1: Statins versus placebo or no treatment, Outcome 61: Sensitivity analysis (funding): triglycerides </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-001.61.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose versus low dose statin, Outcome 1: Major cardiovascular events" data-id="CD007784-fig-0068" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: High dose versus low dose statin, Outcome 1: Major cardiovascular events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose versus low dose statin, Outcome 2: Death" data-id="CD007784-fig-0069" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: High dose versus low dose statin, Outcome 2: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose versus low dose statin, Outcome 3: Stroke" data-id="CD007784-fig-0070" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: High dose versus low dose statin, Outcome 3: Stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose versus low dose statin, Outcome 4: Hospitilisation due to heart failure" data-id="CD007784-fig-0071" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: High dose versus low dose statin, Outcome 4: Hospitilisation due to heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose versus low dose statin, Outcome 5: Serious adverse events" data-id="CD007784-fig-0072" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: High dose versus low dose statin, Outcome 5: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose versus low dose statin, Outcome 6: Elevated liver enzyme" data-id="CD007784-fig-0073" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: High dose versus low dose statin, Outcome 6: Elevated liver enzyme</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007784-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/urn:x-wiley:14651858:media:CD007784:CD007784-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose versus low dose statin, Outcome 7: eGFR [mL/min/1.73 m2]" data-id="CD007784-fig-0074" src="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_t/tCD007784-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: High dose versus low dose statin, Outcome 7: eGFR [mL/min/1.73 m<sup>2</sup>] </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/media/CDSR/CD007784/image_n/nCD007784-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007784-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Statin therapy versus placebo or standard of care for people with chronic kidney disease not requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Statin therapy versus placebo or standard of care for people with chronic kidney disease not requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic kidney disease not requiring dialysis<br/><b>Setting:</b> primary and tertiary care<br/><b>Intervention:</b> statin therapy<br/><b>Comparison:</b> placebo or standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or standard of care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with statin therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major cardiovascular events (MACE)<br/>follow up: mean 46 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1,000<br/>(4 to 5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/>(0.66 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36156 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy reduces major cardiovascular events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>follow up: mean 40 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(2 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/>(0.73 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34978 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy reduces death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rhabdomyolysis<br/>follow up: mean 64 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(0 to 59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.07<br/>(0.13 to 75.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2618 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of statin therapy on rhabdomyolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction<br/>follow up: mean 39 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(1 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55<br/>(0.42 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9475 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy probably reduces myocardial infarction</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke<br/>follow up: mean 40 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1,000<br/>(5 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/>(0.37 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9158 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy probably results in little to no difference in stroke</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney failure<br/>follow up: mean 34 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1,000<br/>(2 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/>(0.91 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6704 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy probably results in little to no difference in kidney failure</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation due to heart failure<br/>follow up: 54 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/>(28 to 99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.37 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>579 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin therapy may result in little to no difference in hospitalisation due to heart failure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the baseline risk of outcomes from observational studies (and its 95%CI) . The relevant studies in the Summary of Findings Table are listed below: </p> <p>Major cardiovascular events and death ‐ <a href="./references#CD007784-bbs2-0110" title="GoAS , ChertowGM , FanD , McCullochCE , HsuCY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine2004;351(13):1296-305. [MEDLINE: 15385656]">Go 2004</a> </p> <p>Rhabdomyolysis ‐ based on the assumed risk of outcomes in the comparison group</p> <p>Myocardial infarction ‐ <a href="./references#CD007784-bbs2-0128" title="MeisignerC , DöringA , LöwelH . Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. European Heart Journal2006;27(10):1245-50. [PMID: 16611670]">Meisinger 2006</a> </p> <p>Stroke and hospitalisation due to heart failure ‐ <a href="./references#CD007784-bbs2-0100" title="BansalN , KatzR , Robinson-CohenC , OddenMC , DalrympleL , ShlipakMG , et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiology2017;2(3):314-8. [PMID: 28002548]">Bansal 2017</a><br/>Kidney failure ‐ <a href="./references#CD007784-bbs2-0105" title="DalrympleLS , KatzR , KesetenbaumB , ShlipakMG , SarnakMJ , Stehman-BreenC , et al. Chronic kidney disease and the risk of end-stage renal disease versus death. Journal General Internal Medicine2011;26(4):379-85. [PMID: 20853156]">Dalrymple 2011</a><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MACE:</b> Major Adverse Cardiac Events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very few events </p> <p><sup>2</sup> Inadequate sequence generation/ generation of comparable groups, resulting in potential for selection bias </p> <p><sup>3</sup> Effect estimates were on both side of the null </p> <p><sup>4</sup> Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate concealment of allocation during randomisation process, resulting in potential for selection bias, </p> <p><sup>5</sup> Only one study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Statin therapy versus placebo or standard of care for people with chronic kidney disease not requiring dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007784-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">List of included studies according to Cochrane review update</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus placebo studies identified in the 2009 and 2014 version of the Cochrane review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus placebo studies identified in the updated 2023 Cochrane review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus statin studies identified in the 2009 and 2014 version of the Cochrane review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Statin versus statin studies identified in the updated 2023 Cochrane review</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0002" title="AbeM , MaruyamaN , OkadaK , MatsumotoS , MatsumotoK , SomaM . Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Journal of Atherosclerosis &amp; Thrombosis2011;18(11):1018-28. [MEDLINE: 21921413]">Abe 2011c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0022" title="HolmeI , CaterNB , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine2008;40(6):456-64. [MEDLINE: 19160529]HolmeI , FayyadR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine2010;267(6):567-75. [MEDLINE: 20141566]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology2004;94(6):720-4. [MEDLINE: 15374773]PedersenTR , FaergemanO , KasteleinJJ , OlssonAG , TikkanenMJ , HolmeI , et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum appears in JAMA. 2005 Dec 28;294(24):3092]. JAMA2005;294(19):2437-45. [MEDLINE: 16287954]">IDEAL 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0003" title="AbeM , MaruyamaN , MaruyamaT , OkadaK , SomaM . A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease. Journal of Atherosclerosis &amp; Thrombosis2015;22(12):1235-47. [MEDLINE: 26156625]">Abe 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0004" title="ClearfieldM , DownsJR , WeisS , WhitneyEJ , KruyerW , ShapiroDR , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health &amp; Gender-Based Medicine2001;10(10):971-81. [MEDLINE: 11788107]ClearfieldM , WhitneyEJ , WeisS , DownsJR , ShapiroDR , SteinEA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk2000;7(2):125-33. [MEDLINE: 10879416]ClearfieldMB , WeisSE , WillisJM , VaseniusKA , McConathyWJ . Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association2002;102(7):377-84. [MEDLINE: 12138952]CuiY , WatsonDJ , GirmanCJ , ShapiroDR , GottoAM , HiseroteP , et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology2009;104(6):829-34. [MEDLINE: 19733719]DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287-93. [MEDLINE: 9264420]DownsJR , ClearfieldM , TyrolerHA , WhitneyEJ , KruyerW , LangendorferA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology2001;87(9):1074-9. [MEDLINE: 11348605]DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22. [MEDLINE: 9613910]Gotto AM Jr, BoccuzziSJ , CookJR , AlexanderCM , RoehmJB , MeyerGS , et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology2000;86(11):1176-81. [MEDLINE: 11090787]KendrickJ , ShlipakMG , TargherG , CookT , LindenfeldJ , ChoncholM . Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases2010;55(1):42-9. [MEDLINE: 19932541]">AFCAPS/TexCAPS 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0008" title="KasaharaM , UeshimaK , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: design of the ASsessment of clinial usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: FR-PO194]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):413A. KimuraG , KasaharaM , UeshimaK , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2017;21(3):417-24. [MEDLINE: 27392909]KimuraG , UeshimaK , KashaharaM , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: ASsessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: SA-O1086]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):5B. KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between the control of LDL-cholesterol level and renal function in CKD patients with hyperlipidemia [abstract no: MP147]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii482. [EMBASE: 617290474]KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial. Clinical &amp; Experimental Nephrology2020;24(5):420-6. [MEDLINE: 31875936]UeshimaK , KasaharaM , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2013;17(2):211-7. [MEDLINE: 22948416]">ASUCA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0041" title="NarayananRP , GittinsM , SiddalsKW , OliverRL , HudsonJE , WhiteA , et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability. European Journal of Endocrinology2013;168(4):543-8. [MEDLINE: 23333902]RutterMK , DaviesRR , CruickshankJK , PraisHR , GittinsM , RobertsC , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): trial results [abstract no: 1207]. Diabetologia2009;52(Suppl 1):S466. [EMBASE: 70068693]RutterMK , PraisHR , Charlton-MenysV , GittinsM , RobertsC , DaviesRR , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabetic Medicine2011;28(1):100-8. [MEDLINE: 21166851]SoranH , LiuY , AdamS , SiahmansurT , HoJH , SchofieldJD , et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. Journal of Clinical Lipidology2018;12(1):44-55. [MEDLINE: 29246729]">PANDA 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0023" title="IkedaH , UraY , NakayamaM . Rosuvastatin reduces urinary protein excretion in patients with chronic glomerulonephritis compared to the pravastatin use: a crossover trial [abstract no: SA-PO274]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):699A. ">Ikeda 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0005" title="IsaacsohnJL , DavidsonMH , HunninghakeD , SingerR , McLainR , BlackDM . Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology2000;86(2):250-2. [MEDLINE: 10913499]KorenMJ , DavidsonMH , WilsonDJ , FayyadRS , ZuckermanA , ReedDP , et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases2009;53(5):741-50. [MEDLINE: 19216014]KorenMJ , DavidsonMH . Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. KorenMJ , HunninghakeDB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology2004;44(9):1772-9. [MEDLINE: 15519006]MullinsCD , RattingerGB , KuznikA , KorenMJ . Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics2008;30 Pt 2:2204-16. [MEDLINE: 19281915]">ALLIANCE 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0012" title="ChaJJ , KimK , MinHS , GheeJ , KimYJ , LeeEY , et al. Effect of fluvastatin treatment on proteinuria in diabetic patients with chronic kidney disease [abstract no: TH-PO656]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):239a. [EMBASE: 641102077]">Cha 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0027" title="KimuraS , InoguchiT , YokomizoH , MaedaY , SonodaN , TakayanagiR . Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes, Obesity &amp; Metabolism2012;14(7):666-9. [MEDLINE: 22268518]">Kimura 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0006" title="Aranda ArcasJL , SanchezR , GuijarroC , AraqueA , PulidoF , PragaM , et al. Effect of pravastatin on hypercholesterolemia associated with proteinuria [Efecto de la pravastatina en la hipercolesterolemia asociada a proteinuria]. Anales de Medicina Interna1994;11(11):523-7. [MEDLINE: 7654898]">Aranda Arcas 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0033" title="Masajtis-ZagajewskaA , NowickiM . Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Renal Failure2018;40(1):700-9. [MEDLINE: 30741616]">Masajtis‐Zagajewska 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0007" title="GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract no: O86]. In: British Renal Society Conference; 2013 May 14-May 16; Manchester, UK. 2013. GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract]. In: Renal Association &amp; British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK. 2011:1043. GuptaA , ChangCL , CollierD , DahlofB , PoulterNR , SeverPS . The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the Ascot-Lipid-Lowering Arm (LLA) [abstract]. Atherosclerosis Supplements2011;12(1):158-9. [EMBASE: 70805024]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: 5A.1]. Journal of Human Hypertension2011;25(10):633-4. [EMBASE: 70537932]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: P1480]. European Heart Journal2011;32:220. [EMBASE: 70533871]LindgrenP , BuxtonM , KahanT , PoulterNR , DahlofB , SeverPS , et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention &amp; Rehabilitation2005;12(1):29-36. [MEDLINE: 15703503]SeverPS , ChangCL , GuptaAK , WhitehouseA , PoulterNR . The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European Heart Journal2011;32(20):2525-32. [MEDLINE: 21873710]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs2004;64 Suppl 2:43-60. [MEDLINE: 15765890]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361(9364):1149-58. [MEDLINE: 12686036]SeverPS , PoulterNR , DahlofB , WedelH , BeeversG , CaulfieldM , et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal2008;29(4):499-508. [MEDLINE: 18175773]SeverPS , PoulterNR , DahlofB , WedelH , CollinsR , BeeversG , et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care2005;28(5):1151-7. [MEDLINE: 15855581]SeverPS , PoulterNR , DahlofB , WedelH . Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension2009;27(5):947-54. [MEDLINE: 19318984]">ASCOT‐LLA 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0009" title="BianchiS , BigazziR , CaiazzaA , CampeseVM . A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193]. American Journal of Kidney Diseases2003;41(3):565-70. [MEDLINE: 12612979]">Bianchi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0049" title="DeedwaniaP , StonePH , Bairey MerzCN , Cosin-AguilarJ , KoylanN , LuoD , et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation2007;115(6):700-7. [MEDLINE: 17283260]DeedwaniaPC , StoneP , FayyadR , LaskeyR , WilsonDJ . Improvement in renal function with intensive statin therapy in older patients without increased muscle symptoms: the SAGE trial [abstract no: SA-PO2762]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):743A. DeedwaniaPC , StonePH , FayyadRS , LaskeyRE , WilsonDJ . Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs &amp; Aging2015;32(12):1055-65. [MEDLINE: 26625880]DeedwaniaPC . Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American Heart Journal2004;148(6):1053-9. [MEDLINE: 15632893]">SAGE 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0010" title="BuemiM , AllegraA , CoricaF , AloisiC , GiacobbeM , PettinatoG , et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clinical Pharmacology &amp; Therapeutics2000;67(4):427-31. [MEDLINE: 10801253]">Buemi 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0062" title="YiYJ , KimHJ , JoSK , KimSG , SongYR , ChungW , et al. Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. Clinical Therapeutics2014;36(8):1182-90. [MEDLINE: 24996489]">Yi 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0013" title="Di LulloL , AddesseR , ComegnaC , FirmiG , GalderisiC , IannacciGR , et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Advances in Therapy2005;22(6):601-12. [MEDLINE: 16510377]Di LulloL , PolitoP . Effects of fluvastatin treatment on lipid profile, inflammatory status and renal function in dyslipidemic patients with chronic renal failure [abstract no: S-PO-0543]. In: 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:195. ">Di Lullo 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0014" title="DummerCD , Thome'FS , ZinganoB , LindosoA , VeroneseFV . Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. Journal of Nephrology2008;21(6):900-8. [MEDLINE: 19034875]">Dummer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0015" title="RemuzziG . Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual RAS blockade: esplanade trial [abstract no: F-PO1221]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):389A. RuggenentiP , PernaA , TonelliM , LorigaG , MotterliniN , RubisN , et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE Trial. Clinical Journal of the American Society of Nephrology: CJASN2010;5(11):1928-38. [MEDLINE: 20671225]">ESPLANADE 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0016" title="FassettRG , CoombesJS , PackhamD , FairleyKF , Kincaid-SmithP . Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology &amp; Nephrology2010;44(1):56-61. [MEDLINE: 20034362]">Fassett 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0017" title="FriedLF , ForrestKY , EllisD , ChangY , SilversN , OrchardTJ . Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. Journal of Diabetes &amp; its Complications2001;15(3):113-9. [MEDLINE: 11358679]">Fried 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0018" title="GheithO , SaadM , SobhM . Nephrotic dyslipidemia, harvest of treatment [abstract no: MP085]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:258. [CENTRAL: CN-00509210] GheithO , SobhM , GazarenS , AhmedH , El BazM . Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no: M182]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. [CENTRAL: CN-00520338] GheithOA , SobhMA , Mohamed Kel-E, El-BazM , El-HusseiniF , GazarinSS , et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612-9. [MEDLINE: 12138263]">Gheith 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0019" title="GoicoecheaM , deVinuesaSG , LaheraV , CachofeiroV , Gomez-CampderaF , VegaA , et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology2006;17(12 Suppl 3):S231-5. [MEDLINE: 17130267]">Goicoechea 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0020" title="HommelE , AndersenP , GallMA , NielsenF , JensenB , RossingP , et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia1992;35(5):447-51. [MEDLINE: 1521727]">Hommel 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0024" title="ImaiY , SuzukiH , SaitoT , TsujiI , AbeK , SarutaT . The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clinical &amp; Experimental Hypertension (New York)1999;21(8):1345-55. [MEDLINE: 10574417]">Imai 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0028" title="LamKS , ChengIK , JanusED , PangRW . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1995;38(5):604-9. [MEDLINE: 7489845]ParvingHH . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1996;39(3):367-8. [MEDLINE: 8721786]">Lam 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0029" title="LeeTM , LinMS , TsaiCH , ChangNC . Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney International2005;68(2):779-87. [MEDLINE: 16014056]LeeTM , SuSF , TsaiCH . Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension2002;40(1):67-73. [MEDLINE: 12105140]">Lee 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0030" title="LintottCJ , ScottRS , BremerJM , ShandBI . Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. American Journal of Cardiology1995;76(2):97-101A. [MEDLINE: 7604809]">Lintott 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0031" title="ArampatzisCA , GoedhartD , SerruysPW , SaiaF , LemosPA , deFeyterP . Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal2005;149(2):329-35. [MEDLINE: 15846273]LemosPA , SerruysPW , deFeyterP , MercadoNF , GoedhartD , SaiaF , et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology2005;95(4):445-51. [MEDLINE: 15695126]SerruysPW , De FeyterPJ , BenghoziR , HugenholtzPG , LesaffreE . The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions2001;4(4):165-72. [PMID: 12036459]SerruysPW , deFeyterP , MacayaC , KokottN , PuelJ , VrolixM , et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002;287(24):3215-22. [MEDLINE: 12076217]">LIPS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0032" title="FassettR , RobertsonI , BallM , GeraghtyD , SharmanJ , CoombesJ . A randomised trial assessing the effects of atorvastatin on arterial stiffness in chronic kidney disease [abstract no: SU193]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912394] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Atorvastatin and the progression of chronic kidney disease: the LORD Trial [abstract no: F-PO1919]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN-00773725] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Baseline serum lipids and renal function in chronic kidney disease patients entering the LORD trial. International Journal of Clinical Pharmacology &amp; Therapeutics2006;44(11):580-8. [MEDLINE: 17176625]FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrology2008;9:4. [MEDLINE: 18366658]FassettRG , CoombesJS , PurseLM , WattsM , ChuggKL , GeraghtyDP . Enrolment in a clinical trial improves renal function [abstract no: SU-PO1057]. Journal of the American Society of Nephrology2003;14(Nov):768A. [CENTRAL: CN-00583896] FassettRG , OliverK , SummersMJ , SmithM , AndersonLM , CoombesJS . Lipid lowering therapy and cognitive function in patients with chronic kidney disease [abstract no: PUB623]. Journal of the American Society of Nephrology2005;16:917A. [CENTRAL: CN-00636136] FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Atorvastatin slows the progression of chronic kidney disease in patients with inflammation [abstract no: TH-PO204]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):158A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with kidney function in CKD patients [abstract no: FR-PO1383]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):432A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with quality of life in CKD patients [abstract no: SA-PO2441]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):680A. FassettRG , RobertsonI , HealyHG , GeraghtyDP , BallMJ , CardinalJW , et al. Effect of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post-hoc analysis of the LORD trial [abstract no: SA-PO2320]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):641A. FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CardinalJW , CoombesJS . Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrology Dialysis Transplantation2012;27(1):182-9. [MEDLINE: 21543653]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis2010;213(1):218-24. [MEDLINE: 20810109]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clinical Nephrology2014;81(2):75-85. [MEDLINE: 24321183]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , SharmanJE , CoombesJS . Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. Journal of Atherosclerosis &amp; Thrombosis2010;17(3):235-41. [MEDLINE: 20032570]FassettRG , RobertsonIK , BallMJ , GeraghtyDP . Atorvastatin slows the progression of CKD in patients with inflammation [abstract no: 066]. Nephrology2011;16(Suppl 1):40-1. [EMBASE: 70532414]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , BurtonNW , CoombesJS . Physical activity levels in patients with chronic kidney disease entering the LORD trial. Medicine &amp; Science in Sports &amp; Exercise2009;41(5):985-91. [MEDLINE: 19346990]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , CoombesJS . Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting. Journal of Renal Nutrition2007;17(4):235-42. [MEDLINE: 17586421]FassettRG , SwansonCE , SharmaS , WhiteA , SinghG . Atorvastatin improves kidney function in chronic kidney disease patients undertaking high intensity exercise [abstract no: 067]. Nephrology2011;16(Suppl 1):41. [PMID: 70532415]SummersMJ , OliverKR , CoombesJS , FassettRG . Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy: The Journal of Human Pharmacology &amp; Drug Therapy2007;27(2):183-90. [MEDLINE: 17253908]">LORD 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0035" title="MoriY , TsuruokaA . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Journal of the Japan Diabetes Society1992;35(3):265-8. [EMBASE: 22147775]MoriY , YokoyamaJ , TsuruokaA , IkedaY . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - a randomized control study. Jikeikai Medical Journal1992;39(4):341-8. [EMBASE: 23068032]">Mori 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0036" title="NakamuraT , UshiyamaC , HirokawaK , OsadaS , InoueT , ShimadaN , et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrology Dialysis Transplantation2002;17(5):798-802. [MEDLINE: 11981066]">Nakamura 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0037" title="NakamuraT , SugayaT , KawagoeY , UedaY , OsadaS , KoideH . Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care2005;28(11):2728-32. [MEDLINE: 16249547]">Nakamura 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0038" title="NakamuraT , SugayaT , KawagoeY , SuzukiT , InoueT , NodeK . Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. American Journal of Nephrology2006;26(1):82-6. [MEDLINE: 16534182]">Nakamura 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0039" title="NellemannB , GormsenLC , DollerupJ , SchmitzO , MogensenCE , RasmussenLM , et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care2007;30(12):3122-4. [MEDLINE: 17804683]NielsenS , SchmitzO , MollerN , PorksenN , KlausenIC , AlbertiKG , et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia1993;36(10):1079-86. [MEDLINE: 8243858]">Nielsen 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0042" title="PanichiV , MantuanoE , PaolettiS , SantiS , Manca RizzaG , CutrupiS , et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. Journal of Nephrology2008;21(1):38-44. [MEDLINE: 18264935]PanichiV , PaolettiS , Manca-RizzaG , TaccolaD , InnocentiM , CastoG , et al. Effect of simvastatin therapy on inflammatory markers and lipids in pre-dialysis patients [abstract no: SP167]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v75. [CENTRAL: CN-00678037] PanichiV , PaolettiS , MantuanoE , Manca-RizzaG , FilippiC , SantiS , et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrology Dialysis Transplantation2006;21(2):337-44. [MEDLINE: 16249194]">Panichi 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0046" title="AsselbergsFW , DiercksGF , HillegeHL , vanBovenAJ , JanssenWM , VoorsAA , et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004;110(18):2809-16. [MEDLINE: 15492322]AsselbergsFW , vanRoonAM , HillegeHL , deJongPE , GansRO , SmitAJ , et al. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke2005;36(3):649-53. [MEDLINE: 15692120]AsselbergsFW , van derHarstP , vanRoonAM , HillegeHL , deJongPE , GansRO , et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis2008;196(1):349-55. [MEDLINE: 17141245]AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]. Journal of the American Society of Nephrology2005;16:36A. [CENTRAL: CN-00583782] AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics2006;28(3):432-44. [MEDLINE: 16750458]AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]. Journal of the American Society of Nephrology2005;16:71A. [CENTRAL: CN-00583784] AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation2006;21(11):3106-14. [MEDLINE: 16720593]BelloAK , deZeeuwD , El NahasM , BrantsmaAH , BakkerSJ , deJongPE , et al. Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation2007;22(6):1619-27. [MEDLINE: 17360767]BrouwersFP , AsselbergsFW , HillegeHL , deBoerRA , GansevoortRT , vanVeldhuisenDJ , et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). American Heart Journal2011;161(6):1171-8. [MEDLINE: 21641365]De JongMA , EisengaMF , vanBallegooijenAJ , BeulensJW , VervloetMG , NavisG , et al. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrology Dialysis Transplantation2021;36(1):121-8. [MEDLINE: 32124925]DiercksGF , JanssenWM , vanBovenAJ , BakAA , deJongPE , CrijnsHJ , et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology2000;86(6):635-8. [MEDLINE: 10980214]GelukCA , AsselbergsFW , HillegeHL , BakkerSJ , deJongPE , ZijlstraF , et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal2005;26(13):1314-20. [MEDLINE: 15820998]PouwelsKB , VisserST , HakE . Effect of pravastatin and fosinopril on recurrent urinary tract infections. Journal of Antimicrobial Chemotherapy2013;68(3):708-14. [MEDLINE: 23111852]vande WalRM , GansevoortRT , van derHarstP , BoomsmaF , Thijs PlokkerHW , vanVeldhuisenDJ , et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension2006;48(5):870-6. [MEDLINE: 17000930]vande WalRM , van derHarstP , GerritsenWB , van derHorstF , PlokkerTH , GansevoortRT , et al. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):177-80. [MEDLINE: 18205096]van derHarstP , AsselbergsFW , HillegeHL , VoorsAA , vanVeldhuisenDJ , vanGilstWH . Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. American Journal of Cardiology2008;102(2):223-5. [MEDLINE: 18602526]">PREVEND IT 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0047" title="RaynerB , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin and diet versus diet alone in patients with idiopathic membranous nephropathy: a preliminary report [abstract]. Kidney International1993;43:1183. RaynerBL , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin (sv) and diet versus diet alone in patients with idiopathic membranous nephropathy (IMN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:76. RaynerBL , ByrneM , vanZyl-SmitR . Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN) [abstract]. Nephrology Dialysis Transplantation1994;9(7):963. [CENTRAL: CN-00261011] RaynerBL , ByrneMJ , vanZyl SmitR . A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clinical Nephrology1996;46(4):219-24. [MEDLINE: 8905205]">Rayner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0048" title="RenkeM , TylickiL , RutkowskiP , NeuweltA , LarczynskiW , ZietkiewiczM , et al. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochimica Polonica2010;57(4):547-52. [MEDLINE: 21079818]">Renke 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0050" title="AlaupovicP , AttmanPO , Knight-GibsonC , MulecH , WeissL , SamuelssonO . Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney International2006;69(10):1865-71. [MEDLINE: 16572113]SamuelssonO , AttmanPO , Knight-GibsonC , MulecH , WeissL , AlaupovicP . Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. American Journal of Kidney Diseases2002;39(1):67-75. [MEDLINE: 11774104]">Samuelsson 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0051" title="SawaraY , TakeiT , UchidaK , OgawaT , YoshidaT , TsuchiyaK , et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Internal Medicine2008;47(17):1505-10. [MEDLINE: 18758125]SawaraY , TakeiT , UchidaK , TsuchiyaK , NittaK . Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease [abstract no: SA166]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912388] ">Sawara 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0052" title="ScanferlaF , ToffolettoPP , RoncaliD , BazzatoG . Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension1991;4(10 Pt 1):868-74. [MEDLINE: 1747221]">Scanferla 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0054" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503-10. [MEDLINE: 16303728]StegmayrBG , BrannstromM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489-97. [MEDLINE: 18161210]StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. In: 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. [CENTRAL: CN-00447842] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. [CENTRAL: CN-00583406] ">Stegmayr 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0055" title="ThomasME , HarrisKP , RamaswamyC , HattersleyJM , WheelerDC , VargheseZ , et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International1993;44(5):1124-9. [MEDLINE: 8264145]">Thomas 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0057" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Beneficial effects of pitavastatin on albuminuria and renal function in essential hypertensive patients with chronic kidney disease [abstract no: TH-PO875]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):307A. [CENTRAL: CN-00773767] ">Tokunaga 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0058" title="TonoloG , CiccareseM , BrizziP , PudduL , SecchiG , CalviaP , et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care1997;20(12):1891-5. [MEDLINE: 9405913]">Tonolo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0059" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0060" title="VermaA , GordonN , RangannaKM , ReddyRS , VermaM . Rosuvastatin reduces high sensitivity-C reactive protein and the decline in renal function in hyperlipidemic patients with chronic kidney disease [abstract no: SA-PO134]. Journal of the American Society of Nephrology2004;15(Oct):329A. [CENTRAL: CN-00583418] VermaA , RangannaKM , ReddyRS , VermaM , GordonNF . Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. American Journal of Cardiology2005;96(9):1290-2. [MEDLINE: 16253600]">Verma 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0061" title="YasudaG , KujiT , HasegawaK , OgawaN , ShimuraG , AndoD , et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Renal Failure2004;26(4):411-8. [MEDLINE: 15462110]">Yasuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0063" title="ZhangA , VertommenJ , Van GaalL , De LeeuwI . Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Research &amp; Clinical Practice1995;29(3):189-94. [MEDLINE: 8591712]">Zhang 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">List of included studies according to Cochrane review update</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007784-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies classified by type of statin therapy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Atorvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cerviastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fluvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lovastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pitavastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pravastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rosuvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Simvastatin (dose)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Simvastatin and ezetimibe (dose)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0005" title="IsaacsohnJL , DavidsonMH , HunninghakeD , SingerR , McLainR , BlackDM . Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology2000;86(2):250-2. [MEDLINE: 10913499]KorenMJ , DavidsonMH , WilsonDJ , FayyadRS , ZuckermanA , ReedDP , et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases2009;53(5):741-50. [MEDLINE: 19216014]KorenMJ , DavidsonMH . Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. KorenMJ , HunninghakeDB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology2004;44(9):1772-9. [MEDLINE: 15519006]MullinsCD , RattingerGB , KuznikA , KorenMJ . Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics2008;30 Pt 2:2204-16. [MEDLINE: 19281915]">ALLIANCE 2000</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0036" title="NakamuraT , UshiyamaC , HirokawaK , OsadaS , InoueT , ShimadaN , et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrology Dialysis Transplantation2002;17(5):798-802. [MEDLINE: 11981066]">Nakamura 2002</a> (0.15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0010" title="BuemiM , AllegraA , CoricaF , AloisiC , GiacobbeM , PettinatoG , et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clinical Pharmacology &amp; Therapeutics2000;67(4):427-31. [MEDLINE: 10801253]">Buemi 2000</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0004" title="ClearfieldM , DownsJR , WeisS , WhitneyEJ , KruyerW , ShapiroDR , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health &amp; Gender-Based Medicine2001;10(10):971-81. [MEDLINE: 11788107]ClearfieldM , WhitneyEJ , WeisS , DownsJR , ShapiroDR , SteinEA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk2000;7(2):125-33. [MEDLINE: 10879416]ClearfieldMB , WeisSE , WillisJM , VaseniusKA , McConathyWJ . Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association2002;102(7):377-84. [MEDLINE: 12138952]CuiY , WatsonDJ , GirmanCJ , ShapiroDR , GottoAM , HiseroteP , et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology2009;104(6):829-34. [MEDLINE: 19733719]DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287-93. [MEDLINE: 9264420]DownsJR , ClearfieldM , TyrolerHA , WhitneyEJ , KruyerW , LangendorferA , et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology2001;87(9):1074-9. [MEDLINE: 11348605]DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22. [MEDLINE: 9613910]Gotto AM Jr, BoccuzziSJ , CookJR , AlexanderCM , RoehmJB , MeyerGS , et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology2000;86(11):1176-81. [MEDLINE: 11090787]KendrickJ , ShlipakMG , TargherG , CookT , LindenfeldJ , ChoncholM . Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases2010;55(1):42-9. [MEDLINE: 19932541]">AFCAPS/TexCAPS 1997</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0037" title="NakamuraT , SugayaT , KawagoeY , UedaY , OsadaS , KoideH . Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care2005;28(11):2728-32. [MEDLINE: 16249547]">Nakamura 2005</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0006" title="Aranda ArcasJL , SanchezR , GuijarroC , AraqueA , PulidoF , PragaM , et al. Effect of pravastatin on hypercholesterolemia associated with proteinuria [Efecto de la pravastatina en la hipercolesterolemia asociada a proteinuria]. Anales de Medicina Interna1994;11(11):523-7. [MEDLINE: 7654898]">Aranda Arcas 1994</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0002" title="AbeM , MaruyamaN , OkadaK , MatsumotoS , MatsumotoK , SomaM . Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Journal of Atherosclerosis &amp; Thrombosis2011;18(11):1018-28. [MEDLINE: 21921413]">Abe 2011c</a> (5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0001" title="BallantyneCM , OlssonAG , CookTJ , MercuriMF , PedersenTR , KjekshusJ . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104(25):3046-51. [MEDLINE: 11748098]Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345(8960):1274-5. [MEDLINE: 7746058]BergK , DahlénG , ChristophersenB , CookT , KjekshusJ , PedersenT . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics1997;52(5):254-61. [MEDLINE: 9520115]ChoncholM , CookT , KjekshusJ , PedersenTR , LindenfeldJ . Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases2007;49(3):373-82. [MEDLINE: 17336698]CreaF , MonacoC , LanzaGA , MaggiE , GinnettiF , CianfloneD , et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology2002;25(10):461-6. [MEDLINE: 12375804]Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology1993;71(5):393-400. [MEDLINE: 8430625]FaergemanO , KjekshusJ , CookT , PyoräläK , WilhelmsenL , ThorgeirssonG , et al. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1998;19(10):1531-7. [MEDLINE: 9820992]GerdesLU , GerdesC , KervinenK , SavolainenM , KlausenIC , HansenPS , et al. The apolipoprotein Ɛ4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation2000;101(12):1366-71. [MEDLINE: 10736278]HaffnerSM , AlexanderCM , CookTJ , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1999;159(22):2661-7. [MEDLINE: 10597756]HaffnerSM . The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care1997;20(4):469-71. [MEDLINE: 9096961]HermanWH , AlexanderCM , CookJR , BoccuzziSJ , MuslinerTA , PedersenTR , et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care1999;22(11):1771-8. [MEDLINE: 10546006]HuskeyJ , LindenfeldJ , CookT , KjekshusJ , PedersenT . Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811] HuskeyJ , LindenfeldJ , CookT , TargherG , KendrickJ , KjekshusJ , et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis2009;205(1):202-6. [MEDLINE: 19124121]JohannessonM , JonssonB , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine1997;336(5):332-6. [MEDLINE: 9011785]JonssonB , CookJR , PedersenTR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999;42(11):1293-301. [MEDLINE: 10550412]JönssonB , JohannessonM , KjekshusJ , OlssonAG , PedersenTR , WedelH . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal1996;17(7):1001-7. [MEDLINE: 8809516]MiettinenTA , GyllingH , StrandbergT , SarnaS . Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ1998;316(7138):1127-30. [MEDLINE: 9552949]MiettinenTA , GyllingH , Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta2007;379(1-2):53-8. [MEDLINE: 17258182]MiettinenTA , PyoräläK , OlssonAG , MuslinerTA , CookTJ , FaergemanO , et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation1997;96(12):4211-8. [MEDLINE: 9416884]PedersenTR , BergK , CookTJ , FaergemanO , HaghfeltT , KjekshusJ , et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine1996;156(18):2085-92. [MEDLINE: 8862101]PedersenTR , KjekshusJ , BergK , HaghfeltT , FaergemanO , FaergemanG , et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements2004;5(3):81-7. [MEDLINE: 15531279]PedersenTR , KjekshusJ , BergK , OlssonAG , WilhelmsenL , WedelH , et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation1996;93(10):1796-802. [MEDLINE: 8635258]PedersenTR , KjekshusJ , PyoräläK , OlssonAG , CookTJ , MuslinerTA , et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology1998;81(3):333-5. [MEDLINE: 9468077]PedersenTR , OlssonAG , FaergemanO , KjekshusJ , WedelH , BergK , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998;97(15):1453-60. [MEDLINE: 9576425]PedersenTR , WilhelmsenL , FaergemanO , StrandbergTE , ThorgeirssonG , TroedssonL , et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology2000;86(3):257-62. [MEDLINE: 10922429]PyoräläK , BallantyneCM , GumbinerB , LeeMW , ShahA , DaviesMJ , et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care2004;27(7):1735-40. [MEDLINE: 15220255]PyoräläK , PedersenTR , KjekshusJ , FaergemanO , OlssonAG , ThorgeirssonG . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care1997;20(4):614-20. [MEDLINE: 9096989]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9. [MEDLINE: 7968073]StrandbergTE , PyoräläK , CookTJ , WilhelmsenL , FaergemanO , ThorgeirssonG , et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet2004;364(9436):771-7. [MEDLINE: 15337403]WilhelmsenL , PyoräläK , WedelH , CookT , PedersenT , KjekshusJ . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal2001;22(13):1119-27. [MEDLINE: 11428852]">4S 1993</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> (20 mg/d and 10 mg/d) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0007" title="GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract no: O86]. In: British Renal Society Conference; 2013 May 14-May 16; Manchester, UK. 2013. GuptaA , ChangC , CollierD , DahlofB , PoulterN , SeverP , et al. The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract]. In: Renal Association &amp; British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK. 2011:1043. GuptaA , ChangCL , CollierD , DahlofB , PoulterNR , SeverPS . The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the Ascot-Lipid-Lowering Arm (LLA) [abstract]. Atherosclerosis Supplements2011;12(1):158-9. [EMBASE: 70805024]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: 5A.1]. Journal of Human Hypertension2011;25(10):633-4. [EMBASE: 70537932]GuptaAK , ChangCL , DahlofB , PoulterNR , SeverPS . Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: P1480]. European Heart Journal2011;32:220. [EMBASE: 70533871]LindgrenP , BuxtonM , KahanT , PoulterNR , DahlofB , SeverPS , et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention &amp; Rehabilitation2005;12(1):29-36. [MEDLINE: 15703503]SeverPS , ChangCL , GuptaAK , WhitehouseA , PoulterNR . The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European Heart Journal2011;32(20):2525-32. [MEDLINE: 21873710]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs2004;64 Suppl 2:43-60. [MEDLINE: 15765890]SeverPS , DahlofB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361(9364):1149-58. [MEDLINE: 12686036]SeverPS , PoulterNR , DahlofB , WedelH , BeeversG , CaulfieldM , et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal2008;29(4):499-508. [MEDLINE: 18175773]SeverPS , PoulterNR , DahlofB , WedelH , CollinsR , BeeversG , et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care2005;28(5):1151-7. [MEDLINE: 15855581]SeverPS , PoulterNR , DahlofB , WedelH . Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension2009;27(5):947-54. [MEDLINE: 19318984]">ASCOT‐LLA 2003</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0012" title="ChaJJ , KimK , MinHS , GheeJ , KimYJ , LeeEY , et al. Effect of fluvastatin treatment on proteinuria in diabetic patients with chronic kidney disease [abstract no: TH-PO656]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):239a. [EMBASE: 641102077]">Cha 2015</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0028" title="LamKS , ChengIK , JanusED , PangRW . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1995;38(5):604-9. [MEDLINE: 7489845]ParvingHH . Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia1996;39(3):367-8. [MEDLINE: 8721786]">Lam 1995</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0038" title="NakamuraT , SugayaT , KawagoeY , SuzukiT , InoueT , NodeK . Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. American Journal of Nephrology2006;26(1):82-6. [MEDLINE: 16534182]">Nakamura 2006</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0008" title="KasaharaM , UeshimaK , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: design of the ASsessment of clinial usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: FR-PO194]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):413A. KimuraG , KasaharaM , UeshimaK , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2017;21(3):417-24. [MEDLINE: 27392909]KimuraG , UeshimaK , KashaharaM , TanakaS , YasunoS , FujimotoA , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: ASsessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: SA-O1086]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):5B. KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between the control of LDL-cholesterol level and renal function in CKD patients with hyperlipidemia [abstract no: MP147]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii482. [EMBASE: 617290474]KuwabaraY , YasunoS , KasaharaM , UeshimaK , NakaoK . The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial. Clinical &amp; Experimental Nephrology2020;24(5):420-6. [MEDLINE: 31875936]UeshimaK , KasaharaM , KoyaD , BabazonoT , SatoT , ImamotoM , et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clinical &amp; Experimental Nephrology2013;17(2):211-7. [MEDLINE: 22948416]">ASUCA 2013</a> (mean 12.5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0026" title="GlynnRJ , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851-61. [MEDLINE: 19329822]RidkerPM , DanielsonE , FonsecaFA , GenestJ , Gotto AM Jr, KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine2008;359(21):2195-207. [MEDLINE: 18997196]RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology2007;100(11):1659-64. [MEDLINE: 18036365]RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266-73. [MEDLINE: 20206456]">JUPITER 2007</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0014" title="DummerCD , Thome'FS , ZinganoB , LindosoA , VeroneseFV . Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. Journal of Nephrology2008;21(6):900-8. [MEDLINE: 19034875]">Dummer 2008</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0009" title="BianchiS , BigazziR , CaiazzaA , CampeseVM . A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193]. American Journal of Kidney Diseases2003;41(3):565-70. [MEDLINE: 12612979]">Bianchi 2003</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0013" title="Di LulloL , AddesseR , ComegnaC , FirmiG , GalderisiC , IannacciGR , et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Advances in Therapy2005;22(6):601-12. [MEDLINE: 16510377]Di LulloL , PolitoP . Effects of fluvastatin treatment on lipid profile, inflammatory status and renal function in dyslipidemic patients with chronic renal failure [abstract no: S-PO-0543]. In: 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:195. ">Di Lullo 2005</a> (80 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0040" title="OhsawaM , TamuraK , WakuiH , KanaokaT , AzushimaK , UnedaK , et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health &amp; Disease2015;14:161. [MEDLINE: 26645467]">Ohsawa 2015</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0024" title="ImaiY , SuzukiH , SaitoT , TsujiI , AbeK , SarutaT . The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clinical &amp; Experimental Hypertension (New York)1999;21(8):1345-55. [MEDLINE: 10574417]">Imai 1999</a> (mean 7.5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0051" title="SawaraY , TakeiT , UchidaK , OgawaT , YoshidaT , TsuchiyaK , et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Internal Medicine2008;47(17):1505-10. [MEDLINE: 18758125]SawaraY , TakeiT , UchidaK , TsuchiyaK , NittaK . Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease [abstract no: SA166]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912388] ">Sawara 2008</a> (2.5 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0016" title="FassettRG , CoombesJS , PackhamD , FairleyKF , Kincaid-SmithP . Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology &amp; Nephrology2010;44(1):56-61. [MEDLINE: 20034362]">Fassett 2010</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0011" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases2009;54(5):810-9. [MEDLINE: 19540640]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364(9435):685-96. [MEDLINE: 15325833]ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2005;48(12):2482-5. [MEDLINE: 16284747]HitmanGA , ColhounH , NewmanC , SzarekM , BetteridgeDJ , DurringtonPN , et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine2007;24(12):1313-21. [MEDLINE: 17894827]NeilHA , DeMiccoDA , LuoD , BetteridgeDJ , ColhounHM , DurringtonPN , et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care2006;29(11):2378-84. [MEDLINE: 17065671]NewmanCB , SzarekM , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes &amp; Vascular Disease Research2008;5(3):177-83. [MEDLINE: 18777490]RaikouM , McGuireA , ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia2007;50(4):733-40. [MEDLINE: 17265034]Soedamah-MuthuSS , ColhounHM , ThomasonMJ , BetteridgeDJ , DurringtonPN , HitmanGA , et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167(2):243-55. [MEDLINE: 12818407]ThomasonMJ , ColhounHM , LivingstoneSJ , MacknessMI , BetteridgeDJ , DurringtonPN , et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine2004;21(8):901-5. [MEDLINE: 15270795]">CARDS 2003</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0015" title="RemuzziG . Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual RAS blockade: esplanade trial [abstract no: F-PO1221]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):389A. RuggenentiP , PernaA , TonelliM , LorigaG , MotterliniN , RubisN , et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE Trial. Clinical Journal of the American Society of Nephrology: CJASN2010;5(11):1928-38. [MEDLINE: 20671225]">ESPLANADE 2010</a> (80 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0057" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Beneficial effects of pitavastatin on albuminuria and renal function in essential hypertensive patients with chronic kidney disease [abstract no: TH-PO875]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):307A. [CENTRAL: CN-00773767] ">Tokunaga 2008</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0029" title="LeeTM , LinMS , TsaiCH , ChangNC . Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney International2005;68(2):779-87. [MEDLINE: 16014056]LeeTM , SuSF , TsaiCH . Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension2002;40(1):67-73. [MEDLINE: 12105140]">Lee 2002</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0060" title="VermaA , GordonN , RangannaKM , ReddyRS , VermaM . Rosuvastatin reduces high sensitivity-C reactive protein and the decline in renal function in hyperlipidemic patients with chronic kidney disease [abstract no: SA-PO134]. Journal of the American Society of Nephrology2004;15(Oct):329A. [CENTRAL: CN-00583418] VermaA , RangannaKM , ReddyRS , VermaM , GordonNF . Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. American Journal of Cardiology2005;96(9):1290-2. [MEDLINE: 16253600]">Verma 2005</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0017" title="FriedLF , ForrestKY , EllisD , ChangY , SilversN , OrchardTJ . Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. Journal of Diabetes &amp; its Complications2001;15(3):113-9. [MEDLINE: 11358679]">Fried 2001</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0019" title="GoicoecheaM , deVinuesaSG , LaheraV , CachofeiroV , Gomez-CampderaF , VegaA , et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology2006;17(12 Suppl 3):S231-5. [MEDLINE: 17130267]">Goicoechea 2006</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0018" title="GheithO , SaadM , SobhM . Nephrotic dyslipidemia, harvest of treatment [abstract no: MP085]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:258. [CENTRAL: CN-00509210] GheithO , SobhM , GazarenS , AhmedH , El BazM . Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no: M182]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. [CENTRAL: CN-00520338] GheithOA , SobhMA , Mohamed Kel-E, El-BazM , El-HusseiniF , GazarinSS , et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612-9. [MEDLINE: 12138263]">Gheith 2002</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0034" title="IshikawaT , MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal2008;72(10):1576-82. [MEDLINE: 18756039]Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal2004;68(9):860-7. [MEDLINE: 15329509]MizunoK , NakayaN , OhashiY , TajimaN , KushiroT , TeramotoT , et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation2008;117(4):494-502. [MEDLINE: 18172039]NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155-63. [MEDLINE: 17011942]NakamuraH , MizunoK , OhashiY , YoshidaT , HiraoK , UchidaY , et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis2009;206(2):512-7. [MEDLINE: 19423108]NakamuraH . Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements2007;8(2):13-7. [MEDLINE: 17586102]TanakaY , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine2008;27(10):1718-33. [MEDLINE: 17922525]TeramotoT , OhashiY , NakayaN , YokoyamaS , MizunoK , NakamuraH , et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal2008;72(10):1569-75. [MEDLINE: 18762707]UchiyamaS , NakayaN , MizunoK , OhashiY , TajimaN , KushiroT , et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences2009;284(1-2):72-6. [MEDLINE: 19423132]YoshidaM , MatsuyamaY , OhashiY . Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials2007;4(4):318-28. [MEDLINE: 17848493]">MEGA 2004</a> (15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0020" title="HommelE , AndersenP , GallMA , NielsenF , JensenB , RossingP , et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia1992;35(5):447-51. [MEDLINE: 1521727]">Hommel 1992</a> (15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0025" title="InukaiK , IuchiT , SumitaT , ItoD , IkebukuroK , ImaiK , et al. Combination therapy with angiotensin receptor blocker (ARB) plus atorvastatin reduced proteinuria in type 2 diabetic patients with diabetic nephropathy. Therapeutic Research2011;32(7):947-53. [EMBASE: 362412882]">Inukai 2011</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0030" title="LintottCJ , ScottRS , BremerJM , ShandBI . Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. American Journal of Cardiology1995;76(2):97-101A. [MEDLINE: 7604809]">Lintott 1995</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0035" title="MoriY , TsuruokaA . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Journal of the Japan Diabetes Society1992;35(3):265-8. [EMBASE: 22147775]MoriY , YokoyamaJ , TsuruokaA , IkedaY . Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - a randomized control study. Jikeikai Medical Journal1992;39(4):341-8. [EMBASE: 23068032]">Mori 1992</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0021" title="CollinsR , ArmitageJ , ParishS , SleighP , PetoR . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361(9374):2005-16. [MEDLINE: 12814710]CollinsR , ArmitageJ , ParishS , SleightP , PetoR . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet2004;363(9411):757-67. [MEDLINE: 15016485]EmbersonJR , NgLL , ArmitageJ , BowmanL , ParishS , CollinsR . N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology2007;49(3):311-9. [MEDLINE: 17239712]MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):23-33. [MEDLINE: 12114037]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22. [MEDLINE: 12114036]MihaylovaB , BriggsA , ArmitageJ , ParishS , GrayA , CollinsR . Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet2005;365(9473):1779-85. [MEDLINE: 15910950]Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery2007;45(4):645-54. [MEDLINE: 17398372]The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine2005;3:6. [MEDLINE: 15771782]">HPS 2002</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0032" title="FassettR , RobertsonI , BallM , GeraghtyD , SharmanJ , CoombesJ . A randomised trial assessing the effects of atorvastatin on arterial stiffness in chronic kidney disease [abstract no: SU193]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-01912394] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Atorvastatin and the progression of chronic kidney disease: the LORD Trial [abstract no: F-PO1919]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN-00773725] FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . Baseline serum lipids and renal function in chronic kidney disease patients entering the LORD trial. International Journal of Clinical Pharmacology &amp; Therapeutics2006;44(11):580-8. [MEDLINE: 17176625]FassettRG , BallMJ , RobertsonIK , GeraghtyDP , CoombesJS . The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrology2008;9:4. [MEDLINE: 18366658]FassettRG , CoombesJS , PurseLM , WattsM , ChuggKL , GeraghtyDP . Enrolment in a clinical trial improves renal function [abstract no: SU-PO1057]. Journal of the American Society of Nephrology2003;14(Nov):768A. [CENTRAL: CN-00583896] FassettRG , OliverK , SummersMJ , SmithM , AndersonLM , CoombesJS . Lipid lowering therapy and cognitive function in patients with chronic kidney disease [abstract no: PUB623]. Journal of the American Society of Nephrology2005;16:917A. [CENTRAL: CN-00636136] FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Atorvastatin slows the progression of chronic kidney disease in patients with inflammation [abstract no: TH-PO204]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):158A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with kidney function in CKD patients [abstract no: FR-PO1383]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):432A. FassettRG , RobertsonI , BallMJ , GeraghtyDP , CoombesJS . Relationships between physical activity and nutrition with quality of life in CKD patients [abstract no: SA-PO2441]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):680A. FassettRG , RobertsonI , HealyHG , GeraghtyDP , BallMJ , CardinalJW , et al. Effect of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post-hoc analysis of the LORD trial [abstract no: SA-PO2320]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):641A. FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CardinalJW , CoombesJS . Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrology Dialysis Transplantation2012;27(1):182-9. [MEDLINE: 21543653]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis2010;213(1):218-24. [MEDLINE: 20810109]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , CoombesJS . Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clinical Nephrology2014;81(2):75-85. [MEDLINE: 24321183]FassettRG , RobertsonIK , BallMJ , GeraghtyDP , SharmanJE , CoombesJS . Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. Journal of Atherosclerosis &amp; Thrombosis2010;17(3):235-41. [MEDLINE: 20032570]FassettRG , RobertsonIK , BallMJ , GeraghtyDP . Atorvastatin slows the progression of CKD in patients with inflammation [abstract no: 066]. Nephrology2011;16(Suppl 1):40-1. [EMBASE: 70532414]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , BurtonNW , CoombesJS . Physical activity levels in patients with chronic kidney disease entering the LORD trial. Medicine &amp; Science in Sports &amp; Exercise2009;41(5):985-91. [MEDLINE: 19346990]FassettRG , RobertsonIK , GeraghtyDP , BallMJ , CoombesJS . Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting. Journal of Renal Nutrition2007;17(4):235-42. [MEDLINE: 17586421]FassettRG , SwansonCE , SharmaS , WhiteA , SinghG . Atorvastatin improves kidney function in chronic kidney disease patients undertaking high intensity exercise [abstract no: 067]. Nephrology2011;16(Suppl 1):41. [PMID: 70532415]SummersMJ , OliverKR , CoombesJS , FassettRG . Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy: The Journal of Human Pharmacology &amp; Drug Therapy2007;27(2):183-90. [MEDLINE: 17253908]">LORD 2006</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0031" title="ArampatzisCA , GoedhartD , SerruysPW , SaiaF , LemosPA , deFeyterP . Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal2005;149(2):329-35. [MEDLINE: 15846273]LemosPA , SerruysPW , deFeyterP , MercadoNF , GoedhartD , SaiaF , et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology2005;95(4):445-51. [MEDLINE: 15695126]SerruysPW , De FeyterPJ , BenghoziR , HugenholtzPG , LesaffreE . The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. International Journal of Cardiovascular Interventions2001;4(4):165-72. [PMID: 12036459]SerruysPW , deFeyterP , MacayaC , KokottN , PuelJ , VrolixM , et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002;287(24):3215-22. [MEDLINE: 12076217]">LIPS 2001</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0045" title="A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1992;45(8):849-60. [MEDLINE: 1624967]Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology1997;79(6):756-62. [MEDLINE: 9070554]BattyGD , WangY , BrouiletteSW , ShielsP , PackardC , MooreJ , et al. Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology &amp; Community Health2009;63(10):839-41. [MEDLINE: 19468018]BrouiletteSW , MooreJS , McMahonAD , ThompsonJR , FordI , ShepherdJ , et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet2007;369(9556):107-14. [MEDLINE: 17223473]ByingtonRP , DavisBR , PlehnJF , WhiteHD , BakerJ , CobbeSM , et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103(3):387-92. [MEDLINE: 11157690]CaroJ , KlittichW , McGuireA , FordI , NorrieJ , PettittD , et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ1997;315(7122):1577-82. [MEDLINE: 9437275]CaroJ , KlittichW , McGuireA , FordI , PettittD , NorrieJ , et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal1999;20(4):263-8. [MEDLINE: 10099920]Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology1995;48(12):1441-52. [MEDLINE: 8543958]CuiJ , ForbesA , KirbyA , MarschnerI , SimesJ , WestM , et al. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials2008;5(6):565-74. [MEDLINE: 19029205]DeFilippisAP , BansalS , BlumenthalRS . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):194-5. [MEDLINE: 18193527]Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology1995;76(12):899-905. [MEDLINE: 7484829]FordI , MurrayH , PackardCJ , ShepherdJ , MacFarlanePW , CobbeSM , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2007;357(15):1477-86. [MEDLINE: 17928595]FreemanDJ , NorrieJ , CaslakeMJ , GawA , FordI , LoweGD , et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes2002;51(5):1596-600. [MEDLINE: 11978661]GlasziouPP , IrwigL , HeritierS , SimesRJ , TonkinA , LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?Annals of Internal Medicine2008;148(9):656-61. [MEDLINE: 18458278]GoldbergRB , MelliesMJ , SacksFM , MoyeLA , HowardBV , HowardWJ , et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998;98(23):2513-9. [MEDLINE: 9843456]HagueW , ForderP , SimesJ , HuntD , TonkinA , LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal2003;145(4):643-51. [MEDLINE: 12679760]Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998;97(15):1440-5. [MEDLINE: 9576423]LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet2002;359(9315):1379-87. [MEDLINE: 11978335]LewisSJ , MoyeLA , SacksFM , JohnstoneDE , TimmisG , MitchellJ , et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine1998;129(9):681-9. [MEDLINE: 9841599]LiakishevAA . Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia2007;47(12):65-6. [MEDLINE: 18260982]LoweG , RumleyA , NorrieJ , FordI , ShepherdJ , CobbeS , et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis &amp; Haemostasis2000;84(4):553-8. [MEDLINE: 11057849]MacfarlanePW , NorrieJ , WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology2007;40(1):101-9. [MEDLINE: 17069838]McEvoyJW , MargeyR , BlakeGJ . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-5. [MEDLINE: 18184967]NestelPJ , BaghurstK , ColquhounDM , SimesRJ , MehalskiK , WhiteHD , et al. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition2005;81(6):1322-9. [MEDLINE: 15941882]PackardCJ , O'ReillyDS , CaslakeMJ , McMahonAD , FordI , CooneyJ , et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine2000;343(16):1148-55. [MEDLINE: 11036120]PfefferMA , KeechA , SacksFM , CobbeSM , TonkinA , ByingtonRP , et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002;105(20):2341-6. [MEDLINE: 12021218]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine1998;339(19):1349-57. [MEDLINE: 9841303]ReidIR , HagueW , EmbersonJ , BakerJ , TonkinA , HuntD , et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet2001;357(9255):509-12. [MEDLINE: 11229669]SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9. [MEDLINE: 8801446]SacksFM , PfefferMA , Moye'L , BrownLE , HammP , ColeTG , et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology1991;68(15):1436-46. [MEDLINE: 1746424]SacksFM , TonkinAM , ShepherdJ , BraunwaldE , CobbeS , HawkinsCM , et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000;102(16):1893-900. [MEDLINE: 11034935]SattarN , GawA , ScherbakovaO , FordI , O'ReillyDS , HaffnerSM , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108(4):414-9. [MEDLINE: 12860911]SattarN , ScherbakovaO , FordI , O'ReillyDS , StanleyA , ForrestE , et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes2004;53(11):2855-60. [MEDLINE: 15504965]Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology1995;76(7):485-91. [MEDLINE: 7653449]ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-7. [MEDLINE: 7566020]ShepherdJ , GawA , West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles &amp; Practice2002;11 Suppl 2:17-30. [MEDLINE: 12444307]ShepherdJ . The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology1995;76(9):113C-7C. [MEDLINE: 7572679]SimesJ , FurbergCD , BraunwaldE , DavisBR , FordI , TonkinA , et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal2002;23(3):207-15. [MEDLINE: 11792135]SimesRJ . Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology1995;76(9):122C-6C. [MEDLINE: 7572681]SoderbergS , ColquhounD , KeechA , YallopJ , BarnesEH , PollicinoC , et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity2009;33(1):123-30. [MEDLINE: 19050671]StewartRA , NorthFM , SharplesKJ , SimesRJ , TonkinAM , WhiteHD , et al. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal2008;121(1269):11-23. [MEDLINE: 18278078]StewartRA , NorthFM , WestTM , SharplesKJ , SimesRJ , ColquhounDM , et al. Depression and cardiovascular morbidity and mortality: cause or consequence?European Heart Journal2003;24(22):2027-37. [MEDLINE: 14613739]StewartRA , SharplesKJ , NorthFM , MenkesDB , BakerJ , SimesJ . Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine2000;160(20):3144-52. [MEDLINE: 11074745]StrejaL , PackardCJ , ShepherdJ , CobbeS , FordI , WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology2002;90(7):731-6. [MEDLINE: 12356386]The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology1999;33(4):909-15. [MEDLINE: 10091815]TonelliM , IslesC , CravenT , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation2005;112(2):171-8. [MEDLINE: 15998677]TonelliM , IslesC , CurhanGC , TonkinA , PfefferMA , ShepherdJ , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110(12):1557-63. [MEDLINE: 15364796]TonelliM , JoseP , CurhanG , SacksF , BraunwaldE , PfefferM , et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ2006;332(7555):1426. [MEDLINE: 16714328]TonelliM , KeechA , ShepherdJ , SacksF , TonkinA , PackardC , et al. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology2005;16(12):3748-54. [MEDLINE: 16251235]TonelliM , MoyeL , SacksF , ColesT , CurhanG . Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):257A-8A. [CENTRAL: CN-00448025] TonelliM , MoyeL , SacksF , CurhanG . Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):252A. [CENTRAL: CN-00448024] TonelliM , MoyeL , SacksFM , ColeT , CurhanGC , Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology2003;14(6):1605-13. [MEDLINE: 12761262]TonelliM , MoyeL , SacksFM , KiberdB , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine2003;138(2):98-104. [MEDLINE: 12529091]TonelliM , SacksF , PfefferM , JhangriGS , CurhanG , Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International2005;68(1):237-45. [MEDLINE: 15954913]TonelliM , SacksF , PfefferM , Lopez-JimenezF , JhangriGS , CurhanG . Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension2006;20(8):560-5. [MEDLINE: 16625234]TsubokuraM , KamiM . Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine2008;358(2):193-4. [MEDLINE: 18193526]WallaceAM , McMahonAD , PackardCJ , KellyA , ShepherdJ , GawA , et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation2001;104(25):3052-6. [MEDLINE: 11748099]WestMJ , NestelPJ , KirbyAC , SchnabelR , SullivanD , SimesRJ , et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal2008;29(7):923-31. [MEDLINE: 18296678]WestMJ , WhiteHD , SimesRJ , KirbyA , WatsonJD , AndersonNE , et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension2002;20(12):2513-7. [MEDLINE: 12473877]West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996;348(9038):1339-42. [MEDLINE: 8918276]WhiteHD , SimesRJ , AndersonNE , HankeyGJ , WatsonJD , HuntD , et al. Pravastatin therapy and the risk of stroke. New England Journal of Medicine2000;343(5):317-26. [MEDLINE: 10922421]ZitoF , LoweGD , RumleyA , McMahonAD , HumphriesSE , WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C&gt;T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis2002;165(1):153-8. [MEDLINE: 12208481]">PPP 1992</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0039" title="NellemannB , GormsenLC , DollerupJ , SchmitzO , MogensenCE , RasmussenLM , et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care2007;30(12):3122-4. [MEDLINE: 17804683]NielsenS , SchmitzO , MollerN , PorksenN , KlausenIC , AlbertiKG , et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia1993;36(10):1079-86. [MEDLINE: 8243858]">Nielsen 1993</a> (15 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0033" title="Masajtis-ZagajewskaA , NowickiM . Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Renal Failure2018;40(1):700-9. [MEDLINE: 30741616]">Masajtis‐Zagajewska 2018</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0050" title="AlaupovicP , AttmanPO , Knight-GibsonC , MulecH , WeissL , SamuelssonO . Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney International2006;69(10):1865-71. [MEDLINE: 16572113]SamuelssonO , AttmanPO , Knight-GibsonC , MulecH , WeissL , AlaupovicP . Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. American Journal of Kidney Diseases2002;39(1):67-75. [MEDLINE: 11774104]">Samuelsson 2002</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0046" title="AsselbergsFW , DiercksGF , HillegeHL , vanBovenAJ , JanssenWM , VoorsAA , et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004;110(18):2809-16. [MEDLINE: 15492322]AsselbergsFW , vanRoonAM , HillegeHL , deJongPE , GansRO , SmitAJ , et al. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke2005;36(3):649-53. [MEDLINE: 15692120]AsselbergsFW , van derHarstP , vanRoonAM , HillegeHL , deJongPE , GansRO , et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis2008;196(1):349-55. [MEDLINE: 17141245]AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]. Journal of the American Society of Nephrology2005;16:36A. [CENTRAL: CN-00583782] AtthobariJ , AsselbergsFW , BoersmaC , deVriesR , HillegeHL , vanGilstWH , et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics2006;28(3):432-44. [MEDLINE: 16750458]AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]. Journal of the American Society of Nephrology2005;16:71A. [CENTRAL: CN-00583784] AtthobariJ , BrantsmaAH , GansevoortRT , VisserST , AsselbergsFW , vanGilstWH , et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation2006;21(11):3106-14. [MEDLINE: 16720593]BelloAK , deZeeuwD , El NahasM , BrantsmaAH , BakkerSJ , deJongPE , et al. Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation2007;22(6):1619-27. [MEDLINE: 17360767]BrouwersFP , AsselbergsFW , HillegeHL , deBoerRA , GansevoortRT , vanVeldhuisenDJ , et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). American Heart Journal2011;161(6):1171-8. [MEDLINE: 21641365]De JongMA , EisengaMF , vanBallegooijenAJ , BeulensJW , VervloetMG , NavisG , et al. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrology Dialysis Transplantation2021;36(1):121-8. [MEDLINE: 32124925]DiercksGF , JanssenWM , vanBovenAJ , BakAA , deJongPE , CrijnsHJ , et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology2000;86(6):635-8. [MEDLINE: 10980214]GelukCA , AsselbergsFW , HillegeHL , BakkerSJ , deJongPE , ZijlstraF , et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal2005;26(13):1314-20. [MEDLINE: 15820998]PouwelsKB , VisserST , HakE . Effect of pravastatin and fosinopril on recurrent urinary tract infections. Journal of Antimicrobial Chemotherapy2013;68(3):708-14. [MEDLINE: 23111852]vande WalRM , GansevoortRT , van derHarstP , BoomsmaF , Thijs PlokkerHW , vanVeldhuisenDJ , et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension2006;48(5):870-6. [MEDLINE: 17000930]vande WalRM , van derHarstP , GerritsenWB , van derHorstF , PlokkerTH , GansevoortRT , et al. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):177-80. [MEDLINE: 18205096]van derHarstP , AsselbergsFW , HillegeHL , VoorsAA , vanVeldhuisenDJ , vanGilstWH . Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. American Journal of Cardiology2008;102(2):223-5. [MEDLINE: 18602526]">PREVEND IT 2000</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0042" title="PanichiV , MantuanoE , PaolettiS , SantiS , Manca RizzaG , CutrupiS , et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. Journal of Nephrology2008;21(1):38-44. [MEDLINE: 18264935]PanichiV , PaolettiS , Manca-RizzaG , TaccolaD , InnocentiM , CastoG , et al. Effect of simvastatin therapy on inflammatory markers and lipids in pre-dialysis patients [abstract no: SP167]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v75. [CENTRAL: CN-00678037] PanichiV , PaolettiS , MantuanoE , Manca-RizzaG , FilippiC , SantiS , et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrology Dialysis Transplantation2006;21(2):337-44. [MEDLINE: 16249194]">Panichi 2006a</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0048" title="RenkeM , TylickiL , RutkowskiP , NeuweltA , LarczynskiW , ZietkiewiczM , et al. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochimica Polonica2010;57(4):547-52. [MEDLINE: 21079818]">Renke 2010a</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0061" title="YasudaG , KujiT , HasegawaK , OgawaN , ShimuraG , AndoD , et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Renal Failure2004;26(4):411-8. [MEDLINE: 15462110]">Yasuda 2004</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0052" title="ScanferlaF , ToffolettoPP , RoncaliD , BazzatoG . Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension1991;4(10 Pt 1):868-74. [MEDLINE: 1747221]">Scanferla 1991</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0047" title="RaynerB , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin and diet versus diet alone in patients with idiopathic membranous nephropathy: a preliminary report [abstract]. Kidney International1993;43:1183. RaynerBL , ByrneM , vanZyl-SmitR . A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin (sv) and diet versus diet alone in patients with idiopathic membranous nephropathy (IMN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:76. RaynerBL , ByrneM , vanZyl-SmitR . Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN) [abstract]. Nephrology Dialysis Transplantation1994;9(7):963. [CENTRAL: CN-00261011] RaynerBL , ByrneMJ , vanZyl SmitR . A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clinical Nephrology1996;46(4):219-24. [MEDLINE: 8905205]">Rayner 1996</a> (25 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0054" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503-10. [MEDLINE: 16303728]StegmayrBG , BrannstromM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489-97. [MEDLINE: 18161210]StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. In: 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. [CENTRAL: CN-00447842] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. [CENTRAL: CN-00583406] ">Stegmayr 2005</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0063" title="ZhangA , VertommenJ , Van GaalL , De LeeuwI . Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Research &amp; Clinical Practice1995;29(3):189-94. [MEDLINE: 8591712]">Zhang 1995</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0052" title="ScanferlaF , ToffolettoPP , RoncaliD , BazzatoG . Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension1991;4(10 Pt 1):868-74. [MEDLINE: 1747221]">Scanferla 1991</a> (10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0053" title="BaigentC , LandrayM . Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). https://www.ctsu.ox.ac.uk/files/download_protocol_en_v5.pdf (accessed 5 October 2023). BaigentC , LandrayMJ , ReithC , EmbersonJ , WheelerDC , TomsonC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011;377(9784):2181-92. [PMID: 21663949]BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International - Supplement2003;63(84):S207-10. [MEDLINE: 12694346]ButlerCR , O'HareAM . Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial. Advances in Chronic Kidney Disease2016;23(1):29-35. [MEDLINE: 26709060]HaynesR , LewisD , EmbersonJ , ReithC , AgodoaL , CassA , et al. Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology2014;25(8):1825-33. [MEDLINE: 24790178]HaynesR , SHARP Collaborative Group. Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):170A. HerringtonW , EmbersonJ , StaplinN , BlackwellL , FellstromB , WalkerR , et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical Journal of the American Society of Nephrology: CJASN2014;9(5):914-9. [MEDLINE: 24626433]HerringtonW , StaplinN , JudgePK , MafhamM , EmbersonJ , HaynesR , et al. Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease. Hypertension2017;69(2):314-22. [MEDLINE: 28028192]HerringtonWG , SHARP Collaborative Group. The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):275A. JudgePK , HerringtonWG . The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):221-2A. [EMBASE: 641101613]KentS , SchlackowI , Lozano-KuhneJ , ReithC , EmbersonJ , HaynesR , et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?BMC Nephrology2015;16:65. [MEDLINE: 25924679]Lamprea-MontealegreJA , StaplinN , HerringtonWG , HaynesR , EmbersonJ , BaigentC , et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN2020;15(1):47-60. [MEDLINE: 31831577]MafhamM , StaplinN , SHARP Collaborative Group. Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):578A. MafhamMM , StaplinN , EmbersonJ , HaynesR , HerringtonW , ReithC , et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation2018;33(2):257-64. [MEDLINE: 28088776]MihaylovaB , SchlackowI , HerringtonW , Lozano-KuhneJ , KentS , EmbersonJ , et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;67(4):576-84. [MEDLINE: 26597925]MihaylovaBN , Lozano-KuehneJP , SchlackowI , HerringtonWG , SHARP Collaborative Group. Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):409A. MortonRL , CassA , MihaylovaBN . The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):795-6A. [EMBASE: 641103963]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate to severe CKD. American Journal of Kidney Diseases2016;67(1):31-9. [MEDLINE: 26385817]MortonRL , SchlackowI , StaplinN , GrayA , CassA , HaynesR , et al. Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii178. [EMBASE: 72206749]ReithC , StaplinN , HerringtonWG , StevensW , EmbersonJ , HaynesR , et al. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology2017;18(1):147. [MEDLINE: 28460629]ReithCA , StaplinN , HerringtonWG . Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):488A. [CENTRAL: 641103416] ReithCA , SHARP Collaborative Group. Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):686A. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495] SchlackowI , KentS , HerringtonW , EmbersonJ , HaynesR , ReithC , et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International2019;96(1):170-9. [MEDLINE: 31005271]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785-94. [MEDLINE: 21095263]StaplinN , HaynesR , HerringtonWG , ReithC , CassA , FellstromB , et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases2016;68(3):371-80. [MEDLINE: 27118687]StaplinN , SHARP Collaborative Group. The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):660A. StoreyB . Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):29A. [PMID: 641102804]StoreyBC , StaplinN , HaynesR , ReithC , EmbersonJ , HerringtonWG , et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International2018;93(4):1000-7. [MEDLINE: 29146277]SukkarL , GallagherM , JardineM , ReithC , CassA , WalkerR . The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]. Nephrology2015;30(Suppl 3):80. [EMBASE: 71996024]SukkarL , TalbotB , JunM , DempseyE , WalkerR , HooiL , et al. Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort. Canadian Journal of Kidney Health and Disease2019;6:2054358119. [MEDLINE: 31662874]TalbotB , CassA , WalkerR , HooiL , JardineM , JunM , et al. Comparing survival in patients with chronic kidney disease across three countries – results from the study of heart and renal protection-extended review. Nephrology2022;28(1):36-43. [PMID: 36309984]TalbotB , SukkarL , SmythB , JunM , JardineM , CassA , et al. Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]. Kidney International Reports2020;5(3 Suppl):S250. [EMBASE: 2005255667]TalbotB , SukkarL , SmythB , JunM , JardineMJ , CassA , et al. Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):639. [EMBASE: 633735077]">SHARP 2010</a> (20 mg/d with ezetimibe 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0055" title="ThomasME , HarrisKP , RamaswamyC , HattersleyJM , WheelerDC , VargheseZ , et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International1993;44(5):1124-9. [MEDLINE: 8264145]">Thomas 1993</a> (40 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0058" title="TonoloG , CiccareseM , BrizziP , PudduL , SecchiG , CalviaP , et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care1997;20(12):1891-5. [MEDLINE: 9405913]">Tonolo 1997</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0059" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a> (20 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>High‐dose statin versus low‐dose statin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0041" title="NarayananRP , GittinsM , SiddalsKW , OliverRL , HudsonJE , WhiteA , et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability. European Journal of Endocrinology2013;168(4):543-8. [MEDLINE: 23333902]RutterMK , DaviesRR , CruickshankJK , PraisHR , GittinsM , RobertsC , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): trial results [abstract no: 1207]. Diabetologia2009;52(Suppl 1):S466. [EMBASE: 70068693]RutterMK , PraisHR , Charlton-MenysV , GittinsM , RobertsC , DaviesRR , et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabetic Medicine2011;28(1):100-8. [MEDLINE: 21166851]SoranH , LiuY , AdamS , SiahmansurT , HoJH , SchofieldJD , et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. Journal of Clinical Lipidology2018;12(1):44-55. [MEDLINE: 29246729]">PANDA 2011</a> (80 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0043" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJ . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET I 2006</a> (40 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0056" title="BarterP , GottoAM , LaRosaJC , MaroniJ , SzarekM , GrundySM , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine2007;357(13):1301-10. [MEDLINE: 17898099]DeedwaniaP , BarterP , CarmenaR , FruchartJC , GrundySM , HaffnerS , et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet2006;368(9539):919-28. [MEDLINE: 16962881]DeedwaniaPC , BittnerV , WengerNK , ShepherdJ , WunCC , BreaznaA , et al. Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):142A. HoJE , WatersDD , KeanA , WilsonDJ , DeMiccoDA , BreaznaA , et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology2012;109(12):1761-6. [MEDLINE: 22459310]JohnsonC , WatersDD , DeMiccoDA , BreaznaA , BittnerV , GretenH , et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology2008;102(10):1312-7. [MEDLINE: 18993147]KasteleinJJ , van derSteegWA , HolmeI , GaffneyM , CaterNB , BarterP , et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation2008;117(23):3002-9. [MEDLINE: 18519851]KhushKK , WatersDD , BittnerV , DeedwaniaPC , KasteleinJJ , LewisSJ , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation2007;115(5):576-83. [MEDLINE: 17261662]KostisJB , BreaznaA , DeedwaniaPC , LaRosaJC . The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension2008;10(5):367-76. [MEDLINE: 18453796]LaRosaJC , GrundySM , KasteleinJJ , KostisJB , GretenH . Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology2007;100(5):747-52. [MEDLINE: 17719314]LaRosaJC , GrundySM , WatersDD , ShearC , BarterP , FruchartJC , et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine2005;352(14):1425-35. [MEDLINE: 15755765]MarkDB , KnightJD , CowperPA , Davidson-RayL , AnstromKJ . Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal2008;156(4):698-705. [MEDLINE: 18926150]OngKL , WatersDD , FayyadR , VogtL , MelamedS , DeMiccoDA , et al. Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin. Journal of the American Heart Association2018;7(2):e007387. [MEDLINE: 29358194]ShahSJ , WatersDD , BarterP , KasteleinJJ , ShepherdJ , WengerNK , et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology2008;51(20):1938-43. [MEDLINE: 18482661]ShepherdJ , BarterP , CarmenaR , DeedwaniaP , FruchartJC , HaffnerS , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29(6):1220-6. [MEDLINE: 16731999]ShepherdJ , BittnerV , WengerNK , DeedwaniaPC , WunCC , BreaznaA , et al. Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):370A. ShepherdJ , BreaznaA , DeedwaniaPC , LaRosaJC , WengerNK , MessigM , et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). American Journal of Cardiology2016;117(8):1199-205. [MEDLINE: 26940556]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN2007;2(6):1131-9. [MEDLINE: 17942759]ShepherdJ , KasteleinJJ , BittnerV , DeedwaniaP , BreaznaA , DobsonS , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology2008;51(15):1448-54. [MEDLINE: 18402899]ShepherdJ , KasteleinJP , BittnerVA , CarmenaR , DeedwaniaPC , BreaznaA , et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings2008;83(8):870-9. [MEDLINE: 18674471]ShepherdJ , WengerNK , WilsonDJ . Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019]. In: 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:44. ShepherdJ , WengerNK . Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology2006;17(Abstracts):809A. [CENTRAL: CN-00653729] ShepherdJ , WuC , ZuckermanAL , WilsonDJ , TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228] ShepherdJ , WunC , WilsonDJ , ZuckermanAL . On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650] ShepherdJ , WunC , ZuckermanAL , WilsonDJ , TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061] WatersDD , GuytonJR , HerringtonDM , McGowanMP , WengerNK , ShearC . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?American Journal of Cardiology2004;93(2):154-8. [MEDLINE: 14715339]WatersDD , LaRosaJC , BarterP , FruchartJC , Gotto AM Jr, CarterR , et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology2006;48(9):1793-9. [MEDLINE: 17084252]WatersDD . Clinical insights from the treating to new targets trial. Progress in Cardiovascular Diseases2009;51(6):487-502. [MEDLINE: 19410683]WengerNK , LewisSJ , WeltyFK , HerringtonDM , BittnerV . Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart2008;94(4):434-9. [MEDLINE: 18070940]">TNT 2004</a> (80 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007784-bbs2-0044" title="IdzerdaNM , PenaMJ , ParvingHH , deZeeuwD , HeerspinkHJ . Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation2019;34(10):1699-706. [MEDLINE: 30184238]KroonenM , StevensJ , De ZeeuwD , HeerspinkHJL . Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):500. [EMBASE: 633769807]deZeeuwD , AnzaloneDA , CainVA , CressmanMD , HeerspinkHJ , MolitorisBA , et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes &amp; Endocrinology2015;3(3):181-90. [MEDLINE: 25660356]">PLANET II 2006</a> (40 mg/d versus 10 mg/d) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies classified by type of statin therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/full#CD007784-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007784-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statins versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.66, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.73, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Rhabdomyolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.13, 75.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.69, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.42, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Revascularisation procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.47, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Hospitilsation due to heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.37, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Kidney failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Doubling serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 End of treatment kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.27, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 CrCl [mL/min]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.19 [0.58, 9.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 eGFR [mL/min/1.73 m²]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.46, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 End of treatment proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.75, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Elevated liver enzymes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.39, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.83, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Onset of diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.71, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Elevated creatine kinase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.20, 3.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.26 [‐64.34, ‐36.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.84 [‐52.56, ‐35.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.02 [‐40.99, ‐11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [‐0.03, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Subgroup analysis (cardiovascular disease): death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 No cardiovascular disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.55, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 Cardiovascular disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.76, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Subgroup analysis (cardiovascular disease): major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.66, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 No cardiovascular disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.46, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.2 Cardiovascular disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.71, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Subgroup analysis (statin dose): major cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.66, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 &lt; 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.37, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 ≥ 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.74, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Subgroup analysis (statin dose): death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 &lt; 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.68, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 ≥ 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.71, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Subgroup analysis (statin dose): withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.82, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 &lt; 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [0.61, 11.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 ≥ 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.77, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Subgroup analysis (statin dose): total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.26 [‐64.34, ‐36.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 &lt; 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐41.16 [‐51.24, ‐31.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.2 ≥ 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐60.28 [‐84.29, ‐36.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Subgroup analysis (statin dose): LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.84 [‐52.56, ‐35.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 &lt; 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐39.42 [‐51.98, ‐26.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.2 ≥ 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐47.69 [‐59.55, ‐35.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Subgroup analysis (statin dose): HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [‐0.03, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 &lt; 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.18, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.2 ≥20 mg/dL simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [‐2.31, 8.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Subgroup analysis (statin dose): triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.02 [‐40.99, ‐11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.1 &lt; 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐38.43 [‐66.72, ‐10.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.2 ≥ 20 mg/day simvastatin equivalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.23 [‐29.18, ‐1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Subgroup analysis (age): total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.26 [‐64.34, ‐36.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.1 &lt; 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐38.28 [‐45.93, ‐30.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.2 ≥ 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐60.48 [‐84.81, ‐36.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Subgroup analysis (age): withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.82, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 &lt; 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.55, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.2 ≥ 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.86, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Subgroup analysis (age): LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.84 [‐52.56, ‐35.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.1 &lt; 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐39.06 [‐50.84, ‐27.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.2 ≥ 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐46.80 [‐58.28, ‐35.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Subgroup analysis (age): HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [‐0.03, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.1 &lt; 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [1.49, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.2 ≥ 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐2.60, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Subgroup analysis (age): triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.02 [‐40.99, ‐11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.1 &lt; 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐33.45 [‐44.75, ‐22.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.2 ≥ 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.37 [‐43.72, ‐3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Subgroup analysis (diabetes mellitus): withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.84, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.36.1 &lt; 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.72, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.36.2 ≥ 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.10, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 Subgroup analysis (diabetes mellitus): death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.37.1 &lt; 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.62, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.37.2 ≥ 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.77, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.38 Subgroup analysis (diabetes mellitus): major cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.66, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.38.1 &lt; 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.56, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.38.2 ≥ 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.69, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.39 Subgroup analysis (diabetes mellitus): total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.26 [‐64.34, ‐36.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.1 &lt; 20% with DM or not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐55.16 [‐77.63, ‐32.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.2 ≥ 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.89 [‐51.36, ‐36.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.40 Subgroup analysis (diabetes mellitus): LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.84 [‐52.56, ‐35.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.1 &lt; 20% with DM or not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐42.19 [‐55.12, ‐29.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.2 ≥ 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐46.09 [‐53.60, ‐38.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.41 Subgroup analysis (diabetes mellitus): HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [‐0.03, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.1 &lt; 20% with DM or not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [‐1.19, 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.2 ≥ 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [‐0.43, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.42 Subgroup analysis (diabetes mellitus): triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.02 [‐40.99, ‐11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.1 &lt; 20% with DM or not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.71 [‐37.17, ‐14.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.2 ≥ 20% with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.53 [‐68.03, 14.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.43 Subgroup analysis (baseline cholesterol): total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.26 [‐64.34, ‐36.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.1 &lt; 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐37.10 [‐43.11, ‐31.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.2 ≥ 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐68.21 [‐96.42, ‐40.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.44 Subgroup analysis (baseline cholesterol): LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.84 [‐52.56, ‐35.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.44.1 &lt; 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐34.01 [‐40.83, ‐27.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.44.2 ≥ 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐58.87 [‐72.67, ‐45.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.45 Subgroup analysis (baseline cholesterol): withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.84, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.45.1 &lt; 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.69, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.45.2 ≥ 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.77, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.46 Subgroup analysis (baseline cholesterol): HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [‐0.03, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.1 &lt; 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [0.98, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.2 ≥ 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.01 [‐2.45, 10.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.47 Subgroup analysis (baseline cholesterol): triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.02 [‐40.99, ‐11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.1 &lt; 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.34 [‐31.33, ‐13.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.2 ≥ 230 mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐35.24 [‐64.04, ‐6.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.48 Subgroup analysis (allocation concealment): death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.1 Low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.70, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.2 High/Unclear RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.49 Subgroup analysis (allocation concealment): total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.26 [‐64.30, ‐36.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.1 Low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.67 [‐39.88, ‐25.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.2 High/Unclear RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐53.66 [‐70.93, ‐36.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.50 Subgroup analysis (allocation concealment): major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.66, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.50.1 Low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.69, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.50.2 High/Unclear RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.45, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.51 Subgroup analysis (allocation concealment): triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.02 [‐40.99, ‐11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.51.1 Low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.22 [‐42.66, ‐17.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.51.2 High/Unclear RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.27 [‐44.38, ‐6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.52 Subgroup analysis (kidney function): end of treatment kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.25, 2.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.52.1 &lt; 55 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [‐3.02, 6.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.52.2 ≥ 55 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.30, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.53 Sensitivity analysis (excluding SHARP): major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.63, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.54 Sensitivity analysis (excluding SHARP): death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.70, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.55 Sensitivity analysis (funding): major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.40, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.55.1 Non‐industry funding/not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.40, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.56 Sensitivity analysis (funding): death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.49, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.1 Non industry funding/not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.49, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.57 Sensitivity analysis (funding): withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.71, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.1 Non industry funding/not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.71, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.58 Sensitvitiy analysis (funding): total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐54.42 [‐71.98, ‐36.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.58.1 Non‐industry funding/not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐54.42 [‐71.98, ‐36.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.59 Sensitivity analysis (funding): LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐47.85 [‐57.72, ‐37.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.59.1 Non‐industry funding/not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐47.85 [‐57.72, ‐37.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.60 Sensitivy analysis (funding): HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [‐0.29, 6.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.60.1 Non‐industry funding/not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [‐0.29, 6.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.61 Sensitivity analysis (funding): triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.28 [‐44.25, ‐10.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.61.1 Non‐industry funding/not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.28 [‐44.25, ‐10.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statins versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007784-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High dose versus low dose statin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.25, 5.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.29, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Hospitilisation due to heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.39, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Elevated liver enzyme <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.67 [2.79, 153.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 eGFR [mL/min/1.73 m<sup>2</sup>] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.00 [‐19.49, ‐2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High dose versus low dose statin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007784.pub3/references#CD007784-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007784.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007784-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007784-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007784-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007784-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD007784-note-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="ko#CD007784-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007784-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="nl#CD007784-note-0017">Nederlands</a> </li> <li class="section-language"> <a class="" href="pl#CD007784-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD007784-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007784-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007784-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007784\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007784\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007784\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007784\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007784\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007784.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007784.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007784.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007784.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007784.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715272692"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007784.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715272696"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007784.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d83041ff9f446',t:'MTc0MDcxNTI3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 